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ABSTRACT 
EXTRACELLULAR MATRIX FOR REPAIR OF GASTROINTESTINAL MUCOSA 
Timothy Joseph Keane Jr., Ph.D. 
University of Pittsburgh, 2016 
Extracellular matrix (ECM) bioscaffolds have been shown to promote site-appropriate functional 
tissue remodeling in multiple anatomic sites, including the gastrointestinal (GI) tract. Discovery 
work over the past 2 decades has identified contributing mechanistic factors of ECM-induced 
tissue remodeling to be the modulation of the innate immune response by the action of 
embedded signaling molecules while naturally occurring cryptic peptide motifs released or 
exposed during ECM degradation and remodeling simultaneously promote stem/progenitor cell 
chemotaxis, proliferation, and differentiation. This immune stimulatory approach, paired with 
rapid restoration of the GI mucosal tissue, represents a novel therapeutic strategy for treating 
disease of the GI tract such as inflammatory bowel disease (IBD). The objective of the present 
thesis was to determine the efficacy of ECM for the repair of GI mucosal tissue. First, ECM was 
isolated from the proximal (esophagus) and distal (colon) of the GI tract to characterize spatial 
differences in the biochemical and mechanical properties of GI ECM. Next, we measured the 
effect of GI-ECM on epithelial cell remodeling and the inflammatory response. Finally, the 
efficacy of ECM for treating colonic mucosal tissue was tested in a rat model of IBD. Results 
show expected spatial changes in ECM along the GI tract with esophageal and colonic ECM 
having unique properties. Exposure of intestinal epithelial cells to GI ECM in-vitro led to 
enhanced epithelial cell remodeling and an increased barrier function. Macrophages exposed to 
degradation products of GI-ECM in-vitro were shown to exhibit an immunoregulatory and anti-
inflammatory phenotype. Finally, an enema hydrogel composed of GI ECM was shown 
effectively treat a rodent model of IBD. We defined effective therapy according to two essential 
physiologic processes that were positively directed by ECMH treatment. First, the colonic 
v 
epithelial barrier function, which protects the host from the relentless barrage of pro-
inflammatory luminal contents, was restored. Second, the pro-inflammatory state of tissue 
macrophages, which propagate inflammation by releasing inflammatory cytokines, was 
resolved. Together, this strategy represents a proactive therapeutic approach and is a distinct 
departure from the immunosuppressive (defensive) and surgical (salvage) methods currently 
used to treat IBD. 
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1.0 THE ROLE OF ECM IN GASTROINTESTINAL (GI) TRACT DEVELOPMENT & DISEASE
1.1 ABSTRACT 
The extracellular matrix (ECM) represents a dynamic complex of structural and soluble 
components that play a vital and regulatory role in countless biological processes. ECM is 
synthesized and secreted by cells beginning at the earliest stages of development and continues 
throughout life in both health and disease. During embryonic development of the gut, ECM largely 
acts as a permissive substrate through asymmetries and spatiotemporal patterning of the ECM. 
Following development, however the role of ECM shifts from permissive to instructive. Dynamic 
reciprocity between cells and ECM results in a context-dependent composition of ECM. Tissue in 
a healthy state is composed of healthy ECM but a change to disease state confers changes to 
both the cellular and ECM components of the tissue. The present review considers the range of 
cell and tissue functions attributable to the ECM molecules during gastrointestinal tract 
development and in disease. The importance of ECM during gut development and morphogenesis 
is highlighted in addition to the often overlooked role of ECM in inflammatory bowel disease. The 
use of ECM for tissue engineering therapies in the gastrointestinal tract represents an emerging 
field of study.   
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1.2 INTRODUCTION 
The extracellular matrix (ECM) represents the composite accumulation of structural and 
functional molecules secreted by the cells of every tissue and organ. In addition to the 
mechanical and structural functions of the ECM, extensive cell signaling activity occurs through 
a variety of soluble and insoluble molecular components.  The resultant phenotypic changes in 
resident cells are manifestations of the essential role that the ECM plays in development, 
maintenance of normal tissue and organ function, the response to injury, and in the progression 
to neoplastic disease1-4.  Stated differently, the ECM is not only a product of cell activity but a 
regulator of cell activity, and therefore central to tissue and organ health and disease. 
The composition and structure of ECM changes with age and in response to alterations 
in the macro- and microenvironments5-8. The relationship between cells and the surrounding 
ECM, and the associated cross talk, has been aptly described as one of “dynamic reciprocity”9.  
The dynamic changes in matrix composition and organization that occur with normal 
tissue/organ development, or with abnormal conditions such as injury, inflammation or 
neoplasia, provide an opportunity to investigate and understand the drivers of such events and 
identify potential biomarkers and therapeutic targets. To a limited extent, such investigations 
have occurred with heart tissue10, skeletal muscle11, and liver12,13, but relatively little has been 
explored in the gastrointestinal tract. The focus of the present manuscript is to provide an 
overview of the role of the ECM during gut development and morphogenesis, and during 
pathology of the gastrointestinal (GI) tract. In addition, a discussion of the potential role of 
biologic scaffold materials composed of ECM for GI tract engineering and regenerative medicine 
is presented. 
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1.3 ROLE OF ECM IN GI TRACT DEVELOPMENT 
Development of the GI tract is highly conserved across vertebrate species. The GI tract begins 
as a simple and uniform embryonic tube that differentiates along the anterior-posterior axis to 
form complex organs from the foregut, midgut, and hindgut regions. The foregut is the precursor 
of the pharynx, esophagus, stomach, liver, gall bladder, pancreas, and the proximal portion of the 
duodenum. The midgut gives rise to the posterior portion of the duodenum, the jejunum, ileum, 
the ascending colon, and two-thirds of the transverse colon. The hindgut is the precursor of the 
distal one-third of the transverse colon, the descending colon, and rectum14. 
1.3.1 Germ Layer Contributions to the Histologic Structures of the GI Tract 
The hollow tubular organs of the GI tract have functions that range from a transit tube 
(esophagus) to digestion (stomach) to nutrient and water absorption (intestine), functions which 
require specialized cell types organized within distinct histologic layers. Although the inner layer 
(mucosa) of each GI segment has unique cellular structures, the histomorphology is similar 
along the GI tract with a distinct luminal mucosa, underlying submucosa, muscularis externa, 
and an abluminal adventia or serosa. The majority of the muscularis externa in the GI tract is 
bound by serosa with the exception of the thoracic esophagus, ascending colon, descending 
colon and the rectum where the muscularis externa is instead surrounded by adventitia15. 
The histologic layers of the GI tract derive from all three germ layers and each germ 
layer contributes to the respective cell population and ECM constituents of the GI tract16 (Figure 
1) The majority of ECM mass in the GI tract arises from the mesoderm, which contributes to
almost all layers beneath the mucosal epithelium, including the lamina propria, the submucosa, 
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vascular elements, muscularis externa, and the adventia and serosa17. Intestinal subepithelial 
myofibroblasts, although their germ layer lineage is uncertain, reside in the mesenchyme at the 
base of intestinal crypts and contribute largely to the ECM of the basement membrane between 
mucosal epithelium and subjacent lamina propria and muscularis mucosa17,18. The endodermal 
germ layer contributes to the majority of luminal structures of the GI tract including the mucosal 
epithelium, mucosal glands, and submucosal glands19.  Lastly, while contributing to only a small 
portion of the GI tract, the ectoderm gives rise to the epithelium in the most proximal (mouth) 
and distal (anus) regions of the GI tract as well as the neural crest-derived submucosal and 
myenteric plexuses18. 
Figure 1. Diagram depicting the origins, regions, and histology of the major segments of the GI-tract. GI 
tissues that arise from the foregut include the esophagus, stomach, and the proximal portion of the duodenum. The 
midgut develops into the posterior portion of the duodenum, the jejunum, ileum, ascending colon and two-thirds of the 
transverse colon. The distal one-third of the transverse colon, and rectum arise from the hindgut of the embryonic 
tube. The epithelium of GI tissues, with its tissue-specific structures (e.g. gastric pits, villi, or crypts) is derived solely 
from the endoderm, whereas the basement membrane arises from both the endodermal and mesodermal germ layer. 
The remaining histological layers of GI tissues including the lamina propria of the mucosa layer, the submucosa, 
musclaris externa, adventitia, and serosa are mesodermal in origin. 
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1.3.2 ECM Components in the GI Tract 
Although substantial progress has been made in the understanding of cellular and genetic 
mechanisms that drive morphogenesis of the GI tract16,18, the contribution of the ECM is not 
completely understood. Once simply thought of as a structural component to provide shape and 
strength, the ECM is now recognized as a dynamic regulator of cell phenotype and function and 
is in a constant state of remodeling as cells differentiate along their site-specific developmental 
pathways20. As with many tissues and organs, the ECM of the GI tract can be divided into two 
main functional compartments: basement membrane (BM) and interstitial ECM21-23. The BM is a 
specialized two-dimensional sheet-like ECM that separates the subjacent connective tissue 
from epithelia, forming an interface between tissues of endodermal and mesodermal origin, and 
is composed mainly of type IV collagen, laminin, entactin, nidogen and sulfated 
proteoglycans21,22. Although the epithelium is derived from the endodermal germ layer, the 
subepithelial BM has a dual origin from both the gut epithelia and mesenchymal cells. BM 
components are present at the epithelial/mesenchymal interface in early developmental stages 
and variations in the spatial distribution of ECM components contribute to morphogenetic 
processes such as cell migration and branching morphogenesis 24. In contrast, the interstitial 
matrix surrounds cells in the stromal connective tissue and consists of both fibrillar structural 
components, such as fibronectin, type I collagen and elastin fibers that confer tensile strength 
and elasticity to the matrix, and non-fibrillar components such as mucopolysaccharides and 
glycosaminoglycans (GAGs) that confer structural support for mesenchymal cells21,23,25. 
Extensive crosslinking of GAGs and collagen provides for a three-dimensional gel like matrix 
which aids in compression and expansion and also may play a role in epithelial-mesenchymal 
cell interactions during stabilization of epithelial layers26. 
6 
1.3.3 The Role of ECM During Gut Development 
In the fully developed adult GI tract, the molecular constituents of the BM and interstitial matrix 
are generally restricted to their respective compartments. However, during early development, 
BM proteins are transiently distributed throughout the mesenchyme. Studies utilizing inter-species 
tissue recombinations have shown that collagen type IV, a major component of the basement 
membrane, is produced by mesenchymal cells rather than cells of the epithelia27. The transient 
and widespread distribution of type-IV collagen within the mesenchyme is paralleled by other 
constituents of the BM including laminin, perlecan, entactin and nidogen24. These major BM 
components are present at the intestinal epithelial/mesenchymal interface during the early stages 
of intestinal development24. However, the mesenchymal origin of BM components is not 
necessarily a general phenomenon for the full repertoire of BM constituents. Although intestinal 
BM contains both laminin A and B chains, only laminin B chains are expressed within the 
mesenchymal interstitial matrix, suggesting an epithelial source for laminin A28. Similarly, the use 
of interspecies associations of rat and chick embryonic tissue shows that intestinal epithelial cells 
are the source of basement membrane heparan sulfate proteoglycans (HSPG)29. The distribution 
of HSPG at the epithelial-mesenchymal interface varies with the stages of intestinal development, 
suggesting that remodeling of this proteoglycan is essential for regulating cell behavior during 
morphogenesis29. These findings show the parallel, and likely dependent, development of 
epithelial differentiation and mesenchymal cell BM production24,30,31.  
Although the expression of known ECM components in the ontogeny of the small intestine 
is similar for other segments of the digestive tract, the spatiotemporal distribution of these ECM 
components is not necessarily mirrored in all tissues of the gut. In the developing small intestine, 
for example, fibronectin expression occurs as early as 10 weeks of gestation and is followed by 
the expression of tenascin only after formation of differentiated epithelial cells lining the villi32,33. 
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Tenascin is a fibronectin antagonist contributing to the process of epithelial cell shedding34. In 
contrast, in the gastric mucosa, tenascin is co-expressed with fibronectin before gastric gland 
formation when the epithelium is composed mainly of undifferentiated cells35,36. The simultaneous 
expression of tenascin and fibronectin at this early developmental stage is unique to the gastric 
mucosa raising the possibility that these ECM components may play a differential role in the 
morphogenesis of the gastric mucosa compared to other tissues of the GI tract. This differential 
pattern of ECM expression and distribution throughout the gastric mesenchyme suggests that 
since GI layers have different origins, functions and fate, each may require a unique ECM 
composition and pattern of expression during morphogenesis of the individual organs of the gut.  
Although a comprehensive analysis of the major ECM components of the entire alimentary 
canal, i.e. the esophagus through the anal canal, has not been reported for the developing fetal 
GI tract, a similar study has been reported for the adult GI tract37. Immunohistochemical analysis 
of type IV collagen α-chains revealed a differential distribution of select α-chains throughout the 
subepithelial BM. Type IV collagen is comprised of six genetically distinct α-chains designated 
α1(IV) to α6(IV) which interact and assemble to form three heterotrimers of α1α1α2, α3α4α5, and 
α5α5α638. Whereas the α1, α2, α5 and α6 chains were shown to be expressed throughout the 
entire GI tract, the α3 and α4 chains are only expressed at restricted regions of the gastric and 
intestinal epithelium37. Compared to the other type IV heterotrimeric molecules, the α3α4α5 
heterotrimer forms a stronger network due to extensive disulfide bonds between cysteine residues 
in α3 and α439. Given the differential expression of α3 and α4 in the stomach and large intestine, 
the α3α4α5 heterotrimer may confer site specific effects, possibly by acting as a selective 
permeability barrier in these regions37. Similarly, in the developing fetal GI tract, the spatial and 
temporal distribution of ECM components may also confer tissue-specific effects during 
morphogenesis of the different segments of the digestive tract.  
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Evidence shows that the BM is required to promote maximal gene transcription in epithelial 
cells. Cell culture studies using laminin-1 as a substratum showed that intestinal epithelial cells 
cultured on a laminin substrate resulted in increased expression of the enterocyte differentiation 
markers lactase and sucrase40. Similarly, lactase expression is inhibited using laminin-1 blocking 
antibodies in co-cultures of embryonic gut epithelial cells and mesenchyme-derived cells41. In 
addition to the physiologic role of ECM as a substrate for cell adhesion, in silico analysis suggests 
that during morphogenesis of the primitive gut tube, the counterclockwise coiling of the intestine 
is at least partially directed by asymmetries in the composition of the ECM42. Despite these 
findings, evidence to support a direct and instructive role of ECM in promoting terminal 
differentiation is lacking in developmental models. In short summary, although it is clear that the 
ECM is essential and required for normal gut development, it appears that the ECM plays more 
of a permissive rather than proactive role in morphogenesis allowing for critical epithelial-
mesenchymal cell interactions and the establishment of cytokine and growth factor paracrine 
signaling16,43-35. This hypothesis is reflected in studies using Null mice harboring deletions of major 
ECM components and integrin receptors. Although not critically examined for intestinal effects, 
these studies failed to provide any obvious indication of a significant proactive influence of 
individual ECM components on GI morphogenesis16,46. In addition, studies have shown that single 
matrix molecules do not allow survival or elicit terminal differentiation of intestinal epithelial cells, 
a process which is only triggered by viable mesenchymal or fibroblastic cells43. However, before 
a conclusive opinion can be drawn on the permissive role of ECM in development, additional 
studies are required to determine if the intricate temporal and spatial changes of the ECM 
observed during gut morphogenesis are a result of developmental reorganization, or if they 
directly confer instructive signals to mediate enterocyte differentiation during GI morphogenesis. 
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1.4 ROLE OF ECM REMODELING IN GASTROINTESTINAL TRACT DISORDERS 
Given the vital role of ECM during development and tissue homeostasis, it follows that disease 
can arise when ECM components are dysregulated. Abnormal ECM is present in diseased 
conditions and reflects the important role of ECM in controlling cell behavior. While it is speculated 
that ECM is largely a permissive factor in development, the role of the ECM is more instructive 
thereafter. Since healthy ECM instructs healthy cell phenotypes, it is logical and plausible that 
ECM dysregulation can promote or initiate disease progression and maintain a disease 
state47,48. 
1.4.1 Inflammatory Bowel Disease (IBD) 
IBD, which includes ulcerative colitis and Crohn’s disease (CD), is a worldwide health 
problem. The debilitating, chronic relapsing disease consists of acute flares followed by 
periods of healing49. The specific etiology of IBD is unknown but genetic predisposition and 
immunologic factors are known contributors. Generally, IBD is characterized by an aberrant 
immune response and defects in intestinal epithelial cell barrier function50. Tissue damage 
associated with IBD has long been considered a downstream effect of disease and not a 
contributing factor. This interpretation has led to development of numerous treatments that 
solely target inflammation, but all treatments to date far have shown limited efficacy. While its 
role is often overlooked, the ECM is a critical component of intestinal inflammation and 
progression of IBD. 
Macroscopic tissue damage and clinical signs of IBD are preceded by changes in 
the ECM. Changes in collagen microarchitecture and thickening of ECM at crypts are evident 
in the colonic mucosa of patients with IBD51. IBD can progress in diametrically opposing 
directions based on the balance of ECM deposition or degradation. For example, CD can 
advance towards 
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stricturing or penetrating disease. Stricturing disease, or fibrostenosis, is the result of excess ECM 
deposition52-54. In contrast, penetrating disease is characterized by ECM destruction and fistulae 
formation54, thereby underscoring the central role of ECM in IBD (Figure 2). 
Figure 2. Schematic representation of normal intestinal wound healing, fistula formation, and 
fibrosis. In response to tissue damage, regulated production and degradation of ECM results in physiologic 
wound healing but IBD can progress in opposing directions based on the balance of ECM deposition or 
degradation. Fibrosis is characterized by excess ECM deposition that results from the coupling of increased 
number of ECM-producing myofibroblasts with increased cell proliferation and decreased apoptosis. In contrast, 
ECM destruction, mediated largely by MMPs, and decreased myofibroblast involvement leads to fistulae formation. 
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ECM remodeling enzymes, such as matrix metalloproteinases (MMPs), have long been 
studied in the context of IBD. Most MMPs are stimulated in response to pro-inflammatory 
cytokines, cell-cell, or cell-ECM interactions55. Collagenases (MMP-1, -8), gelatinases (MMP-2 
and -9), stromelysins (MMP-3), matrilysin (MMP-7), and macrophage elastase (MMP-12) are all 
upregulated in IBD and are among the most studied in the context of CD and UC56-59. Notable 
examples of the effect of these matrix remodeling enzymes can be seen with the gelatinase MMP-
2 and MMP-9. Although MMP-2 is commonly associated with tissue homeostasis, MMP-9 is highly 
expressed in pathologic scenarios and has been implicated as a disease biomarker60-63. The 
gelatinases act on ECM by digesting denatured collagens as well as collagen type IV thus 
contributing to loss of BM integrity, increased permeability and cell invasion64. High levels of MMP-
9 also inhibit wound healing, in part due to modulating ECM-cell interactions and preventing 
epithelial cell adhesion65.  MMP-3, another proteinase considered pivotal for tissue damage in 
IBD, acts on a wide range of ECM substrates (e.g., proteoglycans, types IV, V, IX, and X 
collagens, laminin, and fibronectin)66-68. Not surprisingly, based on its ability to degrade ECM, 
expression of MMP-3 has been associated with fistulae formation in patients with CD69. Both 
MMP-9 and MMP-3 contribute to tissue damage and mediate inflammation in patients with IBD. 
Together, these data suggest a vital role for ECM remodeling in IBD pathogenesis rather than 
simply a consequence of inflammation. 
The individual components of ECM, in addition to their role in structural support and tissue 
maintenance, are active participants in intestinal inflammation. For example, hyaluronic acid (HA) 
is an abundant GAG in the ECM and its degree of polymerization is indicative of ECM integrity. 
Small fragment HA is deposited throughout the inflamed colon in IBD and leads to innate immune 
cell activation70,71, while high-molecular weight HA has been shown to have therapeutic effects 
on experimental colitis72. In addition to HA, other ECM components have been shown to contribute 
to innate immunity, such the interaction of the proteoglycan Lumican with toll-like receptor 4. As 
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shown in mouse models, when Lumincan is absent, animals react to colitis with a dampened 
immune response, increased morbidity, and tissue damage73,74. Given the pivotal role of ECM in 
progression of IBD, development of novel targeted therapeutic approaches may benefit by 
focusing on restoration of ECM integrity and homeostasis in addition to the more typical 
approaches of immunomodulation. 
1.4.2 Fibrosis 
Intestinal injury is a common occurrence, even in healthy individuals, and one that is invariably 
followed by acute inflammation. Acute inflammation triggers a highly regulated wound healing 
process that resolves with two possible endpoints: reconstitution of normal tissue morphology or 
fibrosis. In most cases, rapid restoration of intestinal structure and function occurs and the 
inflammatory response abates. However, if unresolved, acute inflammation progresses to 
chronic inflammation, which can lead to excessive deposition of ECM proteins and associated 
fibrosis. 
Intestinal fibrosis is common amongst IBD patients and the location and extent of fibrosis 
is commensurate with the frequency and chronicity of the inflammatory response52,75,76,77. 
Fibrosis occurs in 5% of patients with UC, and typically remains confined to the mucosa and 
submucosa, and is associated with motility disorders and colonic shortening78. In CD, fibrosis 
extends throughout the depth (thickness) of the bowel and can lead to strictures and intestinal 
obstruction. Fibrosis arises in greater than 30% of patients with CD and this prevalence is likely 
due to extensive ECM deposition52,75,76,77.  
Fibrosis is the downstream consequence of an altered balance between ECM production 
and ECM degradation. In the intestine, multiple cell types have been proposed as potential 
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precursors of ECM-producing myofibroblasts including mesenchymal cells, epithelial and 
endothelial cells, and stem cells, among others78. Myofibroblasts are activated by paracrine and 
autocrine factors, pathogen associated molecular patterns (e.g., enteric microbiota), and 
damage associated molecular pattern molecules (e.g., DNA, RNA, ECM fragments)79-82. These 
ECM-producing cells act in concert and in response to biologic mediators of fibrosis. Intestinal 
healing depends upon restoration of the balance between pro-fibrotic and anti-fibrotic mediators. 
The most widely studied pro-fibrotic factor, TGF-β, is critical for fibrogenesis in multiple organs, 
including the intestine, and TGF-β has been shown to be highly up regulated in fibrotic CD79,83. 
Fibrosis progression is characterized by the coupling of increased number of ECM-
producing cells with increased cell proliferation and decreased apoptosis79-81. Altered ECM 
degradation (e.g., imbalance of MMPs and TIMPs) is another factor contributing to fibrosis 60. 
TIMP-1, for example, is overexpressed in CD fibrosis and plays a combined role in preventing 
ECM degradation and inhibiting myofibroblast apoptosis84.   
Despite advances during the past two decades in development of anti-inflammatory 
drugs, the prevalence of fibrosis in IBD patients has remained largely unchanged. While chronic 
inflammation triggers fibrosis, it is likely that other cellular and molecular pathways exist that 
contribute to the fibrotic response. It is noteworthy that certain chronic inflammatory diseases of 
the intestine, such as celiac disease or lymphocytic colitis, are not complicated by fibrosis. The 
regulation of ECM remodeling in these non-fibrotic diseases, in comparison to IBD, may provide 
clues as to the pathogenesis of intestinal fibrosis and identification of potential therapeutic 
targets. 
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1.4.3 Cancer 
Extracellular components of the cancer microenvironment play a critical role in tumor initiation, 
progression and invasion85. The highly regulated temporal and spatial deposition of ECM during 
embryonic development and tissue/organ homeostasis is markedly altered during cancer 
progression as changes in the biochemical composition and ultrastructure of ECM strongly 
influence both tumor and stromal cell properties86,87. As with fibrosis and IBD, the inflammatory 
response in the tumor microenvironment has been shown to facilitate neoplastic progression in 
GI tissues. Chronically inflamed tissue in the GI tract, such as with Barrett's Esophagus (BE), 
and chronic intestinal or gastric inflammation are highly susceptible to tumor formation due to 
the increased expression of ECM remodeling enzymes88,89. The integrity of the BM has been 
shown to be extensively impaired in digestive cancers, and is affected by both the synthesis of 
new components from contributing epithelial and stromal cells, and degradation from proteolytic 
factors. These breaches in the BM are often located at the invasive front and are associated 
with epithelial–mesenchymal transition90,91. Numerous studies have shown that the increased 
expression and activity of ECM-degrading enzymes are critical determinants of cell migration 
and metastasis, as the BM forms an early natural barrier in the process of tumor cell 
invasion92,93. As a result, proteolytic degradation of the BM is one of the main mechanisms of 
malignant tumor metastasis. This process is orchestrated by the increased expression of MMPs, 
thereby facilitating the invasion of tumor cells. For instance, studies have shown that compared 
to normal colorectal tissue, expression of MMP-2 and -9 are elevated in colorectal cancer, and 
are characteristic of a high invasion and metastatic potential associated with advanced stages 
of malignancy94. Similarly, increased expression of MMP-1, -3, -7, and -10 have been shown to 
be increased in the progression BE to esophageal adenocarcinoma 195.  
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The effect of stromal cells on the tumor microenvironment are most evident in Scirrhous 
Gastric Carcinoma (SGC) which, when diagnosed, has the worst prognosis of all gastric cancer 
types due to rapid expansion and peritoneal dissemination. In SGC, cancer-associated 
fibroblasts have been shown to play a crucial role in ECM remodeling96. In vitro experiments 
have shown that SGC cells and fibroblasts form aggregates capable of inducing extensive 
contraction and mechanical remodeling of the ECM, an event associated with increased 
actomyosin-mediated mechanical remodeling of ECM97. Other innate characteristics of stromal 
fibroblasts, including expression of α-smooth muscle actin and increased contractility, contribute 
to fibrosis in tumor tissue resulting in remodeling and strengthening of the stromal ECM, events 
which are favorable for invasion and metastasis of carcinoma cells98-100. Overall, these results 
underscore the critical role that ECM plays in GI developmental processes, and in the 
progression of disease states.  
1.5 FUTURE PERSPECTIVES 
1.5.1 Role of ECM in Tissue Engineering of the GI Tract 
ECM signaling molecules mediate rapid and functional remodeling of GI tract tissues. Preclinical 
and human clinical studies conducted during the past 15 years have shown that various forms 
ECM can facilitate a constructive and functional regeneration in the GI tract, specifically, the 
esophageal mucosa101,102. ECM bioscaffolds were shown to prevent scarring/stricture, restore 
epithelial and submucosal tissue, and preserve/restore normal esophageal motility in both 
preclinical animal models and human patients101. The results of this clinical concept pilot study 
strongly suggest that ECM signaling molecules induce a fundamental change in the default 
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healing response from the expected inflammation/scarring response toward a restorative “tissue 
formation” paradigm. At least two mechanisms contribute to this positive outcome: 
stem/progenitor cell recruitment (including proliferation, mobilization, and differentiation) and 
modulation of macrophage phenotype toward an anti-inflammatory/regulatory effector cell type. 
ECM materials therefore exhibit promising therapeutic properties for pathologies of the GI tract, 
especially inflammatory conditions such as IBD where immunomodulation and tissue healing 
are critical for positive outcomes103. 
Biomaterials derived from decellularized tissues represent naturally occurring ECM-
based scaffolds consisting of molecules secreted by the resident cells of all tissues and 
therefore, the composition of ECM scaffolds varies depending on tissue source. ECM scaffolds 
have been prepared from multiple regions of the GI tract, including esophagus104, small 
intestine105, and colon106. There are a number of potential therapeutic benefits of ECM scaffold 
materials derived from homologous tissue versus heterologous tissue107-113. The necessity or 
preference for site-specific ECM remains unknown for many tissue engineering applications, 
including those in the GI tract. While tissue specificity may not be necessary for all therapeutic 
applications114,115, studies have shown that site-specific ECM can preferentially maintain tissue-
specific cell phenotypes107-109, promote cell proliferation109-110, induce tissue-specific 
differentiation111,116, and enhance the chemotaxis of lineage-directed progenitor cells112,113,117. In 
the esophagus, site-specific ECM has favorable characteristics that enhance the migration of 
esophageal stem cells and supports the formation of 3D esophageal organoids to a greater 
extent than heterologous ECMs118. ECM scaffolds derived from GI tissues therefore provide a 
novel platform for studying mechanisms of tissue repair and can inform future regenerative 
medicine therapies. 
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1.6 CONCLUSIONS 
The ECM plays both permissive and instructive roles during gut morphogenesis, maintenance of 
healthy tissue, and in the response to injury in adults.  The concept of dynamic reciprocity which 
describes the continuous cross talk between cells and matrix, and the influence of external 
factors that affect the microenvironmental niche, is central to the understanding of the role of the 
ECM in GI tract health and disease.  While most interest in the GI tract has been cell-centric, the 
ECM component of the gut offers opportunities for understanding development and disease, 
identification of biomarkers of disease, and potential therapeutic targets. Tissue 
engineering/regenerative medicine efforts have shown promising early results in the esophagus.  
Possible applications of ECM scaffolds for the remainder of the GI tract remain to be explored.   
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2.0 THE ECM AS A BIOLOGIC SCAFFOLD FOR TISSUE ENGINEERING APPLICATIONS1
2.1 ABSTRACT 
With advancements in biological and engineering sciences, the definition of an ideal biomaterial 
has evolved over the past 50 years from a substance that is inert to one that has select 
bioinductive properties and integrates well with adjacent host tissue. Tissue engineering (TE) 
combines the principles of engineering and biology and generally involves the use of some 
combination of the following: biomaterials, cells, and bioactive molecules 2. The appropriate 
contribution of each factor depends upon the application in question, the strategy for tissue 
replacement, and patient variables such as age, co-morbidities, and other factorsBiomaterials 
are a fundamental component of tissue engineering, which aims to replace diseased, 
damaged, or missing tissue with reconstructed functional tissue. This chapter focuses on the 
role of extracellular matrix as a biomaterial for tissue engineering applications. 
1 Portions of this chapter were adapted from the following publication: 
Keane TJ, Badylak SF. Biomaterials for Tissue Engineering Applications. Seminars in Pediatric Surgery, 
June 2014. DOI:10.1053/j.sempedsurg.2014.06.010 
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2.2 INTRODUCTION 
Scaffold materials for tissue engineering/regenerative medicine can be broadly classified as 
either synthetic or naturally occurring in origin. Regardless of their origin, such scaffold materials 
are intended to support the attachment, maintenance, proliferation, and on occasion the 
differentiation of selected cell populations. In addition, the scaffold must provide adequate form 
and structural support for the intended anatomic site. These requirements are non-trivial and to 
make matters even more challenging, the host response to the presence of the material within 
the mammalian body must be one that allows for functional replacement of the injured or 
missing tissue over the life of the patient. This is particularly important in pediatric patients in 
whom the scaffold must adapt to the growth and development of the surrounding tissues and 
organs.   
It can be argued that the most important measure of a scaffold material is not its 
composition, shape, mechanical properties, porosity, or ability to support cell growth, but rather 
the host response to the scaffold material. Regardless of how ideal the material looks and feels 
at the time of implantation, the true measure of success is how the material looks and feels 1, 5, 
and 10 years after implantation. There are pros and cons for each material and the optimal 
scaffold material for each clinical application will vary. Stated differently, one size does not fit all. 
The present chapter provides a brief overview of common strategies for scaffold design and 
development in the field of tissue engineering/regenerative medicine, with emphasis on the role 
of the ECM in tissue engineering applications. 
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2.3 BIOMATERIALS FOR TISSUE ENGINEERING 
Tissue engineering (TE) combines the principles of engineering and biology and generally 
involves the use of some combination of the following: biomaterials, cells, and bioactive 
molecules 2. The appropriate contribution of each factor depends upon the application in 
question, the strategy for tissue replacement, and patient variables such as age, co-morbidities, 
and other factors. TE strategies can include both in-vitro and in-vivo approaches, and the 
optimal approach for each clinical application will continue to evolve as advances in stem cell 
biology, biomaterial science, and bioreactor technology occur.  Biomaterials play an important, 
in fact indispensible, role in the field of TE. Biomaterials have been used for centuries for 
applications such as intraocular lens replacement and dental fillings, but advancements in cell 
and molecular biology, chemistry, materials science, and engineering have provided much 
broader opportunities for clinical use.   
The definition of the ideal biomaterial has changed considerably during the past 50 years 
and, in fact, will vary between given applications 3. In early biomaterial design, the goal was to 
match mechanical and material properties, and to achieve a level of functional outcome that 
adequately matched the native tissue without invoking tissue damage or a deleterious host 
response. For example, bone cement, stainless steel, and Dacron were used extensively in 
early biomaterials because they were considered to be relatively inert and incited a predictable 
but tolerable foreign body response. Furthermore, these materials had favorable mechanical 
properties. Second-generation biomaterials included materials such as titanium, bioglass, 
PLGA, and collagen. These materials were engineered for biologic use and have bioactive 
properties that include osseointegration (titanium, hydroxyapatite), tissue integration (Bioglass), 
and biodegradation (PLGA, collagen). Many of the aforementioned materials maintain clinical 
relevance, but the field of TE is rapidly moving toward the use of biomaterials that integrate with  
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adjacent tissue and are bioinductive; that is, materials that enhance the regenerative or 
reconstructive capacity of a given tissue or organ. Stated differently, these materials are polar 
opposite to the “inert” biomaterials of 50 years ago. 
A number of biomaterials for TE are available for various clinical applications (Table 1). 
The use of biomaterials should be used in an application-specific nature; that is, a biomaterial 
that achieves success in one application should not necessarily be expected to perform well in 
an application that is very different. For example, with pediatric patients a biomaterial should 
degrade over time or have the capability change shape and size so the engineered tissue can 
grow with surrounding tissue. Further, if a scaffold is biodegradable the biomaterial must provide 
adequate mechanical support during the time of scaffold remodeling 4. 
2.3.1 Improving Synthetic Biomaterials 
Given the advantage of manufacturing reproducibility with synthetic materials, a large amount of 
research has been directed at methods enhance bioactivity. One such approach is to mimic the 
biochemical composition of native ECM. Many of the remodeling functions are associated with a 
number of protein motifs. A variety of ECM-derived adhesion peptides have been incorporated 
within scaffolds for improved cell adhesive properties. These peptides are derived mainly from 
ECM proteins, including fibronectin 5-9, laminin 10-14, collagen 14-20, and elastin 6,21,22. A peptide 
sequence commonly used to modify a scaffold’s cell adhesion properties is RGD, a binding 
domain present in laminin, collagen, and fibronection 23,24. By controlling the spatial 
arrangement of cell binding domains, such as RGD, materials can have cell specific adhesion 
properties that are essential for tissue regeneration.   
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Table 1. Clinically Available Biomaterials for Tissue Engineering 
Product Description Application Company 
Apligraf® Allogeneic fibroblasts on 
a bovine collagen I matrix 
with upper keratinocyte 
cell layer 
Skin Organogenesis 
Oasis® Wound 
Matrix 
Decellularized porcine 
small intestinal 
submucosa 
Skin Cook Biotech 
Integra® Bilayer 
Wound Matrix 
Type I bovine collagen 
with chondroitin-6-sulfate 
and silicone 
Skin Integra Life 
Sciences 
Epicel® Autologous keratinocyte 
cell sheets 
Skin Genzyme 
REGRANEX® PDGF within a hydrogel Skin Healthpoint 
Biotherapeutics 
Carticel® Autologous chondrocytes Cartilage Genzyme 
NeoCart® Autologous chondrocytes 
on type I bovine collagen 
Cartilage Histogenics 
Pura-Matrix™ Hydrogel composed of a 
self-assembling peptide 
(RADA) 
Bone 3DMatrix 
INFUSE® Bone 
Graft 
Recombinant human 
BMP-2 absorbed in a 
bovine type I collagen 
sponge 
Bone Medtronics 
Omniflow® II Polyester mesh with 
cross-linked ovine 
collagen 
Blood 
vessels 
Binova 
Anginera™ Allogeneic fibroblasts on 
vicryl mesh 
Cardiac Theregen 
CardioWrap® Membrane composed of 
a copolymer of 70% L-
lactide and 30% D,L-
lactide 
Cardiac MAST 
Biosurgery, Inc. 
CryoValve® 
SynerGraft 
Pulmonary Heart 
Valve 
Decellularized allogeneic 
pulmonary valve 
Cardiac Cryolife 
Encapsulated Cell 
Technology 
implant 
Polysulfone capsule with 
PET scaffold containing 
immortalized retinal 
epithelial cells 
Retinal Neurotech 
Pharmaceuticals 
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Another important functional cue provided by ECM is proteolytic degradation. An optimal 
rate of scaffold degradation, which will vary between tissues, should be slow enough to provide 
a support for cellular growth but fast enough to not impede the reconstructive process. A 
biochemical method employed for altering biomaterial degradation profiles involves 
incorporation of peptides sensitive to cleavage by enzymes 25. These peptides have been 
designed with cleavage sites that are recognized by enzymes including matrix 
metalloproteinases 26-34, plasmin 28,29, and elastase 35. 
Processes vital to tissue regeneration, such as cell migration, differentiation, and 
proliferation, are dependent on both the presence of specific growth factors as well as their 
spatial and temporal distribution. Growth factors and peptides derived from growth factors have 
been coupled to biomaterials to promote nerve regeneration 36,37, cell proliferation and migration 
38, osteogenesis 39,40, enhanced cell viability, and angiogenesis in ischemic tissues 41. A number 
of biomaterials for growth factor delivery are commercially available. Some examples include 
INFUSE® Bone Graft (Medtronic) which delivers bone morphogenetic protein 2 (BMP2) for 
degenerative disc disease, and REGRANEX® (Healthpoint Biotherapeutics), which delivers a 
recombinant human platelet-derived growth factor (PDGF) known as becaplermin in a hydrogel 
vehicle for treating diabetic ulcers in lower limbs.  
A number of physics-based approaches have been investigated for controlling biologic 
processes. Micro- and nanofabrication technologies made it possible to pattern surfaces with 
very detailed features 42-45 including controlled shape 46-48, mechanical properties 49,50, and 
surface topology 51. The physical characteristics of particles, in turn, have been linked to many 
essential cellular processes. For example, particle shape at the point of initial contact with 
macrophages determines whether or not a macrophage initiates phagocytosis 46. In addition, the 
size of features on patterned substrates has been shown to determine whether cells undergo 
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apoptosis 52 or directed cell differentiation 53.  These examples show that even in the absence of 
biologic activity, particle shape, patterning, and surface topology can direct cellular processes. 
The mechanical properties of a tissue have an important role in tissue morphogenesis 54. 
Likewise, substrate mechanical properties have a profound effect on cell and tissue behavior. 
Changing the elastic properties of the substrate that mesenchymal stem cells were cultured 
upon can facilitate neuronal, myogenic, or osteogenic differentiation dependent upon substrate 
stiffness 55. In addition, mechanical properties have been shown to be alter immune functions, 
such as macrophage phagocytosis 56 and dendritic cell activation 57. 
Clearly, improvements in micro and nano-scale manufacture have led to an improved 
understanding of cellular processes.  However, the mechanism that mediates cell recognition of 
material cues is still poorly understood. Therefore, the possibility to display a single signal or an 
array of signals at the cell–material interface to elicit a given cell response is still a distant goal 
58.  
2.3.2 Naturally Derived Biomaterials 
Naturally derived materials include polymers such as silk and chitosan, purified ECM-based 
molecules including collagen, elastin, and GAGs. While clinical use of biomaterials from natural 
materials, such as alginate (PhytaCare™) and chitosan (HemCon™) as wound dressings and 
silk (Ethicon) as suture material, these biomaterials alone lack the signaling functions and 
mechanical and spatial cues that native ECM contain. 
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2.3.3 The ECM as a Bioscaffold for Tissue Repair 
Rather than attempting to mimic the native ECM physical and biochemical composition by 
synthetic methods, an alternative is to decellularize tissues and use the resulting ECM as 
biologic scaffold. By definition, allogeneic and xenogeneic biologic scaffold materials are 
composed of ECM.  The ECM represents the secreted product of the constituent cells in every 
tissue. The composition and ultrastructure of ECM is a function of the factors that influence the 
phenotype of these resident cells such as mechanical forces, biochemical milieu, oxygen 
concentration, and inherent gene expression patterns. The ECM is in a state of dynamic 
reciprocity with the cells that reside within it; that is, the ECM provides biosignaling and 
biophysical cues which influence the resident cells that, in turn, adjust their gene and protein 
expression patterns to produce a secretome that optimizes the surrounding matrix for cell 
survival and function 59,60. This complex mixture of structural and functional molecules is 
arranged in an ultrastructure that is tissue specific.  These molecules comprise the ligands that 
are arranged in patterns that are ideally suited for the particular cell types present within each 
tissue. Stated differently, the ECM represents Mother Nature’s ideal scaffold material. 
The most abundant protein within mammalian ECM is collagen. Over 20 forms of 
collagen have been described but Type I collagen, the major structural protein present in 
tissues, is the most prevalent form of collagen in ECM 61. Other forms of collagen, such as Type 
III, Type IV and Type VII are present in lesser quantities and provide distinct mechanical and 
physical properties. Second to collagen in quantity within the ECM is fibronectin. Fibronectin is a 
dimeric molecule and exists in soluble and insoluble isoforms. The insoluble isoform is an 
important ECM component that regulates the adhesion, migration, growth, and differentiation of 
many cell types and mediates processes such as wound healing 62. Another protein with a well-
recognized role in cell-matrix interactions is laminin 63.  
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In addition to proteins, the ECM contains various mixtures of glycans. Glycans, including 
glycosaminoglycans and proteoglycans, are molecules which swell in the aqueous spaces 
between protein ﬁbrils and allow diffusion of nutrients 64. Finally, ECM serves as a reservoir for a 
variety of signaling molecules and growth factors such as vascular endothelial growth factor, 
transforming growth factor beta, basic fibroblast growth factor, among others. These factors 
typically exist in inactive forms in the ECM and are preserved to a different extent in most 
bioscaffolds composed of ECM 65. When the ECM scaffold degrades, these signaling molecules 
and growth factors are released. These degradation products have been shown to attract 66 and 
affect the proliferation of stem cells 67. However, the specific roles of these various ECM 
components in remodeling and host response outcomes following ECM scaffold implantation 
are completely unknown.  
The constituent molecules of ECM are highly conserved amongst mammalian species. 
Basement membrane components, for instance, are among the most highly evolutionarily 
conserved proteins 68-70. Basement membranes represent ECM structures which are composed 
of polymeric sheets of laminin, collagen IV, and associated proteins.  Basement membrane 
structures are found on the basal surface of epithelia and provide both a substrate for cell 
attachment and a barrier to cell mixing during embryonic development 71. High cross-species 
homology has been shown for collagens 72,73, fibronectin 74, as well as certain 
glycosaminoglycans 74,75 and growth factors 76. Stated differently, ECM constituents in 
mammalian species are very similar and therefore elicit a similar response when implanted as 
an allogeneic or xenogeneic bioscaffold.  
ECM scaffolds derived from decellularized tissues provide a natural structure that has proven
successful in a number of TE applications 77-79. The ECM from varying species and tissue   
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sources has been used to repair or replace tissues including vascular 80-83, tracheal 84,85, cardiac 
86-89, skeletal muscle 90,91, and esophageal tissues 92-96, among others 97-99. Such allogeneic or
xenogeneic sources are commercially available (Table 2), and as expected the composition of 
ECM scaffolds varies depending on tissue source 100.  
2.4 TISSUE SPECIFICITY OF ECM 
Tissue sources from which ECM scaffolds are prepared include humans (allografts) and 
porcine, bovine, or equine tissue (xenografts). Whether the ECM is derived from allogeneic of 
xenogeneic species, the composition of ECM constructs is affected by donor state (e.g., age, 
disease state). Further, the anatomic site of the raw material source has a strong influence upon 
the device mechanical and material properties, the methods required for adequate 
decellularization and sterilization, and the eventual host response.  
The composition, ultrastructure, and mechanical properties of ECM derived from 
different tissues/organs are distinct; a logical finding since each tissue/organ has a unique 
function. For example, ECM derived from small intestinal submucosa has a preferred collagen 
alignment that leads to anisotropic mechanical behavior of the scaffold, with the preferred 
(longitudinal) fiber direction showing greater stiffness and strength than the circumferential 
direction 101. The collagen fiber alignment of the urinary bladder submucosa and tunica propria, 
in contrast, shows a much more isotropic fiber alignment than SIS 102. An understanding of the 
mechanical properties from different tissues may be an important consideration for matching the 
choice of ECM source tissue with a specific clinical application. 
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Table 2. Source tissue and species of commercial biologic scaffold materials 
Product Species Tissue Application Company 
AlloMax™ Human Dermis Soft tissue Bard Davol 
AlloPatch HD™ Human Dermis Tendon, breast Musculoskeletal 
Transplant Foundation 
NeoForm™ Human Dermis Breast Mentor Worldwide LLC 
GraftJacket® Human Dermis Soft tissue KCI 
Axis™ Human Dermis Pelvic organ 
prolapse 
Coloplast 
Strattice™ Porcine Dermis Soft tissue Lifecell Corp. 
TissueMend® Bovine Dermis Soft tissue Stryker Corp. 
Avaulta®, CollaMend® Porcine Dermis Soft tissue Bard Davol 
Veritas®, Dura-Guard®, 
Peri-Guard® 
Bovine Dermis Soft tissue Synovis Surgical 
Suspend™ Human Fascia lata Pelvic organ 
prolapse 
Coloplast 
Hancock® II, Mosaic®, 
Freestyle® 
Porcine Heart valve Valve 
replacement 
Medtronic Inc. 
Prima Plus Porcine Heart valve Valve 
replacement 
Edwards Lifesciences 
LLC 
Epic, SJM Biocor® Porcine Heart valve Valve 
replacement 
St. Jude Medical Inc. 
IOPatch™ Human Pericardium Opthalmology IOP Inc. 
OrthAdapt®, Unite® Equine Pericardium Soft tissue, 
chronic wounds 
Synovis Orthopedic 
and Woundcare Inc. 
CopiOs® Bovine Pericardium Dentistry Zimmer Inc. 
Lyoplant® Bovine Pericardium Dura mater B. Braun Melsungen
AG 
Perimount® Bovine Pericardium Valve 
replacement 
Edwards Lifesciences 
LLC 
Permacol™ Porcine Porcine 
dermis 
Soft tissue Tissue Science 
Laboratories 
Oasis®,  Surgisis® Porcine Small 
intestine 
Soft tissue Cook Biotech Inc 
Restore® Porcine Small 
intestine 
Soft tissue DePuy Orthopaedics 
FortaFlex® Porcine Small 
intestine 
Soft tissue Organogenesis Inc. 
CorMatrix ECM® Porcine Small 
intestine 
Pericardium, 
cardiac tissue 
CorMatrix® 
Cardiovascular Inc. 
CuffPatch™ Porcine Small 
intestine 
Rotator cuff Athrotek 
Surgisis®, Durasis®, 
Stratasis® 
Porcine Small 
intestine 
Soft tissue Cook SIS 
MatriStem® Porcine Urinary 
bladder 
Soft tissue Acell Inc. 
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The properties of biologic scaffolds also vary with the age of the source animal from 
which the tissue is harvested. Fetal and neonatal mammals have greater wound healing and 
regenerative capacity compared to adult mammals 103. The composition of fetal and neonatal 
ECM is distinctly different from that of adults and plays an important role in tissue development 
104. In fact, distinct remodeling characteristics exist that are attributable to source animal age.
Biologic scaffolds harvested from neonatal animals have been shown to promote a more robust 
constructive remodeling response when compared to scaffolds derived from market weight and 
older animals 105. 
The ECM is said to be in a state of dynamic reciprocity with the resident cells; that is, the 
ECM provides signaling and biophysical cues that influence the cell morphology and phenotype. 
In turn, the cells modify their secreted ECM products in response to microenviromental signals 
including mechanical stimuli, oxygen and nutrient concentration, and all factors that contribute to 
the microenvironmental niche 59. Dynamic reciprocity between ECM and resident cells can also 
be involved in disease progression. For example, healthy colon ECM and CRC-derived ECM 
have been shown to differentially regulate tissue homeostasis and tumorigenesis 106. The 
presence of ‘healthy ECM,’ therefore, is essential to normal tissue functions. Similarly, in 
patients with IBD, changes in quantity and distribution of matrix metalloproteinases (MMPs) has 
been reported in previous studies. For example, MMP2 and MMP9 are upregulated in the colon 
of individuals with IBD 107.However, a separate study has shown that ‘healthy’ ECM is able to 
downregulate MMP2 and MMP9 production in macrophages 108. It is plausible that such a 
mechanism may remediate negative effects of colitis.  
Recent work has described potential benefits of ECM scaffold materials derived from 
homologous tissue versus heterologous tissue when used in selected anatomic locations 109-118. 
However, the necessity or preference for site-specific ECM remains unknown for many 
therapeutic applications. While tissue specificity may not be necessary for all therapeutic 
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applications 92,119,120, some studies have shown that site-specific ECM can preferentially 
maintain tissue-specific cell phenotypes 109-112, promote cell proliferation 111,113, induce tissue-
specific differentiation 114, and enhance the chemotaxis of lineage-directed progenitor cells 115-
117. Zhang et al have shown that ECM derived from liver, skin, and skeletal muscle increases
the proliferation and differentiation potential for site-matched cell types 113. Sellaro and 
colleagues have shown that ECM derived from liver improves the maintenance of sinusoidal 
endothelial cell phenotype 109 and the function of hepatocytes in-vitro 110. More recently, porcine 
myocardial ECM has been shown to improve cardiac progenitor cell function in-vitro 112. Seif-
Naraghi et al have shown that injection of a hydrogel form of cardiac ECM after myocardial 
infarct improves cardiac function and results in increased cardiac muscle mass 89.  
2.5 MECHANISMS OF ECM MEDIATED CONSTRUCTIVE REMODELING 
The fundamental role of a biomaterial in tissue remodeling is to provide structural support and a 
microenvironmental niche that modulates cell attachment and cell behavior. Nature’s template 
for such a biomaterial is the extracellular matrix (ECM); the material secreted by resident cells in 
every tissue and organ. Once thought to exist for the primary purpose of providing structural 
support to tissues, the ECM is now known to consist of a complex milieu of both structural and 
functional molecules that have a dramatic effect upon cell behavior 59,121. The ECM provides not 
only physical support and spatial organization, but also a bioactive microenvironment that 
directs and influences cell functions. The ECM consists of structural proteins (e.g., collagen and 
elastin), cell adhesion proteins (e.g., fibronectin and laminin), and glycans (e.g., 
glycosaminoglycans (GAGs) and proteoglycans). Glycans swell in the aqueous spaces between 
protein ﬁbrils, allowing the diffusion of nutrients and providing a reservoir for signaling molecules 
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and growth factors 64. During tissue regeneration or in response to injury, the ECM is subject to 
extensive and continuous remodeling. Proteolytic degradation of the ECM, as part of the 
remodeling process, provides morphogenic cues in the form of cryptic peptides which influence 
cell survival, proliferation, migration, polarization, and differentiation 59,122-125. Inductive scaffolds 
composed of ECM promote functional tissue remodeling by providing structural support and cell 
signaling cues. 
2.5.1 ECM-mediated remodeling of the Gastrointestinal Tract 
Implantation of biologic scaffolds has led to constructive remodeling in various regions of the GI 
tract. Dramatic advancements have come through study of the esophagus.  In both preclinical 
and clinical studies, biologic scaffolds composed of ECM have been shown to facilitate 
reconstitution of normal mucosa in the esophagus. In a preclinical model, critically sized, 
circumferential defects were repaired with minimal stricture formation and near-normal 
restitution of the esophageal histomorphology when adjacent autologous muscle tissue was 
placed in direct contact with an ECM scaffold at the time of surgery 93. A follow-up preclinical 
study of esophageal transection, designed to reinforce the anastomosis of a “gastric pull-up” 
procedure, showed restoration of a mature epithelium and regeneration of muscle tissue that 
bridged the gap between the native muscle tissue on both sides of the surgical site 94. The 
successful use of ECM was then extended to a preclinical model of aggressive endoscopic 
resection 95. Based upon these preclinical findings, five human patients with diseased 
esophageal mucosa (i.e., Barrett's esophagus and high grade dysplasia and/or mucosal 
adenocarcinoma) were subjected to a long segment, circumferential resection of the mucosa 
and submucosa of the esophagus, and an ECM scaffold material was placed over the site of the 
resected tissue. The ECM scaffold induced restoration of normal mature squamous epithelium, 
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and allowed return to a normal diet without significant dysphagia for all patients.  This most 
recent study provided proof of concept in the clinical setting. We found that a minimally invasive 
endoscopic procedure for treatment of diseased mucosa is possible when combined with the 
use of a biologic scaffold material to promote reconstruction of functional mucosa 92,126. 
2.6 INJECTABLE VS. IMPLANTABLE ECM 
Historically, ECM has been largely used as an implantable physical scaffolding to bridge a 
defect site. In these cases, diseased or defective tissue is removed and the ECM scaffold is 
subsequently placed at the site of tissue resection to induce remodeling of new tissue. However, 
recent studies suggest that this paradigm is only one means by which ECM scaffolds can be 
utilized. Hydrogels can be prepared from ECM scaffolds by enzymatic digestion followed 
physiologic balancing of salt and pH. Such hydrogels have been shown to be deliverable by 
non-invasive methods and serve as a template for tissue repair. The work of Christman et al. 
indicates that injectable ECM hydrogels can serve as a template for cardiac repair following 
myocardial infarct (MI). During MI, a blockage in a coronary artery causes cell death followed by 
an acute inflammatory response. The ECM hydrogel was able to mitigate the harsh 
inflammatory milieu following MI, providing an appropriate environment and a physical scaffold 
to encourage repair and regeneration. This concept—mitigating inflammation and promoting 
remodeling—serves as the foundation to support the use of an ECM hydrogel as a non-invasive 
method to treat UC 
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3.0 PREPARING BIOMATERIALS FROM DECELLULARIZED TISSUES2
3.1 ABSTRACT 
Biologic scaffolds composed of extracellular matrix (ECM) are widely used in both preclinical 
animal studies and in many clinical applications to repair and reconstruct tissues.  Recently, 3-
dimensional ECM constructs have been investigated for use in whole organ engineering 
applications. ECM scaffolds are prepared by decellularization of mammalian tissues and the 
ECM provides natural biologic cues that facilitate the restoration of site appropriate and 
functional tissue. Preservation of the native ECM constituents (i.e., three-dimensional 
ultrastructure and biochemical composition) during the decellularization process would 
theoretically result in the ideal scaffold for tissue remodeling. However, all methods of 
decellularization invariably disrupt the ECM to some degree. Decellularization of tissues and 
organs for the production of ECM bioscaffolds requires a balance between maintaining native 
ECM structure and the removal of cellular materials such as DNA, mitochondria, membrane 
lipids, and cytosolic proteins.  These remnant cellular components can elicit an adverse 
inflammatory response and inhibit constructive remodeling if not adequately removed. Many 
variables including cell density, matrix density, thickness, and morphology can affect the extent 
of tissue and organ decellularization and thus the integrity and physical properties of the 
2 Portions of this chapter were adapted from the following publication: 
Keane TJ, Swinehart I, Badylak SF. Methods of Tissue Decellularization Used for Preparation of Biologic 
Scaffolds and In-vivo Relevance. Methods, March 2015. DOI:10.1016/j.ymeth.2015.03.005 
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resulting ECM scaffold.  This chapter reviews currently used processing techniques for 
preparation of ECM scaffolds. 
3.2 INTRODUCTION 
Biologic scaffold materials composed of extracellular matrix (ECM), and derived via 
decellularization of source mammalian tissues, are widely used for clinical applications that 
involve repair and reconstruction of musculoskeletal tissues, cardiovascular structures, lower 
urinary tract, gastrointestinal tract, and central nervous system, among others 89,92,127-130. Such 
scaffold materials have the potential to promote and facilitate “constructive remodeling” 
processes that form vascularized, innervated, functional tissue. Mechanisms by which these 
constructive remodeling events occur include the recruitment and differentiation of 
stem/progenitor cells 66,67,110,131 and modulation of the innate immune response 132-134. The 
effector molecules responsible for these processes represent a combination of sequestered 
cytokines and chemokines within the matrix, and matricryptic peptides generated or exposed 
during the process of ECM degradation 67,135-137. Thorough decellularization of source tissues to 
generate the ECM scaffolds is critical for realization of the full potential of these ECM mediated 
events. Failure to effectively decellularize the tissue results in retained cell remnants, which can 
act in a manner similar to damage associated molecular pattern molecules (DAMPs) following 
tissue injury. Ineffective decellularization has been shown to be associated with an intense 
inflammatory response which can mitigate or completely inhibit a constructive remodeling 
outcome 138.  
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All methods of decellularization disrupt the structure and composition of the ECM. The 
goal of tissue decellularization is thorough removal of cells and cell remnants while retaining the 
three dimensional ultrastructure and composition of the native ECM to the extent possible. 
Optimal methods of decellularization vary among tissues and organs due to tissue-specific 
factors such as cell density, matrix density, and geometric considerations including tissue 
thickness and shape. Complete removal of all cell remnants is not possible, and 
decellularization processes inevitably and invariably cause some disruption of matrix 
architecture, orientation, and surface ligand landscape.  The specific cellular elements that elicit 
adverse and proinflammatory responses are only partially known.  One objective of the present 
manuscript is to provide guidance as to the effects of various decellularization methods upon 
both the resulting biologic scaffold and the associated host remodeling response and outcome.  
Decellularization methods described include mechanical, chemical, detergent, and enzymatic 
techniques, or combinations thereof. Table 3 provides an overview of decellularization 
processes used for various tissues and organs and the effects of those processes on ECM 
constituents and the host response.  
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Table 3. Decellularization techniques used for various tissues 
Tissue/Organ 
Type 
 Decellularization 
Technique 
Effects on ECM and 
Host Response 
References 
Laminate 
Pericardium 
Urinary 
Bladder 
Intestine 
Amnion 
Dermis 
Freeze/thaw, mechanical 
removal of undesirable 
layers, brief exposure to 
acids/bases, rinse.  Thicker 
laminates may require longer 
exposure to remove cellular 
debris.  
Cellular remnants can 
elicit an adverse immune 
response. Microstructure 
and ultrastructure will be 
altered. 
Increased exposure 
times may damage 
collagen, reduce GAG 
and growth factor 
content. 
139-142
Amorphous Organs 
Adipose 
Brain 
Freeze/thaw, mechanical 
disruption, alcohol/solvent 
treatment, exposure to 
acid/base, rinse. 
Alcohols required for lipid 
solubilization crosslink 
collagen and increase 
tissue stiffness. 
116,143,144
Composite Tissues/Organ Fragments 
Trachea 
Nerve 
Testes 
Uterus 
Freeze/thaw, osmotic 
solutions, detergent 
treatment, enzymatic 
treatment, rinse. 
Detergents can reduce 
growth factor content, 
denature and loosen 
collagen network.  
Residual detergent may 
effect cell migration and 
remodeling. 
145-150
Whole Vital Organs 
Liver 
Lung 
Kidney 
Pancreas 
Freeze/thaw, perfusion of 
decellularization solutions. 
Pressure associated with 
perfusion can disrupt 
ECM. 
Vascular basement 
membranes will be 
affected by solutions 
used for 
decellularization. 
151-156
3.3 DECELLULARIZATION AGENTS AND TECHNIQUES 
Decellularization protocols have been described for nearly every tissue in the body. The 
decellularization methods must be tuned to the tissue of interest and ultimately the intended use 
of the decellularized tissue. It is not uncommon for vastly different protocols, with varied 
detergents and delivery methods, to be described for decellularization of the same tissue. 
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3.3.1 Physical methods 
3.3.1.1  Freeze-thaw: Numerous studies have used multiple freeze-thaw cycles as a method for 
cellular disruption.  This technique can minimize the amounts of chemical agents required for 
effective decellularization.  It has been shown that freeze-thaw cycles do not significantly alter 
the mechanical properties of the ECM 157,158.  Freeze-thaw cycles produce minor disruptions in 
the tissue ultrastructure.  To minimize adverse effects on tissue architecture without impeding 
cell lysis, the use of a cryoprotectant such as 5% trehelose has been suggested 159.    
3.3.1.2    Agitation and immersion: One of the most commonly used techniques for tissue 
decellularization is immersion in chemical, detergent, and/or enzymatic solutions with 
mechanical agitation. Protocols have been described for numerous tissues, including urinary 
bladder 160,161, esophagus 162,163, trachea 84,164, skeletal muscle 165,166 heart valves 167,168, 
peripheral nerve 169, spinal cord 116,170, cartilage 171,172, and dermis 173,174. The length of time for 
each protocol is dependent upon factors such as the degree of agitation and mechanical 
disruption, the concentration and type of chemical/detergent/enzyme used, and the source 
tissue thickness and density. Thin tissues such as the urinary bladder or small intestine may be 
readily decellularized by agitation over a short period of time (e.g., 1-2 hours) of exposure to 
relatively mild peracetic acid. For thin tissues in particular, the degree of cellular removal is a 
function of the aggressiveness of agitation 175. More dense tissues such as dermis and trachea 
require much longer exposure (e.g., 12-72 hours) to combinations of solutions of enzymes, 
alcohols, and/or detergents with constant agitation.  
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Table 4. Esophageal tissue decellularization protocols 
Species Rats (Fischer) Pig (newborn) Rats (Wistar) Pig Pig 
Form 
Intact full 
thickness 
Intact full 
thickness 
Intact full 
thickness 
Intact full 
thickness 
esophagus 
Mucosa and 
submucosa 
Method of 
delivery for 
decellularization 
agent 
Immersion 
and agitation 
rate = N/A 
Immersion Immersion and 
agitation 
rate = N/A 
Luminal 
perfusion, 
rate = 
0.6mL/min 
Immersion and 
agitation on 
rotating shaker 
rate = 300 rpm 
Summary of 
decellularization 
protocol 
48h 10mM 
Tris 
48h 1% Triton 
X-100
6h 400 U/ml
DNase-I/
.125 mg/ml
RNase-A
48h .5% SDS
5 cycles of: 
72h distilled 
water, 
4h 4% 
deoxycholic 
acid,  
3h 2,000 kU 
DNase-I 
24h 4% 
deoxycholic 
acid, 
12h .2 mg/ml 
DNase-1 
3 cycles of: 
24h deionized 
water,  
4h 4% 
deoxycholic 
acid, 
3h 2,000 kU 
DNase-I 
1h 1% trypsin/ 
.05% EDTA,  
30min 1M 
sucrose,   
48h 3% Triton 
X-100,
4h 10% 
deoxycholic 
acid 
2h .1% 
peracetic 
acid/4% 
Ethanol 
2h 100 U/ml 
Dnase-I 
Evaluation of 
decellularization 
efficacy 
• No nuclei
present
on H&E-
stained
section
• No nuclei
present on
H&E-
stained
section
• Lack of
MHC
antigens
• No nuclei
present on
H&E-
stained
section
• DNA
concentrati
on: 140
ng/mg
• No nuclei
present on
H&E-
stained
section
• DNA
concentrati
on: 500
ng/mg
• No nuclei
present on
H&E- and
DAPI-
stained
sections
• DNA
concentrati
on: 50
ng/mg
Reference Bhrany, 2006 Marzaro, 2006 Ozeki, 2006 Totellini, 2012 Keane, 2012 
A number of protocols have been described to achieve decellularization of esophageal 
tissue. These protocols have varied combinations of detergents and enzymes to achieve the 
same goal of decellularization (Table 4). Ionic detergents are used in each of the published 
protocols. Bhrany et al 176 used an SDS-based solution while Marzaro et al. 163, Ozeki et al 177, 
Totonelli et al 178, and Keane et al 162 used a 4% sodium deoxycholate solution as the main 
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decellularization agent. Each of the protocols also required an endonuclease (DNase and/or 
RNase) to remove residual nucleic acids. It is noteworthy that the measurement of 
decellularization efficacy used in each study was unique and common criteria were not used. 
Decellularization efficacy is discussed in more detail in a later section. Undoubtedly, the 
resultant esophageal ECM for each protocol was distinct and unique. The “optimal” technique 
will depend upon the intended use of the ECM scaffold and upon factors such as 
cytocompatibility and intended clinical application.  
Table 5. Effects of decellularization on tissue mechanical properties 
Tissue source species Pig Pig Rat 
Delivery method of 
decellulariazion agent 
Immersion Immersion and 
agitation on rotating 
shaker at 300 RPM 
Immersion 
Summary of protocol 17 cycles of: 
48h Deionized water 
4h 4% deoxycholic acid 
4h 2,000 kU DNase-I 
48h 3% Triton X-100 
2h .1% peracetic 
acid/4% Ethanol 
2 cycles of: 
4h 4% deoxcholic acid 
3h 50kU/ml DNAse-1 
41h Deionized water  
Measured effects on 
mechanical properties 
• Maintained strain
ability similar to
native trachea
• Decrease in
tracheal volume
compared to native
trachea
• Increased tissue
compliance
compared to
native trachea
• Maintained strain
ability similar to
native trachea
• Decreased elastic
modulus compared
to native trachea
 Immersion and agitation protocols have also been investigated for the decellularization 
of tracheal tissue. However, compared to the esophagus, effective decellulariarization of the 
trachea is challenging due to the presence of hyaline cartilage rings. As a result, the protocols 
described by Remlinger et al. 84, Jungebluth et al 179, Zang et al , 180, and Haykal et al 181 result 
in a tracheal matrix that contains residual chondrocyte material within the tracheal rings. These 
groups propose that decellularization reduces antigenicity (measured by the reduction or loss of 
41 
MHC antigens) of the scaffold to a degree that allows tissue remodeling to occur. Each of the 
protocols also results in measureable alternations to the tissue mechanics (Table 5). Whether 
these effects are critical to the clinical use is debatable as Macchiarini et al 182 adapted the 
protocol described by Jungebluth et al 179 and showed that implantation of decellularized human 
tracheal ECM reseeded with autologous airway epithelial and bone marrow cells provides for 
mechanical properties that allow relatively normal function in the immediate post operative 
period and absence of evidence for classic tissue rejection. Elliott et al 183 also reported the 
successful use of a similar construct in a pediatric patient. At two years post-surgery, the patient 
had a functioning airway with the construct exhibiting appropriate growth thereby eliminating the 
need for future surgical interventions 183.  
3.3.1.3  Use of pressure for decellularization: Pressure gradients can be applied to tissue  
during decellularization to accelerate and improve the efficiency of delivering cell-lysing agents 
into the tissue and forcing cellular debris out of the tissue. For hollow tissues such as blood 
vessels and the intestinal tract, luminal perfusion with a pressure gradient can be useful. 
Montoya et al 184 compared the use of luminal perfusion vs. agitation alone in the 
decellularization of umbilical veins. The study showed that the pressure-based decellularization 
process with a flow rate of 50 mL/min with pulse frequency of 2 Hz removed all cells from the 
tissues as determined by histologic examination. In contrast, traditional rotary agitation (100 
RPM) showed retention of whole cells and cellular components. This study also showed that the 
use of a pressure gradient compared to passive diffusion techniques has only minor effects on 
the mechanical properties and molecular components of the resulting ECM construct.  Bolland 
et al 185 have used a pressure gradient to decellularize urinary bladder tissue by combining 
immersion and agitation with cyclic bladder distension.  The authors showed that cytoskeletal 
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components of the smooth muscle cells are maintained but the basement membrane 
components are removed during the decellularization process. 
High hydrostatic pressure has been reported as a method that can eliminate or reduce 
exposure time to harsh detergents in the decellularization of tissues. At a controlled 
temperature, Funamoto et al 186 decellularized porcine blood vessels by immersion in saline and 
subsequent exposure to increasing pressure up to 980 MPa. Normal atmospheric pressure was 
then reestablished by step-wise reduction of pressure. Sasaki et al 187 similarly decellularized 
porcine cornea using high hydrostatic pressure of over 1,000 MPa. Both studies showed that 
the use of high pressure led to more effective removal of cellular components when compared 
to detergent-based methods under normal atmospheric conditions. DNA content in tissues 
decellularized by detergent-based methods ranged from 0.3-2.3 μg/mg, but after high 
hydrostatic pressure decellularization, corneas and blood vessels contained 0.1 μg/mg and 
undetectable levels of DNA, respectively 186,187.  High hydrostatic pressure has been shown to 
reduce GAG content to a greater degree than immersion/agitation methods 188,189. It is 
necessary to avoid the freezing phase when using high hydrostatic pressure in order to maintain 
native ECM structure.  Studies have shown that the pressurization effect damages both 
collagen and elastin fibers and alters their mechanical properties 190.   
3.3.1.4  Supercritical fluids for decellularization: A recently described method of tissue 
decellularization utilizes the unique properties of a supercritical fluid. The low viscosity and high 
transport characteristics of a supercritical fluid allow for simple and short decellularization 
protocols. The advantages of supercritical decellularization include the use of an inert substance 
(e.g. carbon dioxide) for cell removal and minimal alteration of ECM mechanical properties. 
Further, tissues can be obtained in a dry condition following decellularization and thus eliminate 
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the need for lyophilization; a commonly used technique to facilitate long term storage. Carbon 
dioxide forms a critical fluid under moderate conditions (at a temperature of 32°C and pressure 
of 7.4 MPa) and has been shown to effectively remove cells from aortic tissue after only 15 
minutes when placed in an ethanol solution 191. The widespread applicability of supercritical 
fluids for decellularization of other tissues remains to be determined. 
3.3.2  Chemical and biologic agents for decellularization 
3.3.2.1   Alkalines and Acids for decellularization: Solutions at an extreme pH can increase 
the efficacy of cell removal but can impart substantial changes to the ECM constituents. 
Tomoshi et al 192 have shown that increasing the pH of an 8 mM CHAPS solution during lung 
decellularization increases the effectiveness of cell and cytoskeletal protein removal. However, 
highly alkaine CHAPS (pH 12) disrupted ECM architecture and resulted in a more fibrotic 
response compared to the lungs (less effectively) decellularized in 8mM CHAPS at pH 8 and pH 
10 following subcutaneous implantation. The use of acidic or alkaline solutions during 
decellularization therefore requires a balanced approach to achieve effective decellularization 
without severe detriment to the ECM constituents. 
Alkaline bases denature chromosomal and plasmid DNA. Commonly used alkaline 
bases include ammonium hydroxide, sodium sulphide, sodium hydroxide, and calcium 
hydroxide 173,193-196.   Such compounds have been used in the decellularization of dense tissues 
such as dermis 173,193, but alkalines are likely to degrade structural component of the matrix 
including collagen to some degree. Sheridan et al 195 used 0.5M NaOH and sonication to 
controllably degrade small collagen fibrils of decellularized pig arterial tissue to increase access 
of cells during the recellularization process.  Mendoza-Novela et al 197 showed that a calcium 
oxide treatment results in a dramatic reduction in GAG content and altered viscoelastic 
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properties of pericardial tissue.  The use of bases in a decellularization procedure can also 
eliminate growth factors from the resulting ECM and reduce mechanical properties of dermal 
ECM constructs 142.  
Acids are used to dissociate DNA from the ECM by solubilizing cytoplasmic components 
and disrupting nucleic acids. Acids can also denature ECM proteins including GAGs, collagen, 
and growth factors. It is important to optimize the dose and exposure time when acids are used 
for decellularization. Peracetic acid, applied at 0.1% (v/v) in a single wash for 2 hours, and 
combined with appropriate mechanical methods and rinsing, can thoroughly decellularize thin 
tissues such as small intestinal submucosa and urinary bladder matrix (UBM). Acids commonly 
used for decellularization include deoxycholic acid and acetic acid 177,198.  However, acetic acid 
has been shown to cause damage and removal of collagens from ECM with a corresponding 
reduction in construct strength 199. 
3.3.2.2         Non-Ionic detergents: Non-ionic detergents are generally considered to be gentle 
detergents that solubilize proteins while maintaining native protein structure and enzymatic 
activity.  However, success in achieving effective decellularization varies with non-ionic 
detergents such as X-100 196,200-206, likely as a result of differences in source tissue composition 
and architecture. For example, in attempts to decellularize aortic valve tissue, Grauss et al 207 
reported little to no cell removal for 1-5% Triton X-100 treated rat aortic valve, while Liao et al 208 
showed effective decellularization of porcine aortic valve using 1% Triton X-100. These results 
highlight the fact that differences in tissue density and cellularity require a decellularization 
process that is adapted to the tissue of interest and there is no “one size fits all” decellularization 
process. While commonly considered to be preferred detergent for decellularization procedures 
209 210, like all decellularization agents, Triton X-100 alters properties of ECM, including the 
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formation of a more open collagen network in anterior cruciate ligament ECM 211 and removal of 
GAGs in pericardial tissue 212. 
3.3.2.3    Ionic detergents: Ionic detergents are strong detergents that can completely 
disrupt cell membranes and fully denature proteins. Sodium dodecyl sulfate (SDS), sodium 
deoxycholate, and Triton X-200 are among the most commonly used ionic decellularization 
agents because they effectively solubilize cytoplasmic membranes, lipids, and DNA 184,213-216. 
SDS is commonly used to denature and unravel proteins for polyacrylamide gel electrophoresis 
(SDS-PAGE) and will also disrupt covalent bonds between proteins when used in 
decellularization procedures. To minimize adverse effects on the remaining matrix constituents 
of the decellularized tissue, protocols that use SDS would ideally use multiple low-concentration 
washes with short exposure time, or apply SDS at a decreased temperature 200. SDS can 
achieve adequate cell removal and retain collagens, glycoproteins, and fiber orientation for rat 
thick aortic heart muscular tissue 217, monkey kidney 200, and rat tendon 201. Other reports 
suggest SDS reduces GAGs by 50% 97, and significantly reduces growth factor content 173. 
Some denaturation of collagen has been reported, but SDS also targets the cytoskeletal protein 
vimentin, to completely remove the tethered nuclear envelopes 202.  It should be noted that SDS 
can be difficult to completely remove from the remaining matrix and can adversely affect 
cytocompatibility. 
3.3.2.4      Zwitterionic detergents: The net zero electrical charge on the hydrophilic groups of 
zwitterionic detergents protects the native state of proteins during the decellularization process. 
Examples of zwitterionic detergents include 3-[(3-cholamidopropyl) dimethylammonio]-1-
proppanesulfonate (CHAPS), sulfobetaine-10 (SB-10) and SB-16 213. SB-10 and SB-16 show 
greater ECM preservation and better cell removal than non-ionic detergents 215, and CHAPS 
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retains more collagen, GAGs, and elastin 99,218,219 than SDS ionic detergent while still removing 
95% of nuclear material. However, the efficiency of cell removal of zwitterionic detergents has 
been disputed 220. The use of detergents for retaining the basement membrane complex of 
urinary bladder was assessed using various detergents and surprisingly the zwitterionic 
detergent (8 mM CHAPS) were destructive to the collagen network. The basement membrane 
integrity of CHAPS treated bladders was disrupted to a similar extent as those treated with 1% 
SDS, whereas the basement membrane complex was less disrupted when other ionic 
detergents (4% sodium deoxycholate) and non-ionic detergents (3% Triton X-100) were used 
209. 
3.3.2.5   Alcohols: If cell membranes are permeablized, the polar hydroxyl groups of 
alcohols can diffuse into the cell where alcohols replace intracellular water, and lyse the cell by 
dehydration 221,222.   Ethanol or methanol may be used as a final wash to remove residual 
nucleic acids from tissue. Moreover, the nonpolar carbon chain of alcohols dissolves nonpolar 
substances such as lipids 184. Ethanol and isopropanol delipidize tissue and are used to remove 
phospholipids in liver, adipose tissue, and cornea 193,223-225. However, Levy et al 226 showed 
ethanol pretreatment of tissue alters the collagen structure by crosslinking the ECM. Lumpkins 
et al 216 used a 75% ethanol/-25% acetone mixture to decellularize the porcine 
temporomandibular joint disc. After 24 hours, the tissue had no visible cell nuclei, but was three 
times as stiff as the native tissue. 
3.3.2.6   Enzymatic agents: Enzymatic agents include proteases (e.g., trypsin, dispases), 
esterases (phospholipase A2), and nucleases (e.g., DNase, RNase), and are advantageous 
because of their specificity for biologic substrate. Trypsin selectively cleaves cell adherent 
proteins on the carboxyl side of the amino acids arginine or lysine to detach cells from the tissue 
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surface. Trypsin has been shown to be effective for decellularizing adjuvant, but long exposure 
times damage the collagen matrix 193,204,224. Meyer et al 204 showed 0.5% trypsin causes 
extensive damage to aortic valve ECM following 48h exposure. Brown et al 224 used 0.02% 
trypsin for 1h with negligible change in tissue architecture for porcine adipose decellularization. 
Prasertsung et al 193 suggest 1% trypsin not be used longer than 24h to prevent collagen 
damage in porcine dermis.  
Dispase II is a bacterial protease that selectively cleaves fibronectin and collagen IV in 
the basement membrane, and is used to separate epithelial sheets from the substratum 227,228. 
Dispase II is used in the initial steps of decellularization for many tissues, including porcine skin 
and corneas, but requires subsequent treatment with other agents to achieve adequate 
decellularization 193,229. The decellularization agents that are used in conjuncton with Dispase 
depend upon tissue specific factors. For example, porcine corneas can be decellularized with 4 
mg/ml Dispase II for 45 min followed exposure to hypertonic (12h in 1.5 M NaCl at 200rpm) or, 
more effectively, ionic detergent (12h in 0.1% SDS at 200rpm) 228. Dispase II (0.24 mg/ml for 3h) 
was also used to decellularize porcine skin but required pretreatment in strongly alkaline 20% 
sodium sulfide, hypertonic 1M NaCl, 85% glycerol, and 2/1 (v/v) chloroform/methanol for hair, 
epidermis, and fat removal 193. 
DNase and RNase are endonucleases that hydrolyze deoxyribonucleotide and 
ribonucleotide chains, respectively. Typically, these enzymatic agents are added to detergent 
treatments if effective decellularization is not achieved with detergents alone, to help remove 
residual DNA 205,206,230,231.  When a 24-hour SDS treatment of rat aortic valves still had remaining 
nuclei, Grauss et al 230 added an additional 1 hour step of DNase (20 ug/mL) and RNase (0.2 
mg/mL) to produce a completely acellular material based on hematoxylin and eosin staining. 
Likewise, phospholipase A2 is often added to detergent treatments. Phospholipase A2 can 
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hydrolyze the phospholipid component of tissues such as cornea, which preserves the collagen 
ultrastructure and proteogylcans, but can result in reduction in GAGs 232,233.   
A special consideration when using enzymatic methods for decellularization is activity 
inhibition by natural protease inhibitors released from lysed cells. Prasertsung et al 193 found the 
activity of trypsin to decrease by 60% after 12 hours, and cell removal percentage significantly 
increased with more frequent enzyme refreshments.  The addition of certain protease inhibitors 
(e.g., phenylmethylsulfonyl fluoride (PMSF), aprotonin, leupeptin) may partially ameliorate this 
limitation 175.  
3.3.2.7   Chelators and toxins: Ethylenediaminetetraacetic acid (EDTA) and ethylene glycol 
tetracetic acid (EGTA) are commonly used chelating agents that bind divalent metal cations at 
cell-adhesion sites of the ECM. This sequestering causes cell dissociation from the ECM. EDTA 
and EGTA can be used with trypsin 118,206,221,234 or detergents 99 to ensure complete removal of 
cell nuclei while retaining the major constituents of the ECM. However, this procedure may 
leave some cellular remnants 206,221. Because the successful applications of EDTA and EGTA 
are typically used in combination with other decellularization agents, the direct effect of these 
chemicals on ECM has not been determined. 
Latrunculin B, a marine toxin, offers an alternative to detergent methods as a powerful 
disruptor of the actin cytoskeleton. When latrunculin B was applied to skeletal muscle with 
hypertonic solutions and DNAse, no intact nuclei remained in the tissue. GAGs were reduced by 
40%, but collagen content and fibrillar ultrastructure remained largely unchanged 166.  
3.4  PERFUSION DECELLULARIZATION OF WHOLE ORGAN CONSTRUCTS 
Vascular perfusion is a technique that is intended to preserve the three-dimensional architecture 
of an organ while eliminating the parenchymal cell population. Since all cells are in close 
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proximity to a vascular network, perfusion through the vasculature is an efficient method for 
delivery of decellularizing agents.  For obvious reasons however, effects of these agents upon 
the components of the vascular basement membrane must be considered when perfusion 
techniques are used. 
Decellularization of the heart via vascular perfusion has been used to generate a three-
dimensional scaffold that preserves the geometry of the native organ. By cannulating the aorta, 
Ott et al 235 have shown that retrograde perfusion of decellularization agents, including 1% SDS 
and 1% Triton X-100, is an effective method for removal of cell material from a rat heart with the 
vascular network remaining intact throughout the process. Recellularization with cardiomyocytes 
showed that the ECM was compatible with cell growth and the recellularized tissue had a small 
degree of contractility. Wainwright et al 87 have shown that the vascular perfusion can be scaled 
up to larger organs using a porcine heart. While still using retrograde coronary perfusion, the 
decellularization of the porcine heart required the successive perfusion of trypsin and 
detergents, and a progressive increase of perfusion pressure. 
Perfusion decellularization, alone or in combination with tracheal flushing, has been 
applied to lung tissue by a number of investigators 236-240 These groups have demonstrated that 
perfusion decellularization is effective both in small animal models as well as large animal and 
human lungs. However, the methodology has varied significantly among studies as outlined in.  
Several groups began decellularization procedures with freeze/thaw cycles.  Cortiella et al 
demonstrated that freezing was necessary to completely remove nuclei and DNA 241. Perfusion 
with detergent solutions is common in lung decellularization procedures, however the type of 
detergent and length of exposure time vary dramatically.  Ott et al 242 used vascular perfusion of 
1% SDS at physiologic pressure to decellularize rat lungs in 2 hours. Another method published 
by Peterson et al 99 utilized the zwitterionic detergent, CHAPS, and perfused the airway 
compartment via the trachea rather than the vasculature. Price et al 243 perfused both the airway 
50 
and vascular compartments but did not use continuous perfusion techniques. Instead, the lungs 
were repeatedly incubated under static conditions in solutions of Triton X-100, sodium 
deoxycholate, DNase, and bleach. Cortiella et al 114 perfused lungs via the airway compartment 
with 1% SDS while the tissue was circulated in a bioreactor system for approximately five 
weeks. Nichols et al perfused lungs with 1% SDS for five days following a freeze/thaw cycle 244. 
All five groups showed that the lung ECM could be repopulated with cells. Cortiella et al 114 used 
a homogenous mouse embryonic stem cell population for reseeding and showed that the ECM 
was capable of promoting site-appropriate differentiation without the addition of further growth 
factors. After reseeding the decellularized lungs with cells, orthotopic transplantation was 
performed by Ott et al 242 and Peterson et al 99. Vascular leakage was evident upon implantation 
in recipient rats in both studies, and these lung constructs did not function for more than a few 
hours.  Despite significant differences in decellularization techniques, all groups have shown 
removal of nuclei and reduction in DNA content as well as preservation of lung microstructure 
together with the major components of the ECM such as collagen, laminin, elastin, and GAGs. 
Further studies are necessary, however, to compare the effects of each protocol on the ECM 
composition and, more importantly, on the suitability for recellularization and the host response 
following implantation.  
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SDS 
149,153,245,248-253
• Improves removal of
cytoplasmic and nuclear
material
• Effective for cellular
removal when used alone
• Concentration and
exposure time vary widely
among protocols and for
different source animals
• More detrimental to
mechanical properties
than other detergents
• Residual SDS is harmful
Triton X-100 
149,153,245-248,250-253
• Only effective for cellular
removal when used in
conjunction with other
agents
• Concentration and
exposure time vary widely
among protocols
• Effective for removal of
residual SDS
Sodium Deoxycholate 
149,251
• Not sufficient for cellular
removal when used
without additional
decellularization agents
• Ionic detergents damage
matrix components 
Trypsin 
246,251
• Only effective for cellular
removal when used in
conjunction with other
agents
• May be used to reduce
amount or time of
exposure to harsh
detergents
• Can damage collagen
structure
Peracetic Acid 
246,Wang, 2014 #357,251
• Not effective for cellular
removal when used alone
• Can denature ECM
proteins, damaging
collagen and reducing
growth factor content
Ethanol 
246
• Not effective for cellular
removal when used alone
• Can alter ECM structure
by crosslinking collagen
Ammonium Hydroxide 
247,251
• Effective for cellular
removal when used in
conjuction with Triton X-
100
• The combination of
ammonium hydroxide and
Triton X-100 is effective
for decellularization and
maintains mechanical
properties better than
SDS/Triton X-100
The liver is another example of an organ that has been decellularized by perfusion. 
Antegrade perfusion via the portal vein has resulted in a decellularized tissue with maintained 
vascular networks. Table 6 highlights the techniques and agents that have been used for 
perfusion-based liver decellularization along with considerations for the use of each agent. 
Uygun et al 97 used increasing concentrations of SDS (0.1-1%) followed by 1% Triton X-100 to 
Table 6. Results and considerations for varying decellularization methods 
Method/Agent Result Considerations 
Freeze/thaw 
149,245-247
• Not required for complete
decellularization
• May be useful for tissue
storage
• Effects of freeze/thaw vs.
fresh have not been
examined
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achieve decellularization of rat liver whereas the protocol published by Shupe et al 254 used 
increasing concentrations of Triton X-100 followed by 0.1% SDS. Shupe et al also demonstrated 
that perfusion with Triton X-100 alone was not sufficient for decellularization and SDS was 
required for complete nuclear removal. The protocol used by Uygun et al was optimized by 
DeKock et al 250 who decellularized rat liver with 1% Trition X-100 follwed by 1% SDS in 1 hour.  
Soto-Gutierrez et al 255 published an effective decellularization protocol that, unlike those 
previously reported, excludes the use of harsh detergents, such as SDS. Using this method they 
report that growth factor content retained within the matrix was 30-50% of the native tissue. 
Kajbafzadeh et al 251 compared the protocol developed by Uygun et al to 4 other protocols for 
the decellularization of sheep liver.  The authors determined that increasing concentrations of 
SDS followed by Triton X-100 achieve effective decellularization, however, the mechanical 
properties of the resulting ECM are poor compared to protocols that do not use SDS.  They 
suggest that the best protocol to completely decellularize the liver while maintaining mechanical 
properties is perfusion with 0.05% ammonium hydroxide followed by 0.5% Triton X-100.  
Following decellularization, similar to other tissues, the liver is a translucent and white acellular 
matrix. The vascular network is maintained and can be visualized by perfusion of a colored dye 
(Figure 3).  Multiple studies have shown that integral components of the basement membrane, 
collagen IV and laminin, remain in the decellularized liver while intact cells are removed 
245,246,248-250.  Following decellularization, the matrix has been recellularized, via portal vein 
perfusion, with rat liver progenitor cells 248, human fetal liver cells 249, and human liver progenitor 
cells 153.  For up to 8 hours following heterotopic transplantation in a rat, the hepatocytes 
maintained functional synthesis of albumin and lactate dehydrogenase 248.  
Intact renal constructs have been prepared by perfusion decellularization. Ross et al 256 
developed a protocol for decellularization of mouse kidney using solutions of Triton X-100, 
DNase, and SDS. The ECM was supportive of tissue-specific differentiation of embryonic stem 
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cells. Song et al 257 used SDS to perfuse cadaveric rat kidneys at a pressure of 40 mm Hg. 
Renal ECM components were maintained including the glomerular and tubular 
basementmembrane, which serve essential roles in renal filtration and reabsorption. The 
scaffolds were recellularized with endothelial cells and a heterogeneous neonatal kidney cell 
population. In vitro, the recellularized construct produced urine and cleared creatine nearly 20% 
as well as cadaveric kidney, with urine production also demonstrated following orthotropic 
transplantation. For more information on perfusion decellularization of whole organ constructs 
refer to 258 and  77. 
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3.5  EFFECTS OF RESIDUAL DETERGENTS FROM DECELLULARIZATION 
It has been suggested that the presence of residual SDS within ECM biomaterials has severe 
cellular toxicity and may be responsible for discouraging cellular ingrowth 149,206. Rieder et al 206 
demonstrated that scaffolds decellularized using SDS were unable to be recellularized due to 
Figure 3. Perfusion decellularization of rat liver. The cadaveric rat liver (A) is cannulated 
through the portal vein. Following the decellularization protocol, the matrix is devoid of cells 
and has a white/translucent appearance (B). Perfusion decellularization allows for the 
maintenance of an intact vascular network, visualized by injection of a colored dye (C). Scale 
bar = 1 cm.  
This image cannot currently be displayed.
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the toxic effects of the ionic detergent, whereas, scaffolds prepared with 0.25% tert-octylphenyl-
polyoxyethylen in combination with sodium-deoxycholate enabled host recellularization.   
Cebotari et al 157 examined detergent levels remaining in the wash solution following 
decellularization with SDS or a combination of SDS and SDC using solid phase extraction and 
high performance liquid chromatography (HPLC).  They determined that a detergent 
concentration of <50 mg/L in the wash solution did not influence the receptiveness of the matrix 
to reseeding with endothelial cells.  The authors also showed that the combination of SDS and 
SDC was more easily washed out from the tissue. 
Another method for quantification of residual SDS takes advantage of the fact that SDS 
and methylene blue produce blue compounds under acidic conditions.  This colorimetric assay 
allows for quantification of residual SDS in the ECM scaffold.  The lower cytotoxic threshold for 
SDS is approximately 10 ug/mg dry weight.  Wang et al showed that following SDS perfusion 
with BSA or PBS reduces the residual SDS to well below this level and washing with Triton X-
100 results in almost complete removal of residual SDS. 
Sansoto et al 259 assessed the effects of the SDS compared to high hydrostatic pressure 
on the decellularization of uterine tissue and their subsequent effects on tissue regeneration in 
vivo. Their methods achieved effective decellularization as shown by H&E staining and 
quantification of residual DNA.  Analysis of the in vivo host response showed that cells migrated 
into the area surrounding the grafts but only the sample that was decellularized using high 
hydrostatic pressure stimulated cell migration into the graft.  Cells did not migrate into 
decellularized grafts generated using SDS treatment.   
Decellularization methods can clearly affect the host response to biologic scaffolds.  
However, it remains possible that these effects are due to differences in structure and 
composition as a result of the decellularization process rather than due to residual detergent in 
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the material after processing with SDS.  Gratzer et al 260 found that the level of repopulation and 
viability of cells were the same regardless of washing technique and resulting level of residual 
SDS in the tissue.  These data suggest that alterations in tissue matrix biochemistry or structure 
from SDS treatment are responsible for low cell repopulation observed in SDS decellularized 
anterior cruciate ligament.  Additional studies are necessary to determine if this holds true for 
other tissues. 
3.6  ESTABLISHING METRICS FOR EFFECTIVE DECELLULARIZATION 
While it is unlikely that any decellularization protocol will completely remove all cell remnants, 
cell components that do remain (e.g., DNA, phospholipids) can be quantitatively assayed. Until 
recently, no quantitative metric has been suggested to evaluate the efficacy of a 
decellularization protocol 175. It is important to note that for most studies reviewed in the present 
manuscript, no objective criteria were used to assess degree of decellularization. Only one 
study to date has related quantitative degree of decellularization to host remodeling outcome 138. 
Commercially available scaffolds are regulated by the FDA and therefore are subject to 
sterility guidelines (see section 5) and endotoxin amounts. Endotoxin is a complex 
lipopolysaccharide (LPS) that is a major part of the gram-negative bacteria cell wall. Endotoxins 
are especially abundant in the gut, the tissue source for small intestine submucosa. The FDA 
standard for a biologic scaffold eluate is 0.5 EU/mL, and 0.06 EU/mL for cerebrospinal devices. 
While the exact level of endotoxin concentration necessary to elicit an adverse reaction is 
unknown, dermal matrices spiked with 20 times the FDA limit had similar immune responses to 
devices below the FDA standard suggesting that the current endotoxin standard may fall well 
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below the levels required to elicit an acute proinflammatory response 261. While strict guidelines 
for some metrics do exist, the FDA does not yet have guidance related to remnant cellular 
content in commercially available decellularized tissues. 
The definition of effective decellularization varies greatly across published reports. 
Decellularization has been defined as a lack of positive staining for intact nuclei and cellular 
antigens (e.g., MHC-1). Other definitions include a “significant” reduction in dsDNA content 
compared to native tissue as criteria for decellularization.  The increased clinical use of ECM-
based scaffolds is prompting the need for established decellularization guidelines. A recent 
report recommended tissue decellularization criteria that utilize nucleic acid content as a basis. 
The three-part criteria include: 1) No visible nuclei upon histologic evaluation via hematoxylin 
and eosin and DAPI stains, 2) The remaining double stranded DNA (dsDNA) content should not 
exceed 200 base pair in length, and 3) the amount of dsDNA should not exceed 50ng per mg of 
dry weight of the material 175. These criteria were shown to make a difference in the host 
response in a separate study 138.  
The criteria referenced above may be too stringent, sufficient, or too liberal; and these 
criteria may not be appropriate for all source tissues from which such bioscaffolds are prepared. 
It is unknown but likely that the threshold level of cellular content necessary to elicit a 
proinflammatory host response will vary depending on anatomic location. In addition to nucleic 
acid content, it may be necessary to assay cellular components such as remnant mitochondria.  
Mitochondria are evolutionarily derived from bacteria, bear damage associated molecular 
patterns (DAMPS) and may elicit a proinflammatory host response if present above some 
threshold level 262.  As a greater understanding of the association between specific cellular 
components and the host response is achieved, the criteria may need to be revised or 
supplemented. 
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3.7  TERMINAL STERILIZATION OF DECELLULARIZED TISSUES 
There are many examples of biologic scaffold products composed of decellularized tissues.  
These include dermis, small intestine, urinary bladder, mesothelium, pericardium, and heart 
valve.  These products are used for repair applications in soft tissue, tendon, chronic wounds, 
breast reconstruction, opthamology, dentistry, valve replacement and others.  Biologic scaffolds 
from decellularized xenogenic source tissue are typically regulated by the Food and Drug 
Administration (FDA) as medical devices.  This classification requires that the methods used to 
terminally sterilize ECM products are adherent to directed guidelines regarding bacterial load 
(e.g., ISO/DIS 1135-1, ISO/DIS 1137-1).  Incubation with peracetic acid has been used as a 
decellularization agent for biologic scaffolds and has also been shown to be an effective 
sterilization method for polymeric scaffolds 263.  However, incubation with acid may not provide 
sufficient penetration of ECM bioscaffolds to achieve satisfactory sterilization.  Terminal 
sterilization methods such as ethylene oxide exposure, gamma irradiation, and electron beam 
irradiation achieve effective sterilization but are known to alter ECM ultrastructure and 
mechanical properties.  The effect of terminal sterilization on ECM structure is a particular 
concern for hydrogel forms of ECM because sterilization methods can have significant effects 
on the rheologic properties of the hydrogel.  While all biologic scaffolds must pass sterility 
testing prior to their approval for clinical use, it will be important for regulatory agencies to 
consider the effects of terminal sterilization on the structure and biologic activities of these 
materials. For more information on terminal sterilization, see Appendix 12.4 (page 211). 
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4.0 THE HOST RESPONSE TO ECM3
4.1  ABSTRACT 
The clinical use of biologic scaffold materials has become commonplace. Such scaffolds are 
composed of extracellular matrix (ECM), or components of ECM, derived from allogeneic or 
xenogeneic tissues. Such scaffold materials vary widely in their source tissue, processing 
methods, and sterilization methods. The success or failure of an ECM scaffold for a given 
application is dependent on the host response following implantation; a response that is largely 
mediated by the innate immune system and which is influenced by a numerous factors, 
including the processing methods used in the preparation of biologic scaffolds. The present 
chapter reviews various aspects of the host response to biologic scaffolds and factors that affect 
this response. In addition, some of the logistical, regulatory, and reconstructive implications 
associated with the use of biologic scaffolds are discussed. 
3 Portions of this chapter were adapted from the following publication: 
Keane TJ, Badylak SF. The Host Response to Allogeneic and Xenogeneic Biologic Scaffold Materials. 
Journal of Tissue Engineering and Regenerative Medicine, February 2014. DOI:10.1002/term.1874 
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4.2  INTRODUCTION 
Scaffolds and surgical mesh materials composed of mammalian extracellular matrix (ECM) are 
commonly used for the repair and reconstruction of a variety of tissues including 
musculoskeletal tissues 90,264, cardiovascular structures 265,266, esophagus 92,96, lower urinary 
tract 267,268 , and body wall 269,270. These materials are typically prepared by the decellularization 
of a source tissue such as dermis, small intestine, or urinary bladder, among others (Table 1). 
Scaffolds are derived from allogeneic or xenogeneic source tissues and can have unique 
regulatory considerations that are dependent upon the tissue of origin.  
Clinical outcomes vary from excellent 1,92,271,272 to poor 271,273 and the reasons for this 
disparity in clinical performance are partially understood. Processing methods play a prominent 
role in the host response to biologic scaffold materials. For example, inadequate 
decellularization of the source tissue results in retained cellular debris within the extracellular 
matrix and elicits a proinflammatory response 138. Similarly, sterilization methods 161 and 
lyophilization 274 affect mechanical and material properties and the associated clinical 
performance. Age of the animal from which the tissue is harvested has been shown to affect 
mechanical and compositional properties of porcine derived xenogeneic scaffold material 105. 
Finally, and the main focus of this manuscript, a factor that would logically play a prominent role 
in the clinical outcome is the host immune response to these allogeneic and xenogeneic 
materials. With the exception of studies focused upon the Galα1-3Galβ1-4GlcNAc-R (Gal) 
epitope 275-277, there has been surprisingly little attention given to this issue.  
The number of biologic scaffolds composed of allogeneic and xenogeneic ECM 
implanted during the past 15 years worldwide exceeds several million, including many cases of 
individual patients receiving repeated implants. No documented report of zoonotic infection 
exists following xenogeneic whole organ or tissue transplants. Therefore the use of these 
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materials can clearly be considered safe from the standpoint of infectious disease.There have 
been suggestions of an immune-mediated cause of unfavorable outcomes 278,279, but evidence 
based support of such a phenomenon in the clinical setting is lacking.  It should be noted 
however that the recipient uniformly and immediately responds to presence of these materials 
following implantation. In fact, such a response is not only acceptable but necessary for a 
constructive remodeling outcome 280. The present manuscript describes various aspects of the 
host response to allogeneic and xenogeneic scaffold materials and the factors that affect this 
response.  
4.3  RAW MATERIAL SOURCE OF BIOLOGIC SCAFFOLDS 
Tissue sources from which ECM scaffolds are prepared include humans (allografts) and 
porcine, bovine, or equine tissue (xenografts). Whether the ECM is derived from allogeneic of 
xenogeneic species., the composition of ECM constructs is affected by donor state (e.g., age, 
disease state). Further, the anatomic site of the raw material source has a strong influence upon 
the device mechanical and material properties, the methods required for adequate 
decellularization and sterilization, and the eventual host response.  
The composition, ultrastructure, and mechanical properties of ECM derived from 
different tissues/organs are distinct; a logical finding since each tissue/organ has a unique 
function. For example, ECM derived from small intestinal submucosa has a preferred collagen 
alignment that leads to anisotropic mechanical behavior of the scaffold, with the preferred 
(longitudinal) fiber direction showing greater stiffness and strength than the circumferential 
direction 101. The collagen fiber alignment of the urinary bladder submucosa and tunica propria, 
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in contrast, shows a much more isotropic fiber alignment than SIS 102. An understanding of the 
mechanical properties from different tissues may be an important consideration for matching the 
choice of ECM source tissue with a specific clinical application. 
The properties of biologic scaffolds also vary with the age of the source animal from 
which the tissue is harvested. Fetal and neonatal mammals have greater wound healing and 
regenerative capacity compared to adult mammals 103. The composition of fetal and neonatal 
ECM is distinctly different from that of adults and plays an important role in tissue development 
104. In fact, distinct remodeling characteristics exist that are attributable to source animal age.
Biologic scaffolds harvested from neonatal animals have been shown to promote a more robust 
constructive remodeling response when compared to scaffolds derived from market weight and 
older animals 105. 
4.4  INNATE AND ADAPTIVE RESPONSE TO BIOLOGIC SCAFFOLD MATERIALS 
The innate and acquired immune response to whole organ transplantation is well recognized 
and understood. However, the response to acellular xenogeneic or allogeneic biologic scaffold 
materials has been studied much less and is   poorly understood compared to that of the 
response to whole organs. Preformed circulating antibodies and/or T cell activation are central 
phenomena to whole organ rejection. Tissue destruction occurs as a result of complement 
activation or direct T cell-mediated lysis of donor cells, activation of accessory cells, and/or 
alloantibody production 281. As the genetic difference between host and donor cells increases, 
the severity of the adverse immune response increases. Xenografts (i.e., tissue or organ 
transplants between different species) are not used clinically because such grafts (i.e., the 
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resident cells) evoke a robust and hyperacute or acute rejection response. Ultimately, whether 
mediated by humoral or cellular mechanisms, the host immune recognition of donor antigens 
present on transplanted cells incites a response that, in the absence of immunosuppression, 
results in graft rejection.  
The host response to biologic scaffold materials composed of (acellular) ECM involves 
both the innate and acquired immune system but is distinct and different from the response to 
whole organs which contain donor cells. By definition, materials composed of ECM are devoid 
of cells. The immune response is affected by ECM device-speciﬁc variables including the 
intended clinical application (e.g., anatomic site of implantation), the source of the raw 
material/tissue from which the ECM is harvested, and the processing steps involved in 
manufacturing an approved medical device. The implantation of an ECM scaffold is inevitably 
coupled with tissue injury at the surgical site. The default mammalian host response following 
tissue injury includes a well-documented series of overlapping events (hemostasis, 
inflammation, proliferation, and remodeling) that culminates in the deposition of dense fibrous 
connective tissue (i.e., scar) 282. The clinical success of a biologic scaffold is largely attributed to 
its ability to modulate this default wound healing response toward the mitigation of scar tissue 
deposition and the formation of site-specific functional tissue (i.e., constructive remodeling) 283. 
The mechanisms by which ECM constructs promote constructive remodeling are only partially 
understood. 
An adaptive immune response to biologic scaffolds has been described previously; 
specifically, a correlation between T helper (Th) cell response and constructive remodeling 
outcomes has been shown following implantation of an ECM scaffold derived from porcine small 
intestinal submucosa (SIS-ECM) 284,285. T cells are classified as either cytotoxic or helper T cells. 
Further, Th cells are phenotypically divided into Th1 or Th2 effector cells, which have a distinct 
immune response with respect to cytokine and chemokine expression and effector action. Th1 
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polarization is associated with a pro-inflammatory response, whereas Th2 polarization is 
associated with a regulatory, anti-inflammatory, wound healing and constructive remodeling 
response. In a mouse model of abdominal wall defect, SIS-ECM elicited Th2 cytokine 
expression but not Th1 cytokine expression and constructive remodeling 285. Similarly, a clinical 
study with the use of SIS-ECM showed that a Th2 polarized cytokine and antibody isotype 
profile was associated with tissue acceptance 286. Repeat exposure to xenogeneic ECM failed to 
cause sensitization or a Th1 type response in a mouse model, and in fact, accentuated the Th2 
response 284. Although recipients of SIS–ECM scaffolds recognize the material as “non-self” and 
produce antibodies, these antibodies appear to be limited to the Th2 profile, a finding consistent 
with their ability to induce constructive remodeling and avoid a classic tissue rejection response 
287. In fact, this response may be one of the primary mechanisms by which ECM scaffolds
produce constructive tissue remodeling. 
4.5  MACROPHAGE PARTICIPATION IN ECM MEDITATED TISSUE REMODELING 
While a humoral response is elicited following allogeneic or xenogeneic ECM implantation, a 
robust cellular response also occurs.   This cellular response, which consists mainly of 
macrophages, represents the innate arm of the immune system and in large part determines the 
downstream events which occur following recognition of the implanted ECM material. Several 
studies have shown the determinant role of macrophages in constructive remodeling outcomes 
280. In fact, although it may not be immediately intuitive, constructive remodeling outcomes are
delayed or inhibited when there are deficiencies in macrophage number and/or their function 
288,289. Interestingly, it has recently been shown that amphibian tissue regeneration is dependent 
upon a macrophage presence and participation 290. 
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Similar to the Th1/Th2 polarization schemes for lymphocytes described above, 
phenotypic macrophage polarization has been described. 291-294. Macrophage phenotypes exist 
along a spectrum that ranges from M1 to M2. The pro-inflammatory M1 phenotype is 
characterized by pathogen killing and facilitates classic signs of inflammation via secretion of 
proinflammatory cytokines such as IL12 and TNF-α. In contrast, the anti-inflammatory M2 
macrophage promotes immunoregulation, tissue repair, matrix deposition and constructive 
tissue remodeling. The concept of macrophage phenotype has been evaluated in the context of 
the host response to implanted ECM scaffold materials and has been shown to be a strong 
predictor of bioscaffold remodeling and functional outcome 132,133,295. ECM scaffolds that 
promote constructive remodeling are associated with a prevalence of M2 macrophages. The 
default host response to tissue injury is characterized by an early M1 macrophage 
predominance followed by a late switch to M2, occurring concurrently with the resolution of 
inflammatory processes and generally results in the formation of localized scar tissue. However, 
certain biologic scaffolds have been shown to modulate the default immune response. During 
ECM-facilitated remodeling, the early macrophage response is predominantly M1 with a 
relatively quick shift to M2 prevalence after about 72 hours 133. As remodeling continues, the M2 
macrophage phenotype is sustained and is usually associated with a site-appropriate tissue 
remodeling outcome rather than scar tissue formation.  
It is noteworthy that chemical crosslinking of ECM scaffolds which inhibits bioscaffold 
degradation is associated with an M1 proinflammatory macrophage response. Furthermore, 
remnant cellular material within ECM scaffolds (i.e., ineffective decellularization) will alter the 
host response and promote an M1 macrophage response 138,296. Although much remains to be 
understood regarding the innate immune response to ECM based biologic scaffolds, it is clear 
that such a response is not only desirable, but required if constructive and functional remodeling 
outcomes are to be expected. 
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4.6  XENOGENIEC VS. ALLOGENEIC TISSUE SOURCE: LOGISTICAL AND 
REGULATORY CONSIDERATIONS 
There are limited studies that directly compare allogeneic vs. xenogeneic scaffolds for specific 
applications. Although allogeneic scaffold materials may be intuitively superior to xenogeneic 
materials because of genetic similarities, there are other considerations which mitigate their 
clinical utility. For example, allograft tissues and organs are in limited supply and have a greater 
risk of disease transmission than tissues of xenogeneic origin.  In contrast, xenogeneic tissues 
are typically in abundant supply through the agricultural supply chain and, as previously noted, 
the constituents of the extracellular matrix are highly conserved across species boundaries. The 
choice of allogeneic vs. xenogeneic scaffold materials is also influenced by factors that extend 
beyond biology such as regulatory, cost reimbursement, and logistical considerations, some of 
which are discussed below. Regardless of tissue origin, the importance of effective 
decellularization 175 of these ECM scaffolds, while not directly regulated, cannot be overstated 
for good remodeling outcomes.  
In the United States, the Food and Drug Administration (FDA) regulates human tissue 
products and the tissue banks that supply allografts. Tissue banks can voluntarily gain 
accreditation of the American Association of Tissue Banks (AATB) and the AATB sets industry 
standards to regulate the retrieval, processing, storage, and distribution of human tissue 
products. 
Allografts are procured from individuals whose families have consented to tissue 
donation. The tissue bank prescreens donors and the recovery of tissue occurs in hospital 
operating rooms and other settings regulated by the FDA including morgues and funeral homes. 
Donors should be relatively healthy, prescreened for HIV, Hepatitis, and any behavior that may 
compromise the integrity of the donor tissue. The FDA provides minimum requirements for 
donor screening while additional recommendations are provided by the AATB. However, the 
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ultimate responsibility of setting minimum requirements and validating procedures is the 
responsibility of the tissue bank or company marketing the product. Allogeneic biologic scaffold 
processing methods are generally proprietary, but the design and validation of processing 
methods must be in accordance with FDA Good Tissue Practices. The methods, packaging, 
and storage of the allogeneic biologic scaffolds vary widely. The FDA classifies most allogeneic 
tissue as a Human Cell and Tissue/Product (HCT/P) and not as a medical device. As a result, 
unlike xenogeneic scaffolds, there are not specific sterilization techniques or requirements for 
sterility levels for most allogeneic ECM scaffolds. 
Xenogeneic biologic scaffolds have historically been classified as medical devices by the 
FDA and must meet the requirements for a medical device. This classification has proven 
effective since safety of these materials has been established. Processing techniques used in 
the production of xenogeneic ECM scaffolds are also proprietary and include methods of 
decellularization and terminal sterilization. The device must meet a sterility assurance level that 
is appropriate for the given application. Patient-related considerations for the use of xenogeneic 
scaffolds should also be considered prior to use. For example, certain social and religious 
groups may oppose the use of animal tissue in any form 297. 
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5.0 OBJECTIVES
Ulcerative colitis (UC) is the most common form of inflammatory bowel disease, and represents 
a significant global health problem. Since the 1930s, the fundamental approach to treatment has 
not changed. Pharmacologic treatment (e.g., 5-amino salicylic acid, immunosuppressives), 
and/or surgical intervention (e.g., colectomy) have been the two basic tenets of patient care. 
Almost a century later, these two approaches remain the clinical standard of care even though 
results are unacceptable. More than 50% of patients suffer from severe systemic side effects 
and disease recurrence. We propose a distinctly different, nonsurgical/ nonpharmacologic 
approach which will: (1) abate the inflammatory “flares” not by immunosuppression but rather by 
promoting alternative activation of the local innate immune cell population, and (2) induce rapid 
replacement of the colonic mucosal barrier function not by providing a physical barrier between 
the denuded colonic submucosa and luminal contents, but rather by local stem cell recruitment, 
mitogenesis, and differentiation to restore a normal mucosal epithelial structure. 
This two-pronged approach will be tested by local delivery (enema) of naturally occurring 
signaling molecules present within a hydrogel form of mammalian extracellular matrix (ECM). 
This proposal attempts to determine whether diseased mucosa can be successfully remodeled 
into healthy mucosa using an ECM scaffold based regenerative medicine approach. Developing 
a regenerative medicine strategy to repair or replace native colonic mucosal tissue is central to 
the improvement of UC and IBD therapy, as repair of the diseased tissue and replacement with 
new, healthy tissue would essentially cure an affected patient. In stark contrast to current 
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surgical intervention, a regenerative medicine approach utilizing an ECM hydrogel would be 
non-invasive and would result in colon preservation. If successful, this therapeutic strategy 
would represent a quantum leap forward for the millions of patients affected by UC, and 
potentially identify new diagnostic and therapeutic targets for a wide variety of chronic 
inflammatory diseases. 
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6.0 CENTRAL HYPOTHESIS AND SPECIFIC AIMS
Central Hypothesis: ECM hydrogels will support constructive remodeling of GI tissue by 
modulation of the microenvironment and local immune cells. 
Specific Aim 1: To prepare, quantitatively describe, and compare gastrointestinal extracellular 
matrix (GI-ECM) bioscaffolds derived from porcine esophagus and colon.  
Corollary Hypothesis: GI tissue can be effectively decellularized while retaining tissue-specific 
properties. 
Rationale: The composition and structure of ECM are directly attributed to the cell population of 
the tissue from which the ECM is derived. The use of ECM derived from a heterologous tissue 
source has been shown to enhance remodeling outcomes in a number of tissues; however 
several unsuccessful outcomes have also been reported. Advantages of site-specific ECM (i.e., 
ECM derived from the tissue to be treated) have been recently described. It is plausible that, in 
contrast to heterologous ECM, an ECM derived from GI tissue would contain the appropriate 
biochemical constituents to support remodeling of GI tissue. Quantitatively characterizing the 
biochemical composition of different ECMs may highlight one or more molecular cues 
necessary for the maintenance of lower vs. upper GI tissue. 
Specific Aim 2: To characterize the effect of GI-ECM on the remodeling and inflammatory 
response of intestinal epithelial cells and macrophages, respectively. 
Corollary Hypothesis: Exposure of IECs to ECM will enhance their barrier function. 
Macrophages exposed to degradation products of GI-ECM will polarize towards M2.
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Rationale: Effective treatment of UC requires (1) a reduction in inflammatory state and (2) rapid 
reformation of a robust epithelial barrier. The body’s largest reservoir of macrophages is found 
in the mucosa of the GI tract 298. These macrophages are positioned in the lamina propria (LP) 
and are uniquely suited to protect against bacteria/pathogens that have breached the mucosa 
and to clear dead cells and debris while maintaining a secretome that is largely devoid of 
inflammatory cytokines 299. With UC, a defect in the integrity of the mucosal barrier leads to 
excessive uptake of luminal contents and disrupts the regulatory nature of the mucosal immune 
system. LP macrophages are increased in number in UC with enhanced production of 
inflammatory cytokines (e.g., IL1b, TNF, IL6). ECM hydrogels have been shown to induce a shift 
in macrophage phenotype towards an anti-inflammatory secretome profile (TNFαlow/IL-1βlow/
IL-1RAhigh). Therefore, it is feasible that solubilized ECM could similarly down-regulate 
macrophage production of pro-inflammatory cytokines that are known to have deleterious effects 
on the epithelial barrier 300.  
Specific Aim 3: To determine the efficacy of ECM in treating inflamed colonic mucosal tissue.  
Corollary Hypothesis: Topical application of ECM hydrogels will mitigate the inflammatory 
response in colitic rats by modulating the microenvironmental milieu towards an anti-
inflammatory state and thereby facilitating constructive remodeling of colonic mucosa.   
Rationale: Inflammation mitigation and remodeling (i.e., restoration of colonic epithelial barrier) 
is central to effect treatment of UC.  Preclinical and clinical studies have shown that ECM can 
facilitate the repair of neo-esophageal tissue following mucosal resection in both healthy and 
diseased subjects. While the mechanisms that governs ECM-mediated remodeling are not fully 
understood, positive remodeling outcomes are consistently accompanied by a temporal 
modulation of the local immune response. In-vivo, a shift towards an M2, immunomodulatory 
macrophage phenotype accompanies ECM scaffold implantation in muscle defect models. 
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Preliminary in-vitro data suggest the GI ECM degradation products also drive an M2 
macrophage bias. Preclinical studies will determine whether the effects of degraded ECM are 
robust enough to alter the tissue microenvironment from a pro-inflammatory state to one that is 
not only anti-inflammatory but also supportive of functional tissue remodeling in vivo.  
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7.0 PREPARATION AND CHARACTERIZATION OF A BIOLOGIC SCAFFOLD FROM
ESOPHAGEAL MUCOSA4 
7.1  ABSTRACT 
Biologic scaffolds composed of extracellular matrix (ECM) are commonly used to facilitate a 
constructive remodeling response in several types of tissue, including the esophagus. Surgical 
manipulation of the esophagus is often complicated by stricture, but preclinical and clinical 
studies have shown that the use of an ECM scaffold can mitigate stricture and promote a 
constructive outcome after resection of full circumference esophageal mucosa. Recognizing the 
potential benefits of ECM derived from homologous tissue (i.e., site-specific ECM), the objective 
of the present chapter was to prepare, characterize, and assess the in-vivo remodeling 
properties of ECM from porcine esophageal mucosa.  The developed protocol for esophageal 
ECM preparation is compliant with previously established criteria of decellularization and results 
in a scaffold that maintains important biologic components and an ultrastructure consistent with 
a basement membrane complex.  Perivascular stem cells remained viable when seeded upon 
the esophageal ECM scaffold in vitro, and the in-vivo host response showed a pattern of 
constructive remodeling when implanted in soft tissue.  
4Portions of this chapter have been adapted from the following publication: 
Keane TJ, Londono R, Carey RM, Carruthers CA, Reing JE, Dearth CL, D’Amore A, Medberry CJ, 
Badylak SF. Preparation and Characterization of a Biologic Scaffold from Esophageal Mucosa. 
Biomaterials, September 2013. DOI:10.1016/j.biomaterials.2013.05.052 
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7.2  INTRODUCTION 
The default mechanism of mammalian tissue repair typically results in scar tissue deposition, a 
protective and favorable response in most tissues. However, this scar tissue formation is 
associated with adverse clinical consequences including stricture in select anatomic locations 
such as the esophagus.  Preclinical studies have shown that placement of an extracellular 
matrix (ECM) scaffold derived from heterologous tissue is capable of restoring a functional 
esophagus with minimal stricture and normal esophageal motility following circumferential 
mucosal resection 93. A clinical report involving patients with stage 1 esophageal 
adenocarcinoma corroborated this finding and provided proof-of-concept in the clinical setting 
92,126.  While heterologous ECM was successful in reducing stricture formation, the remodeled 
tissue did not fully reconstitute all components of normal esophageal tissue; for example, 
glandular tissue was absent. Delivery of the scaffold also required temporary placement of an 
intraluminal stent to allow integration of the scaffold with the subjacent tissue. A possible 
advantage of a site-specific, homologous ECM could be more rapid integration and faithful 
remodeling of the esophageal mucosa. 
Recent work has described potential benefits of ECM scaffold materials derived from 
homologous tissue versus heterologous tissue when used in selected anatomic locations 109-118. 
While tissue specificity is not necessary for all therapeutic applications 92,119,120, some studies 
have shown that site-specific ECM can preferentially maintain tissue-specific cell phenotypes 
109-112, promote cell proliferation 111,113, induce tissue-specific differentiation 114, and enhance the
chemotaxis of lineage-directed progenitor cells 115-117.  It is plausible therefore that a site-specific 
esophageal mucosal ECM may promote similar effects and further improve clinical outcomes in 
esophageal mucosa repair.  The harvesting and preparation of an ECM scaffold requires tissue 
specific methodologies for optimal outcomes 274,301-304. 
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Biologic scaffolds composed of ECM, when prepared by methods designed to preserve 
structure and composition of the native source tissue, contain bioactive molecules including 
growth factors (e.g., vascular endothelial growth factor (VEGF) 136, basic fibroblast growth factor 
(bFGF) 65) and glycosaminoglycans (GAGs) 135. The composition, ultrastructure, and 
mechanical properties of an ECM construct are affected by the methods used to decellularize 
the source tissue as well as the methods of sterilization and storage of such bioscaffolds 
161,175,274. Therefore, the methods of preparing ECM scaffolds intended for use in the repair and 
reconstruction of the esophageal mucosa must be carefully considered as regenerative 
medicine strategies are developed for this intended therapeutic application. 
The objective of this chapter was to prepare, characterize, and determine the in-vitro 
cytocompatibility and in-vivo host response of ECM derived from porcine esophageal mucosa 
(emECM). Esophagi were collected and decellularized by a method sufficient to meet stringent 
decellularization criteria: specifically no visible intact nuclei by hematoxylin and eosin staining, 
remnant DNA concentration less than 50 ng/mg dry weight, and DNA fragment length less than 
200 basepairs 175. Biochemical and mechanical properties of the ECM were then characterized 
by quantitative and qualitative measures.  
7.3  MATERIALS AND METHODS 
7.3.1  Harvest and preparation of ECM from porcine esophagus 
Esophagi were harvested from market weight (240–260 lbs) pigs and split longitudinally. 
The mucosa and submucosa were isolated by mechanical separation from the muscularis 
propria. The luminal surface was gently abraded to remove squamous epithelium. The tissue 
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that remained was composed primarily of the basement membrane, lamina propria, muscularis 
mucosa, and submucosa.  This tissue was then subjected to a series of immersion treatments 
as follows: 1% trypsin/0.05% EDTA (Invitrogen, Carlsbad, CA) for 1 h at 37°C on a rocker plate, 
deionized water for 15 min, 1.0 M sucrose (Fisher Scientific, Pittsburgh, PA) for 30 min, 
deionized water for 30 min, 3.0% Triton X-100 (Sigma Aldrich, St. Louis, MO) for 48 h, 
deionized water for 15 min, PBS (Fisher Scientific) for 15 min, 10% deoxycholate (Sigma 
Aldrich) for 4 h, deionized water for 30 min, 0.1% peracetic acid (Rochester Midland Corp., 
Rochester, NY) in 4.0% ethanol for 4 h, 100 U/ml DNAse (Invitrogen) for 2 h on a rocker plate, 
followed by 15 min washes with PBS, deionized water, PBS, and deionized water. All 
treatments were performed at room temperature with agitation on a shaker plate at 300 RPM 
unless otherwise stated. For cytocompatibility evaluation and in-vivo remodeling evaluation, 
chemically cross-linked emECM (XL-emECM) scaffolds were used as negative controls. 
Chemically cross-linked bioscaffolds have been shown to consistently inhibit a constructive 
remodeling response 270,305.  Cross-linking was achieved by immersion in 0.01 M carbodiimide 
for 24 hours with multiple subsequent washes in PBS over 48 hours. All devices were 
lyophilized and sterilized using ethylene oxide.  
7.3.2  Assessment of DNA content 
DNA was extracted from representative samples (n=6) of emECM. For DNA extraction, 
lyophilized ECM scaffolds were powdered using a Wiley Mill and filtered through a 60-mesh 
screen. One hundred milligrams of lyophilized, powdered emECM was digested with proteinase 
K digestion buffer (100 mM NaCl, 10 mM Tris–HCl (pH = 8), 25 mM EDTA (pH = 8), 0.5% SDS, 
0.1 mg/mL proteinase K) at 50 °C for 24 hr. The digest was extracted twice using 25:24:1 (v/v/v) 
phenol/chloroform/isoamyl alcohol. DNA was precipitated from the aqueous phase at −20 °C 
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with the addition of 2 volumes of ethanol and 0.1 volume of 3 M sodium acetate (pH = 5.2). The 
DNA was then centrifuged at 10,000 g for 10 min and resuspended in 1 mL of TE buffer (10 mM 
Tris (pH = 8), 1 mM EDTA). 
The concentration of each extracted DNA sample was determined using Quant-iT 
PicoGreen dsDNA Assay Kit (Invitrogen) following the manufacturer’s recommended protocol. A 
standard curve was constructed by preparing samples of known DNA concentrations from 0 to 
1000 ng/mL and concentration of DNA was found by linear interpolation of the standard curve. 
Samples were read using SpectraMax M2 Plate Reader (Molecular Devices, Sunnyvale, CA). 
DNA samples were diluted to ensure their absorbance properties fell within the linear region of 
the standard curve. 
To determine the fragment size of remnant DNA, equal concentrations of extracted DNA 
from each sample were separated on a 2% agarose gel containing 0.5% ethidium bromide and 
visualized with ultraviolet transillumination using a reference 100 bp ladder (New England 
BioLabs, Ipswich, MA). All assays were performed in quadruplicate.  
7.3.3  Immunolabeling and histochemistry 
A set of slides (n=6) was stained to visualize the extent of cell removal with a standard 
hematoxylin and eosin (H&E) protocol. Antigen retrieval was performed for immunolabeling 
studies using a 0.01 M citrate buffer (pH=6) heated to 95-100°C. Slides were placed in the hot 
buffer for 20 min and subsequently rinsed in PBS (3 × 5 min). Sections were placed in pepsin 
solution (0.05% pepsin/0.01 M HCl) at 37°C for 15 minutes. After rinsing in PBS (3 × 5 min), the 
samples were blocked in blocking buffer (2% goat serum/1% bovine serum albumin/0.1% Triton 
X-100/ 0.1% Tween) for 1 hr at room temperature. The sections were then incubated in the
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blocking buffer with rabbit polyclonal collagen IV antibody (1:500 dilution, Abcam, Cambridge, 
UK), rabbit polyclonal laminin antibody (1:200 dilution, Abcam), or mouse monoclonal 
fibronectin (1:200 dilution, Abcam) overnight at 4°C in a humidified chamber. Sections were 
subsequently rinsed in PBS (3 × 5 min). Endogenous peroxidase activity was quenched by 
rinsing sections in a 3% hydrogen peroxide in methanol solution for 30 min followed by rinsing in 
PBS (3 × 5 min). Biotinylated goat anti-rabbit or goat anti-mouse secondary antibodies (Vector 
Laboratories, Burlingame, CA) were diluted 1:200 in blocking buffer and added to the sections 
for 30 min at 25 °C and sections were subsequently rinsed in PBS (3 × 5 min). The slides were 
then incubated in detection solution (VectaStain® Elite ABC Reagent, Vector Laboratories) for 
30 minutes at 37°C. After rinsing the slides, peroxidase substrate, 3,3′-diaminobenzadine 
(ImmPACT™ DAB, Vector Laboratories) was prepared as per manufacturer instructions and 
sections were incubated while being visualized under a microscope to time the color change for 
subsequent section staining intensities. Tissues were rinsed in water (3 × 5 min). Sections were 
dipped in hematoxylin (Thermo Shandon, Pittsburgh, PA) for 1 min for a nuclear counterstain 
and subsequently rinsed in PBS (3 × 5 min).  
7.3.4  Sulfated glycosaminoglycan assay 
Sulfated glycosaminoglycan (sGAGs) concentration in esophageal ECM samples was 
determined using the Blyscan Sulfated Glycosaminoglycan Assay Kit (Biocolor Ltd, Belfast, 
Northern Ireland). For extraction of sGAGs, lyophilized ECM scaffolds were powdered using a 
Wiley Mill and filtered through a 60-mesh screen. Samples were prepared by digestion of 
50 mg/ml dry weight of each sample with 0.1 mg/ml proteinase K in buffer (10 mM Tris–HCl, pH 
8, 100 mM NaCl, 25 mM EDTA) for 48 hr at 50°C. Digested samples were assayed following the 
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manufacturer’s protocol, and the assay was performed in duplicate on three different emECM 
sample. 
7.3.5  Growth factor assay 
The concentration of basic fibroblast growth factor (bFGF) and vascular endothelial growth 
factor (VEGF) in urea-heparin extracts of emECM samples was determined with the Quantikine 
Human FGF basic Immunoassay, Human VEGF Immunoassay (R&D Systems, Minneapolis, 
MN). Each assay for bFGF and VEGF was performed in quadruplicate. The ELISA assays are 
cross-reactive with porcine growth factors and do not measure activity. 
7.3.6  Scanning electron microscopy 
Scanning electron micrographs were taken to examine the surface topology of emECM. Prior to 
final lyophilization, samples were fixed in cold 2.5% (v/v) glutaraldehyde (Electron Microscopy 
Sciences, Hatfield, PA) in PBS for at least 24 hr, followed by three washes in PBS. Fixed 
samples were then dehydrated using a graded series of alcohol (30, 50, 70, 90, 100%) for 
15 min each, followed by 15 min in hexamethylenediamine (Fisher) and subsequent air-drying. 
The dried samples were sputter coated with a 3.5 nm layer of gold/palladium alloy using a 
Sputter Coater 108 Auto (Cressington Scientific Instruments, Watford, UK) and imaged with a 
JEOL JSM6330f scanning electron microscope (JEOL, Peabody, MA) at 100× and 500× 
magnifications. 
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7.3.7  Perivascular stem cell (PVSC) culture 
Perivascular stem cells isolated by flow cytometry from fetal muscle 306,307 were used in all 
experiments. These cells (CD146+/NG2+/CD34-/CD144-/CD56-) have been previously shown to 
represent a distinct population of perivascular cells obtained after positive selection and 
stringent exclusion of hematopoietic, endothelial, and myogenic cells, and which are able to  
 differentiate into mesodermal lineages 307,308. Isolated cells were cultured in high-glucose 
Dulbecco's modified Eagle's medium (Invitrogen) containing 20% fetal bovine serum (Thermo), 
100 U/mL penicillin, and 100 μg/mL streptomycin (Sigma Aldrich) at 37°C in 5% CO2. 
 In-vitro cell viability assays were performed using single layer sheets of ECM. PVSCs 
(0.5×106) were cultured for 48 hr on 2cm diameter circular sheets of emECM or XL-emECM. 
Cell viability was compared to growth on tissue culture plastic (TCP) using LIVE/DEAD® 
Viability/Cytoxicity Kit (Invitrogen) following manufacturer’s guidelines. Capturing 4 random 
fields across the emECM scaffold, the live and dead cells were imaged with green fluorescent 
calcein-AM (cAM) and red fluorescent ethidium homodimer-1 (EtH1), respectively. 
Quantification of live and dead cells was achieved using a custom image analysis algorithm 
developed using the cell profiler image analysis package 309,310. This custom algorithm identified 
and quantified the number of cAM+ (live) and EtH1+ (dead) cells present on the emECM 
scaffolds. These results were then expressed as a percentage of total cells. 
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7.3.8  In-vivo cytocompatibility 
All procedures were performed in accordance with the National Institute of Health (NIH) 
guidelines for care and use of laboratory animals and with approval of the Institutional Animal  
Care and Use Committee (IACUC) at the University of Pittsburgh. Sprague Dawley rats (female; 
250-350g) were anesthetized with 1.5-3% isoflurane and maintained at a surgical plane of
anesthesia.  The surgical site was shaved, disinfected with a betadine solution, and an incision 
was made into the ventrolateral abdominal wall.  Bilateral partial thickness abdominal body wall  
defects 261 were created by excision of a 1cm2 piece of tissue comprising the internal and 
external oblique muscles but leaving the transversalis muscle intact 270. Size matched emECM 
or XL-emECM scaffolds were then sutured into the defect site using nonresorbable 4-0 proline 
sutures at each of the 4 corners of the device.  The skin was closed using 3-0 resorbable vicryl 
sutures.  Rats were euthanized at 14 or 35 days post-implantation and implant sites were 
identified by nonresorbable sutures.  The implant site containing emECM devices and adjacent 
tissue site were isolated and placed in 10% neutral buffered formalin. Fixed samples were 
paraffin embedded and cut into 6 μm sections. The sections from 14 and 35 days post-op were 
stained with H&E for a qualitative and semiquantitative histomorphologic analysis that evaluated 
cell infiltration, multinucleated giant cells, vascularity, connective tissue, encapsulation, and 
scaffold degradation. Two blinded investigators scored the sections according to a previously 
established and validated semi-quantitative scoring method 132,270. Using quantitative scoring 
criteria (Table 7) biologic scaffolds can be grouped according to chronic inﬂammation and 
foreign body response (quantitative score < 5), early inﬂammatory cell inﬁltration with decreased 
cellularity and little evidence of constructive remodeling at later time points (5 < quantitative 
score < 10), and early inﬁltration by inﬂammatory cells and signs of constructive remodeling at a 
later time point (quantitative score>10). 
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Table 7. Semiquantitative scoring criteria for day 14 and day 35 explants 
Day 14 
Scoring Criteria 
3 2 1 0 
Cellular Infiltration 
(per 40x field) 
>150 cells 75-150 cells 1-75 cells 0 cells 
Connective Tissue 
Organization 
Highly organized 
connective tissue 
present 
Moderately 
organized 
connective tissue 
present 
Unorganized 
connective tissue 
throughout 
disrupted original 
scaffold 
Original scaffold 
intact 
Degradation No scaffold present Some scaffold present Mostly present No degradation 
Encapsulation No encapsulation Minimal encapsulation 
Moderate 
encapsulation 
Dense 
encapsulation 
Multinucleated Giant Cells 
(per 40x field) 
0 cells 1 cell 2-5 cells >5cells
Vascularity 
(per 40x field) >10 vessels 6-10 vessels 2-5 vessels 0-1 vessel
Day 35 
Scoring Criteria 
3 2 1 0 
Connective Tissue 
Organization 
Highly organized 
connective tissue 
present 
Moderately 
organized 
connective tissue 
present 
Unorganized 
connective tissue 
throughout 
disrupted original 
scaffold 
Original scaffold 
intact 
Degradation No scaffold present Some scaffold present Mostly present No degradation 
Encapsulation No encapsulation Minimal encapsulation 
Moderate 
encapsulation 
Dense 
encapsulation 
Multinucleated Giant Cells 
(per 40x field) 
0 cells 1 cell 2-5 cells >5cells
Muscle Ingrowth Organized muscle throughout scaffold 
Muscle cells 
present in scaffold 
center 
Muscle cells 
present at scaffold 
periphery 
No muscle 
ingrowth 
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Immunolabeling of macrophages was performed on tissue sections from day 14 explants. 
Paraffin embedded sections were deparaffinized with xylene and rehydrated through a graded 
ethanol series. Heat-mediated antigen retrieval was performed with 0.01 M citrate buffer (pH=6) 
at 95-100 °C for 25 min. The tissue sections were subjected to Tris-Buffered Saline Tween-20 
(TBST) for 15 min, followed by incubation in blocking buffer (2% horse serum albumin/1% 
bovine serum albumin/0.05% Tween-20/0.05% Triton X-100) for 1 h. The primary antibodies, 
diluted in blocking buffer, were added to the slides for 16 hr at 4 °C in a humidified chamber. 
The slides were then washed three times in PBS prior to the addition of the secondary antibody 
for 1 hr in a humidified chamber at room temperature. DAPI was used as a nuclear 
counterstain. The primary antibodies used in this study were mouse anti-rat CD68 (1:150, AbD 
Serotec, Raleigh, NC), goat polyclonal CD206 (Santa Cruz Biotech, Santa Cruz, CA), rabbit 
anti-rat CD86 (1:150, Abcam) and mouse anti-rat CD68 (1:50, Serotec, Raleigh NC). The 
secondary antibodies used were Alexa Fluor® donkey anti-mouse 594 (1:200, Invitrogen), Alexa  
Fluor® donkey anti-goat 488 (1:200, Invitrogen) and donkey anti-rabbit IgG-PerCP-Cy5.5 (1:300, 
Santa Cruz). CD68 is a pan-macrophage marker. CD86 is an M1 marker. CD206 is an M2 
marker. All primary antibodies were confirmed to cross-react with rat epitopes. The sections 
were imaged at random fields along the interface of the native tissue and ECM scaffold. 
Quantification of M1/M2 polarization was achieved using a custom image analysis algorithm 
developed using the cell profiler image analysis package 309,310. This algorithm identified and 
quantified the number of CD68+ CD86+ (M1 phenotype) and CD68+ CD206+ (M2 phenotype) 
cells present within the tissue sections. Any cells that co-expressed these markers were not 
counted. These numbers were then expressed as a ratio of M2/M1.  
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7.3.9  Biomechanical testing 
The passive biaxial mechanical properties were characterized for the native esophageal 
mucosa and emECM (n=8). A detailed description of the testing device and methods used for 
planar biaxial testing has been reported previously 311. Briefly, samples were affixed to 250 g 
load cells (Model 31, Honeywell, Columbus, OH) with two loops of suture attached to each side 
with four hooks, and deformation was measured from a four marker array. Samples were tested 
in PBS at room temperature under an equibiaxial stress protocol from a 0.5 g tare load to 250 
kPa after 10 cycles of preconditioning with a cycle time of 30 s. All data was referenced to the 
post-preconditioned free-float state. The maximum strain for each sample was then defined as 
the strain at the maximum tested stress of 250 kPa.  
The suture retention analysis we performed according to a previously described protocol 
312. Briefly, a 2-0 prolene suture with a taper needle was passed through the specimen with a 2 
mm bite depth, and tied with a square knot and the loop attached to an Instron machine, and 
pulled at a constant rate of 10 cm/min 312. Two locations were tested per sample and eight 
samples were tested per group. Samples were thoroughly rehydrated prior to testing. 
7.3.10   Statistical analysis 
An independent samples t-test was used to determine whether the DNA, growth factor, and 
GAG content, and mechanics of the emECM were different than that of native esophagus 
(p<0.05). A one-way analysis of variance (ANOVA) was used to determine differences in the 
percentage of viable cells in culture. Macrophage phenotype ratio between XL-emECM and 
emECM was compared using an independent samples t-test. A two-way ANOVA with post-hoc 
Tukey test was performed to determine differences in biomechanical properties with the two 
independent variables being axes and material. All data are reported as mean ± standard error. 
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7.4  RESULTS 
7.4.1  Decellularization efficacy 
The degree of decellularization following the described method was assessed using previously 
established guidelines for decellularization 175. The concentration of remnant DNA in emECM 
(48 ± 6.4 ng/mg) was markedly less (p<0.001) than that in native esophageal tissue (855 ± 24 
ng/mg) (Figure 4A). Residual DNA was present only in fragments less than 200 bp in length 
(Figure 4B).   
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Figure 4. Decellularization efficacy. Decellularization of emECM was assessed by the 
amount and size of remaining DNA and histologically by hematoxylin and eosin (H&E). The 
amount dsDNA in emECM was less than 50ng/mg, which was significantly less (asterisk; 
p<0.001) than native tissue (A). DNA fragment length was assessed by gel electrophoresis 
using a reference 100 bp ladder (B). No intact nuclei were visible after decellularization by 
H&E staining (C). Data represented as mean ± standard error. Scale bar = 100 μm. 
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7.4.2  Biochemical and ultrastructural characteristics of esophageal ECM 
The concentration of sGAGs in emECM (226 ± 19 mg/g) was not different (p=0.37) compared to 
the concentration of sGAGs in native esophagus (188 ± 28 mg/g) (Figure 5A). Quantification of 
growth factors showed no detectable levels of VEGF were present following decellularization. 
However, bFGF was retained after decellularization (63 ± 16 ng/g) (Figure 5B) in a lesser 
amount than that in native tissue (3585 ± 100 ng/g) (p<0.001).      
Figure 5. Retention of biologic components. Growth factor protein and 
glycosaminoglycans (GAGs) remain after decellularization. The amount of (A) GAGs and (B) 
basic fibroblast growth factor (bFGF) remaining after decellularization was measured. Data 
represented as mean ± standard error. Asterisk signifies p <0.05. 
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In addition to measuring the concentration of remaining sGAGs and growth factors, the 
preservation and spatial distribution of basement membrane proteins, collagen IV and laminin, 
and a non-basement membrane protein, fibronectin, was examined. Immunolabeling showed 
the presence of collagen IV (Figure 6B) and laminin (Figure 6D) that was predominant along the 
luminal surface of the emECM (marked by “L”). Positive staining for fibronectin was present and 
distributed throughout the emECM scaffold (Figure 6F). 
Figure 6. Immunolabeling of collagen IV, laminin, and fibronectin in emECM samples. 
Dark brown indicates positive stain. Immunolabeling of native tissue (A,C,E) is shown as a 
comparison to emECM (B,D,F). L indicates luminal surface. Scale bar = 200 μm. 
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Lastly, SEM images of the luminal and abluminal surface of emECM showed a smooth 
surface on the luminal surface of the emECM (Figure 7A,C). The abluminal surface, however, 
had a more textured and fibrous structure (Figure 7B,D).    
Figure 7.  Scanning electron micrographs (SEM) of emECM surface. The luminal surface 
of the emECM scaffold was characterized by a smoother surface (A,C) compared to the 
abluminal surface which was more textured and fibrous (B,D) 
7.4.3  Biomechanical properties 
The equibiaxial stress response of the native esophagus showed anisotropic behavior with a 
maximum strain of 83% and 18% in the circumferential and longitudinal direction, respectively 
(Figure 8A,B). The emECM showed similar anisotropy, but had a lower compliance along both 
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axes, with the circumferential strain reaching only 10.5% (Figure 8A,B). The decellularized 
tissue had 30% lower suture retention strength than the native esophagus (Table 8).   
Table 8. Native esophagus and emECM suture retention test 
Treatment 
Native emECM 
Mean Standard Error Mean Standard Error 
Suture Retention 
Strength (N)* 
2.42 0.24 1.73 0.17 
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Figure 8. Native and decellularized esophagus mechanical characterization. The 
equibiaxial stress response was characterized along the circumferential and longitudinal axes 
(A). The maximum strain defined at a stress of 250 kPa for both circumferential (C) and 
longitudinal (L) axes (B). Significant differences (p<0.05) between the circumferential and 
longitudinal axes of the same sample are denoted as the following: (*) as different from 
circumferential. Significant differences between samples in each axis are denoted as the 
following: (^) as different from native. Data represented as mean ± standard error. 
7.4.4  Cytocompatibility 
When cultured on emECM and XL-emECM, quantification of PVSC cell viability in-vitro showed 
no difference when compared to tissue culture plastic (p=0.67).  Both conditions resulted in over 
98% viability following 48 hours in culture (Figure 9). 
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Figure 9. Cytocompatibility of emECM and XL-emECM. The viability of perivascular stem 
cells (PVSCs) after 48 h culture on emECM (A), XL-emECM (B), and tissue culutre plastic 
(TCP) was assessed. Percentage of live cells was quantified and compared across groups 
(C). Data represented as mean ± standard error. Scale bar = 50 μm. 
In-vivo host response to emECM was examined at both 14 and 35 days post-
implantation in a rat abdominal body wall model. The host response to emECM scaffolds 
showed a robust mononuclear cell response throughout the partially degraded scaffold at 14 
days (Figure 10A) and yielded a histologic score of 11.4. Along the interface between the 
emECM scaffold and native tissue, the macrophage response was predominantly of the M2 
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phenotype (Figure 11A) with a ratio of M2/M1 macrophages of 1.29 ± 0.21 (Figure 11C). By 35 
days post-implantation, the original material was not identifiable by histologic evaluation and the 
remodeling site was composed of organized host connective tissue and islands of skeletal 
muscle at the periphery that extended into the center of the remodeling site (Figure 10B). 
Figure 10.  In-vivo cytocompatibilty. Tissue sections were stained with H&E at 14 and 35 
days after implantation of emECM (A,B) and XL-emECM (C,D). Histomorphologic sections 
were evaluated and scored according to previously established criteria (E).  Scale bar= 100 
μm 
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Semiquantitative histomorphologic analysis of emECM at day 35 resulted in a total score 
of 12. In contrast, the host response to XL-emECM was characterized by little to no cellular 
infiltration or vasculature within the chemically cross-linked bioscaffold, a dense population of 
mononuclear macrophages at the host-scaffold interface, the deposition of disorganized 
connective tissues surrounding the implanted test article, and little to no degradation of the 
material at 14 days (Figure 10C). The cellular response along the scaffold and native tissue 
interface was shown to be predominantly macrophages of the M1 phenotype (Figure 11B) with 
an M2/M1 ratio of 0.19 ± 0.03, which was less than (p<0.001) the M2/M1 ratio in emECM. By 
35 days, the XL-emECM was still largely intact and showed no infiltration of skeletal muscle 
(Figure 10D). 
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Figure 11. In-vivo macrophage response. Macrophage immunolabeling in emECM (A) and 
XL-emECM (B) in explants 14 d after implantation was quantified and represented as a ratio
of M2/M1 phenotype (C). Dashed line indicates the interface of native tissue (marked by a
triangle) and the surgical site. Data represented as mean ± standard error. Scale bar = 50 μm. 
7.5  DISCUSSION 
Although current clinical applications of ECM-based biologic scaffolds have included the use of 
devices originating from heterologous tissue sources, recent studies have suggested there may 
be an advantage to using ECM derived from homologous tissue (i.e., site-specific) 109-111,115. This 
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concept is based upon the fact that ECM from different tissue sources have distinct and specific 
properties, including the ultrastructure and composition; i.e., a tissue specific 
microenvironmental niche.  
The necessity or preference for site-specific ECM remains unknown for many 
therapeutic applications. Zhang et al have shown that ECM derived from liver, skin, and skeletal 
muscle increases the proliferation and differentiation potential for site-matched cell types 113. 
Sellaro and colleagues have shown that ECM derived from liver improves the maintenance of 
sinusoidal endothelial cell phenotype 109 and the function of hepatocytes in-vitro 110. More 
recently, porcine myocardial ECM has been shown to improve cardiac progenitor cell function 
in-vitro 112. Seif-Naraghi et al have shown that injection of a hydrogel form of cardiac ECM after 
myocardial infarct improves cardiac function and results in increased cardiac muscle mass 89. 
Although the present study showed that the emECM facilitates a constructive remodeling 
response in a heterologous location and excellent in-vitro cytocompatibility, any site specific 
benefit in the esophageal mucosa (homologous) location has not yet been tested. 
The importance of effective decellularization is well recognized 138,175. While protocols for 
decellularizing the esophagus have been reported, little has been described with focus on the 
esophageal mucosa.  Bhrany et al developed a rat full thickness esophageal scaffold that was 
able to support epithelial cell growth 176. Marzaro et al decellularized intact porcine esophagus 
and seeded with autologous smooth muscle cells for repair of an esophageal muscularis defect 
163. Using a similar protocol, Totonelli et al decellularized intact esophagus using luminal
perfusion 313. These groups reported decellularization of the entire esophagus, including both 
muscularis externa and mucosa. However, the efficacy of these decellularization protocols, 
characterization, and cytocompatibility of the scaffold were not investigated in a comprehensive 
manner.  
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Protocols for esophageal decellularization have been reported but have been conducted 
using non-porcine species and/or have used harsh detergents such as sodium dodecyl sulfate 
(SDS) 176,314. SDS, as an ionic detergent, destroys the cell membrane and denatures protein—
altering the collagen structure in ECM 213. Thus, SDS has the associated drawback of 
ultrastructure disruption 242,315,316 and growth factor elimination 173. A loss of ECM structure is 
also associated with variability in biomechanical properties 317. Therefore, the use of SDS was 
avoided in the present study. 
Studies have shown the requirement for retention of at least a portion of the submucosal 
tissue to promote constructive remodeling of the esophagus over stricture and scarring 93. The 
use of emECM would therefore appear a more logical strategy for clinical translation. The 
methods of the current study thoroughly decellularized esophageal mucosa with the use of mild 
detergents while preserving the anisotropic mechanical properties and bioactive molecules. The 
described method effectively removed cellular components while maintaining ECM constituents 
and basement membrane proteins, collagen IV and laminin, in a contiguous pattern at the 
surface of the emECM material. Scanning electron micrographs of the luminal surface of 
emECM showed a smooth contour that was also consistent with an intact basement membrane 
surface. The basement membrane complex may be of importance to esophageal mucosal 
remodeling because of its natural function of supporting the growth of epithelial cell populations 
318-320.  The emECM scaffold was cytocompatible with perivascular stem cells, which were
shown to survive and proliferate when cultured on the scaffold. 
The role of the host response to biologic ECM scaffolds is a topic of interest and has 
been reviewed in detail elsewhere 321. Briefly, the successful therapeutic efficacy of biologic 
scaffolds is attributed largely to the ability of these ECM-derived materials to modulate the 
innate immune response in favor of a constructive remodeling outcome over 
scarring/encapsulation. Key mediators of the innate immune response are macrophages—a 
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highly plastic and heterogeneous cell population 292,322. Appropriately prepared biologic scaffolds 
have been shown to elicit a macrophage response that is predominantly of an anti-inflammatory 
(M2) phenotype which has been associated with a downstream constructive remodeling 
response (i.e., formation of functional, site-appropriate tissue) 132,133,305.  However, when biologic 
scaffolds are prepared using harsh decellularization methods, are chemically cross-linked, or 
are inadequately decellularized, a robust proinflammatory (M1) macrophage phenotype is 
observed at the in-situ interface of host tissue and ECM scaffold and ultimately results in chronic 
inflammation, encapsulation, and fibrosis 132,314. In the present study, implantation of emECM 
scaffolds in an established rodent model was associated with a predominant M2 macrophage 
response after 14 days and was shown to remodel in a constructive fashion with a 
histomorphologic score comparable to urinary bladder matrix (UBM-ECM) and small intestinal 
submucosa ECM (SIS-ECM) 90,132,270. These findings are consistent with the predictive 
association of the M2 phenotype with constructive remodeling outcomes 132. 
The objective of this chapter was to develop and characterize an emECM scaffold but 
was limited by a number of factors. The effects of emECM on esophageal cells were not 
studied. Instead, perivascular stem cells were used because they are well-characterized 307 and 
have been used in a number of studies to evaluate the cytocompatibility of a variety ECM 
scaffolds 308. In addition, while retention of growth factor proteins was used as an indicator of the 
relative mildness of the decellularization protocol, the activity of the growth factors was not 
determined and the effect of the presence of these growth factors in the overall remodeling 
process is unknown. While the M2/M1 macrophage phenotype ratio has been shown to be 
strongly associated with a constructive remodeling response in several anatomic locations, a 
direct cause-effect relationship has yet to be established. Finally, the present study observed 
the in-vivo compatibility and constructive remodeling response of the emECM scaffold in a well-
characterized abdominal wall defect model, a heterologous anatomic site. Thus, the potential 
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benefits of ECM derived from homologous tissue (i.e., the use of emECM in an esophageal 
mucosal resection model) remain unknown. 
7.6  CONCLUSION 
Porcine esophageal mucosa was effectively decellularized with the use of a relatively mild 
detergent-based protocol. The emECM scaffold maintained structural proteins and an 
ultrastructure consistent with a basement membrane complex. Likewise, retention of sGAGs 
and bFGF was shown. Compared to native esophageal mucosal tissue biomechanics, the 
emECM scaffold was expectedly less compliant but retained similar anisotropy. The emECM 
biologic scaffold was conducive to stem cell viability in-vitro and was associated with a host 
innate immune response consisting predominantly of M2 macrophages and a more robust 
constructive remodeling response when compared to XL-emECM biologic scaffolds in-vivo. 
Future studies aimed at investigating the specific physical and/or biochemical factors 
responsible for the constructive remodeling outcome and the utility of an emECM biologic 
scaffold in an esophageal location are warranted. 
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8.0 PREPARATION AND CHARACTERIZATION OF A BIOLOGIC SCAFFOLD FROM
COLONIC MUCOSA5 
8.1  ABSTRACT 
Gastrointestinal pathologies, injuries, and defects affect millions of individuals each year. While 
there are diverse treatment options for these individuals, no ideal solution exists. The repair or 
replacement of gastrointestinal tissue therefore represents a large unmet clinical need. 
Biomaterials derived from extracellular matrix scaffolds have been effectively used to repair or 
replace numerous tissues throughout the body in both pre-clinical and clinical studies. Such 
scaffolds are prepared from decellularized tissues and the biochemical, structural, and biologic 
properties vary depending upon the source tissue from which the ECM is derived. Given the 
potential benefit of a site-specific ECM scaffolds for some applications, the objective of the 
present chapter was to prepare, characterize, and determine the in vitro and in vivo cell 
response to ECM derived from porcine colon. Results show that porcine colon can be effectively 
decellularized while retaining biochemical and structural constituents of the source tissue. Two 
forms of coECM, scaffold and hydrogel, were shown to be cell-friendly and facilitate the 
polarization of macrophages towards an M2 phenotype both in-vitro and in-vivo.  
5 Portions of this chapter were adapted from the following publication: 
Keane TJ, Dziki J, Castelton A, Faulk DM, Messerschmidt V, Londono R, Reing JE, Velankar SS, 
Badylak SF. Preparation and Characterization of a Biologic Scaffold and Hydrogel Derived from Colonic 
Mucosa. Journal for Biomedical Materials Research Part B. October 2015. DOI:10.1002/jbm.b.33556 
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8.2  INTRODUCTION 
The gastrointestinal (GI) tract is composed of a series of hollow muscular tubes that perform a 
variety of functions including mastication, digestion, motility, nutrient absorption, and waste 
excretion, among others. Such functional diversity requires organization of specialized cell and 
tissue types, and repair following injury or disease is imperative for the health of the host. 
Pathologies such as inflammatory bowel disease affect up to 4 million patients per year 323 and 
short bowel syndrome affects an additional 20,000 individuals in the United States alone 324. 
Diseases such as these have very limited therapeutic options and are the cause of tremendous 
morbidity and health care expenditures. Biomaterials and/or regenerative medicine strategies to 
address such problems will require the creation of a microenvironment that supports the 
cultivation, recruitment, differentiation, and maintenance of the specialized cell types required 
for normal GI function.  
Biomaterial-mediated approaches to GI replacement must not only provide a mechanical 
support structure for cell growth but also be amenable to cell infiltration, allow for gas and 
nutrient exchange, and be compatible with the host innate immune system. Both synthetic and 
biologic scaffold materials have been manufactured and studied for GI repair / replacement 
applications and each are associated with their respective advantages and disadvantages 
325,326. Synthetic scaffolds such as poly-lactic acid or poly-caprolactone allow for tunable 
materials that can be tailored for specific applications. However, synthetic scaffolds invariably 
elicit proinflammatory and/or a foreign body response upon implantation that may result in 
encapsulation, fibrosis, and loss of function 327. Compatibility of scaffold materials with the host 
immune system has been shown to be a critical determinant of downstream functional tissue 
remodeling 328.  
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Biologic scaffold materials, such as those composed of extracellular matrix (ECM) 
derived via decellularization of source tissues, can provide a compatible and instructive 
template for endogenous cell infiltration and differentiation, recapitulate the natural niche, and 
degrade to allow for complete host tissue replacement with associated release or exposure of 
bioactive matricryptic peptide sites. Implanted ECM bioscaffolds promote a favorable host 
immune response by induction of an M2-like macrophage phenotype.  This immune modulation 
is typically associated with a functional constructive remodeling outcome. However, the 
properties and composition of ECM bioscaffolds are often variable and are critically dependent 
on factors such as source tissue anatomic site and age 105, use of chemical cross-linking agents 
67,280, method of decellularization 138, manufacturing processes, and terminal sterilization 
methods 329, among others. The potential benefits of utilizing ECM scaffolds derived from 
homologous source tissue include the retention of tissue-specific cell phenotypes 109,110, 
enhancing tissue-specific differentiation 118, and promoting chemotaxis and proliferation of 
progenitor cells 86. Previous reports have shown that regions of the porcine GI system such as 
the small intestine (i.e., SIS) and esophagus can be decellularized and retain essential 
ultrastructural components, endogenous growth factors, and biomechanical strength  330-336 162. 
The suitability of these scaffolds for GI repair applications including treatment of esophageal 
disease, short bowel syndrome, ulcerative colitis, Crohn’s disease, or mucositis, has not been 
extensively investigated.  
The objective of the present chapter was to prepare, characterize, and determine the in 
vitro and in vivo cytocompatibility of ECM bioscaffolds derived from porcine colon. DNA content, 
retention of ultrastructural and biochemical molecules, biomechanical properties, in vitro 
cytocompatibility, and the in vivo host macrophage response were examined both quantitatively 
and qualitatively and compared across sheet, hydrogel, cross-linked, and incompletely 
decellularized forms of porcine colon ECM. 
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8.3  MATERIALS AND METHODS 
8.3.1  Preparation of colonic ECM (coECM) 
Colons were collected from market weight pigs (approximately 6 months of age and 260 lbs) at a 
local abattoir (Thoma’s Meat Market, Saxonburg, PA). The colon was rinsed in water to remove 
contents and frozen at -20C until use. Colonic submucosa was mechanically isolated from the 
surrounding tissue and then delipidized and decellularized. Native colonic submucosa prior to 
delipidization and decellularization was used as a control group. For preparation of coECM, 
submucosa was subject to agitated washes of 2:1 (v/v) chloroform to methanol (30 min with 
stirring), 3 washes each of 100%, 90%, and 70% ethanol (5 minutes each), 3 washes of deionized 
water (5 min), 0.02% Trypsin/0.05% EDTA (1h at 37 °C), twice with deionized water (5 min), 4% 
sodium deoxycholate (30 min), twice with deionized water (5 min), 4% sodium deoxycholate (30 
min), deionized water (2 x 5 min), 0.1% peracetic acid in 4% ethanol (2h), PBS (15 min), deionized 
water (2 x 15min), and PBS (15 min). Solutions were agitated on a shaker at 300 rpm and room 
temperature unless otherwise stated.  
A subset of coECM scaffolds was subjected to chemical cross-linking (XL) using 10mM 
carbodiimide for 24h at room temperature with constant stirring. The XL-coECM was then washed 
extensively in PBS for 48h with stirring and then lyophilized to dry. For in-vitro cell growth, in-vivo 
implants, and suture retention strength experiments, the colonic submucosa, XL-coECM, and 
coECM were vacuum pressed to form a 4-layer device. The devices used for cell culture and in-
vivo implantation were sterilized by ethylene oxide.  
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8.3.2  Hydrogel preparation 
Hydrogels were prepared from coECM as previously described 337. Briefly, lyophilized scaffolds 
were powdered using a Wiley Mill and filtered through a 60 mesh screen (<250 μm particle size). 
The comminuted ECM was then digested in 1 mg/mL porcine pepsin (Sigma Aldrich, St. Louis, 
MO) in 0.01 N HCl for 48 h under constant stir rate at room temperature. Gelation was induced 
by neutralization at 4°C of pH and salt concentration with the respective addition of one-tenth 
digest volume of 0.1 N NaOH and one-ninth digest volume of 10x PBS. Gelation was then 
achieved by placing the neutralized digest in a non-humidified incubator at 37°C for 1 h for in-vitro 
studies.  Gelation of coECM hydrogels for in-vivo studies was accomplished by direct injection of 
the neutralized digest over the site of abdominal wall defect. ECM concentrations of 4 and 8 
mg/mL were evaluated by turbidometric and rheologic assays. Cell culture and in-vivo 
experiments were conducted with 8 mg/mL coECM hydrogels. 
8.3.3  Determining decellularization efficacy 
8.3.3.1  Histologic analysis: Scaffolds (native colonic submucosa and coECM) and native 
colon tissue were fixed in 10% neutral buffered formalin for 24h. The fixed samples were then 
paraffin embedded and 5μm sections were cut onto slides. Slides were stained with hematoxylin 
and eosin (H&E) or 4’,6-onDiamidino-2-phenylindole (DAPI) to visualize the presence of nuclear 
material. 
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8.3.3.2     DNA concentration and fragment analysis: Residual DNA content of the ECM was  
quantified by powdering samples with a Wiley Mill using a 60-mesh from separate preparations 
(n = 4) of lyophilized coECM. Samples (100 mg) were digested in 0.1 mg/mL proteinase K 
digestion buffer at 50 °C for 24 hours. DNA was extracted twice in phenol/chloroform/isoamyl 
alcohol and centrifuged at 10,000g (10 min at 4 °C). The aqueous phase, containing the DNA, 
was then mixed with 3 M sodium acetate and 100% ethanol, frozen on dry ice for 20 minutes, 
centrifuged at 10,000g (10 min at 4 °C), pouring off the supernatant, adding 70% ethanol, 
repeating centrifugation, removing supernatant, and drying the remaining DNA pellet. When dry, 
the pellet was resuspended in TE buffer (10mM Tris/1mM EDTA) and the DNA concentration was 
quantified utilizing a PicoGreen Assay (Invitrogen) following manufacturer’s instructions. The 
fragment length of remnant DNA in the samples was then visualized with gel electrophoresis on 
a 1% agarose gel with a 100bp ladder (Invitrogen) containing ethidium bromide. 
8.3.3.3     Phospholipid measurement: Homogenates were prepared from 40 mg of lyophilized 
and comminuted tissue or ECM in 2 mL of homogenization buffer (50mM Tris pH 7.4/ 20mM 
CaCl2/ 0.5% Triton X-100). Samples were homogenized on ice 5 times for 15 sec using a 
PowerGen 500 Homegenizer (Fisher Scientific, Pittsburgh, PA).  Samples were centrifuged at 
2,000×g for 20 min at 4°C and the supernatant extract was collected. A second extraction was 
completed on the remaining pellet, as above, using 1 mL of extraction buffer. The extracts were 
combined and measured for phospholipid content using EnzyChrom Phospholipid Assay Kit 
(BioAssay Systems, Hayward, CA) according to manufacturers instructions. 
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8.3.4  Glycosaminoglycan and growth factor measurement 
The concentration of sulfated glycosaminoglycan (sGAG) and non-sulfated GAG in coECM 
samples was determined using the Blyscan Sulfated Glycosaminoglycan Assay Kit (Biocolor 
Ltd, Belfast, Northern Ireland) and Hyaluronan Quantikine ELISA Kit (R&D Systems, 
Minneapolis, MN), respectively. The concentration of non-sulfated GAG, hyaluranic acid (HA), 
was measured using neutralized pepsin digests as described above. Digested samples were 
assayed following the manufacturer’s protocol, and the assay was performed in duplicate on 
three different coECM samples. 
The concentration of basic fibroblast growth factor (bFGF) and vascular endothelial 
growth factor (VEGF) in urea-heparin extracts of coECM samples was determined with the 
Quantikine Human FGF basic Immunoassay, Human VEGF Immunoassay (R&D Systems). 
Each assay for bFGF and VEGF was performed in quadruplicate. The ELISA assays are cross-
reactive with porcine growth factors and do not measure activity. 
8.3.5  Immunohistochemistry 
Antigen retrieval was performed on de-paraffinized slides with 5 μm sections using a 
0.01 M citrate buffer (pH=6) heated to 95-100°C. Slides were placed in the hot buffer for 20 min 
and subsequently rinsed in PBS (3 × 5 min). Sections were placed in pepsin solution (0.05% 
pepsin/0.01 M HCl) at 37°C for 15 minutes. After rinsing in PBS (3 × 5 min), the samples were 
blocked in blocking buffer (2% goat serum/1% bovine serum albumin/0.1% Triton X-100/ 0.1% 
Tween) for 1 hr at room temperature. The sections were then incubated in the blocking buffer 
with rabbit polyclonal laminin antibody (1:200 dilution, Abcam), or mouse monoclonal fibronectin 
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(1:200 dilution, Abcam) overnight at 4°C in a humidified chamber. Sections were subsequently 
rinsed in PBS (3 × 5 min). Endogenous peroxidase activity was quenched by rinsing sections in 
a 3% hydrogen peroxide in methanol solution for 30 min followed by rinsing in PBS (3 × 5 min). 
Biotinylated goat anti-rabbit or goat anti-mouse secondary antibodies (Vector Laboratories, 
Burlingame, CA) were diluted 1:200 in blocking buffer and added to the sections for 30 min at 
25 °C and sections were subsequently rinsed in PBS (3 × 5 min). The slides were then 
incubated in detection solution (VectaStain® Elite ABC Reagent, Vector Laboratories) for 30 
minutes at 37°C. After rinsing the slides, peroxidase substrate, 3,3′-diaminobenzadine 
(ImmPACT™ DAB, Vector Laboratories) was prepared per manufacturer instructions and slides 
were incubated while being visualized under a microscope to time the color change for 
subsequent section staining. Tissues were rinsed in water (3 × 5 min). Sections were dipped in 
hematoxylin (Thermo Shandon, Pittsburgh, PA) for 1 min for a nuclear counterstain and 
subsequently rinsed in PBS (3 × 5 min).  
8.3.6  Scanning electron microscopy 
Scanning electron microscopy was used to examine the surface topology of the luminal and 
abluminal sides of native porcine colonic tissue, submucosal tissue, and colonic ECM.  Samples 
were fixed in 2.5% glutaraldehyde in 1X PBS for 60 min, cut into blocks of 8 mm3, and washed 
thoroughly in 1X PBS three times at 15 min each. Samples were then fixed in 1% OsO4 in 1X 
PBS for 15 min each, dehydrated in graded series of alcohol (30–100%) baths for 15 min each. 
Samples were then critically point dried with hexamethyldisiloxane, mounted on studs, sputter 
coated and stored in a desiccator until imaged. SEM images were captured using a JEOL 6335F 
Field Emission SEM instrument with a backscatter detector. 
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8.3.7  Mechanical testing of coECM scaffolds 
8.3.7.1    Planar biaxial testing: Planar biaxial mechanical testing was performed as previously  
described 338.  Briefly, a 15 mm x 15 mm sample of each tested material was acquired. Thickness 
was measured from the center of each material using a Starret® caliper model 1010. Four fiducial 
markers were placed in the center of the square on the luminal surface after the removal of excess 
loose connective tissue and fat. Deformations were measured optically by tracking this four 
marker array. Two loops of suture of equal length were attached to each side of the specimens 
with four stainless steel hooks, and 500 g Model 31 load cells (Honeywell) were used to acquire 
load values. Biaxial testing was conducted with the circumferential and longitudinal specimen 
axes aligned with the device axis and submerged in a bath at room temperature. The biaxial 
testing system was automated, allowing the marker locations and axial forces to be continuously 
recorded with custom marker tracking and data acquisition software 311. 
Specimens were first preconditioned by cyclically loading the specimens to the desired 
maximum equibiaxial stress of 250 kPA for ten cycles using a cycle time of 30 s per cycle to 
quantify the quasi-static response. Immediately following the preconditioning cycles, the 
specimen was completely unloaded and imaged in its post-preconditioned free-floating 
configuration. The stress-stretch plot reported in this study start from a 5 g preload that is 
referenced to the post-precondition free float state, which was used to ensure test response 
repeatability. The response of the eight samples from each group was averaged after a three 
point linear interpolation at representative stress values and reported with standard error. The 
maximum strain for each sample was then defined as the strain at the maximum tested stress of 
250 kPa. 
110 
8.3.7.2     Suture retention testing: The suture retention test has been previously described 339.  
The suture retention strength was performed according to ANSI/AAMI VP20-1994 Guidelines for 
Cardiovascular Implants-Vascular Prostheses. The suture retention strength was defined as the 
force required to pull a suture through the full thickness of the material. A 2-0 Prolene suture with 
a SH taper needle was passed through the test article with a 2-mm bite depth using a simple 
suture technique. The specimen was clamped at one end while the suture was attached to the 
uniaxial mechanical testing machine (Instron Model 3345 single column materials testing system) 
and pulled at a constant rate of 10 cm/min according to the aforementioned standard. Two tests 
were performed 1.5 cm apart on the same edge of the test article and the maximum load was 
recorded for each test. 
8.3.7.3   Rheologic testing of coECM hydrogels: The rheological charcteristics of coECM   
hydrogels at 4 and 8 mg/mL were determined with a rheometer (AR2000, TA instruments, New 
Castle, DE) operating with a 40 mm parallel plate geometry. The temperature was controlled 
within 0.1 °C using a Peltier plate. Pre-gels were pH neutralized on ice and were immediately 
loaded onto the rheometer plate pre-cooled to 10 °C. Mineral oil was spread along the edge (i.e. 
the free surface of the hydrogel) to minimize evaporation. After loading, the steady shear viscosity 
was measured by applying a stress of 1 Pa at a frequency of 0.159 Hz. The temperature was then 
increased to 37 °C to induce gelation and a small amplitude oscillatory strain of 0.5% was 
imposed to track the gelation kinetics. After complete gelation, a creep test (1 Pa for 20 s) was 
performed to verify that there was no slip between the ECM hydrogels and rheometer plates.  
8.3.7.4  Turbidometric gelation kinetics: The gelation kinestics of coECM hydrogels was  
evaluated turbidometrically 337,340. Briefly, neutralized pre-gel solutions of coECM at 4 and 8 
mg/mL concentrations were prepared on ice. For each ECM concentration, 100 μL/well was 
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added to a 96-well plate and placed into a plate reader (Spectramax M2, Molecular Devices, 
Sunnydale, CA) pre-warmed to 37°C. Absorbance at 405 nm was read every 2 min for 60 min 
and the readings were scaled from 0 (initial absorbance) to 100% (maximum absorbance). The 
time to half gelation (t1/2) was defined as the time at 50% absorbance. Gelation rate was defined 
as the slope of the linear region of the gelation curve. The lag time (tlag) was defined as the 
intercept of the linear region of the gelation curve with 0% absorbance.  
8.3.7.5    In-vitro cytocompatibility: In vitro cytocompatibility was determined using a Live/Dead  
Viability/Cytotoxicity Kit (Invitrogen) following the manufacturer’s directions. Briefly, 1 cm2 
multilaminates of colonic ECM (coECM), cross linked colonic ECM (XL-coECM), or scraped native 
colon were sterilized with ethylene oxide. 8 mg/ml coECM hydrogels were prepared as described 
above. Intestinal epithelial cells (IEC6; ATCC) were cultured and maintained in complete growth 
media consisting of 5% fetal bovine serum (FBS) (Gibco), 0.1 U/ml bovine insulin, 100 ug/ml 
penicillin, 100 U/ml streptomycin. IECs were seeded at 1 x 106 cells/scaffold for 48 h. Cell viability 
was compared to growth on tissue culture plastic (TCP). Cells were stained with 4 mM green 
fluorescent calcein-AM (cAM) and 2 mM red fluorescent ethidium homodimer-1 (EthD-1) to detect 
viable and dead cells, respectively. Images were taken with a Zeiss Axiovert microscope capturing 
3 random fields across the scaffold. Quantification of percentage of live and dead cells was 
completed using a custom CellProfiler pipeline. Cell-seeded scaffolds were then fixed in 2% 
paraformaldehyde and formalin, embedded in paraffin, and sectioned for hematoxylin and eosin 
(H&E) staining.  
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8.3.8  In-vitro macrophage response 
Primary murine bone marrow derived macrophages were isolated as described previously 134. 
Briefly, bone marrow was isolated from the femur and tibia of C57bl/6 mice and cultured for 7 
days in 100 ng/ml MCSF to derive naïve (MΦ) macrophages. Macrophages were then activated 
with 20 ng/ml IFNγ and 100 ng/ml lipopolysaccharide (LPS) to derive M1 macrophages, 20 
ng/ml IL-4 to derive M2 macrophages, or 200 ug/ml of solubilized colonic ECM for 18 hours. 
Macrophages were then fixed with 2% paraformaldehyde for immunolabeling or lysed for 
western blot analysis. Cells were incubated in blocking buffer consisting of 0.1% Triton-X 100, 
0.1% Tween-20, 2% bovine serum albumin (BSA), and 4% goat serum for 1 hour at room 
temperature. Following blocking, cells were incubated in the following primary antibodies diluted 
in blocking buffer for 16 h at 4 °C: (1) anti-F4/80 (abcam) at 1:200, (2) anti-iNOS (abcam) at 
1:100, or 37 anti-RELMα (Fizz1, Peprotech) at 1:200. Cells were washed with phosphate 
buffered saline (PBS) and incubated in secondary antibodies diluted in blocking solution for 1 
hour at room temperature: (1) Alexa Fluor 488 goat anti-rat at 1:200, (2) AlexaFluor 488 donkey 
anti-rabbit at 1:200. Cells were then washed with PBS and counterstained with DAPI nuclear 
stain. The assay was completed on four separate days (n=4) and cells were imaged using a 
Zeiss Axiovert microscope with exposure times standardized using classically polarized 
(IFNy/LPS or IL-4) internal controls. Percentage of F4/80, iNOS, and Fizz1 positive cells were 
quantified using CellProfiler.  
Western blotting was performed to analyze an additional marker of M2 macrophages. 
Cells were lysed and lysates were boiled at 95°C for 5 minutes and loaded at 100 ug/well in a 4-
20% gradient polyacrylamide SDS page gel. Separated proteins were transferred to PVDF 
membranes using a wet-transfer set up and incubated for 16 hours in 3% milk, TBS-T to prevent 
non-specific antibody binding. Membranes were incubated in the following primary antibodies for 
18 h in 3% milk at 4 °C: (1) polyclonal anti-rabbit mannose receptor (Abcam, Cambridge, MA) at 
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1:714 dilution for an M2 marker or (2) monoclonal anti-mouse β-actin (Santa Cruz, Dallas, TX) at 
a dilution of 1:1000 as a loading control. Three blots completed on separate days (n=3) and were 
visualized using a LICOR Odyssey fluorescent imaging scanner. Densitometry of protein 
expression was standardized to the loading control. 
8.3.9  In-vivo cytocompatibility 
8.3.9.1 Abdominal wall defect model: The partial thickness abdominal wall defect model for 
evaluation of the host response to biomaterials is well established 270,330. Surgical plane of 
anesthesia was achieved via inhalation of 2% isoflurane in oxygen. The surgical site was prepared 
by shaving the lateral abdominal region on both sides of each animal, followed by scrubbing, and 
draping. Animals were placed in a lateral decubitus position and incisions were made along the 
midaxillary line. The skin and subcutaneous tissues medial to the incision were separated from 
the underlying muscle tissues. A 1.5 cm by 1.5 cm section of the external and internal oblique 
layers of the ventral lateral abdominal wall were excised while the underlying transversalis fascia 
and peritoneum were left intact. The muscle defect was subsequently repaired with a size-
matched piece of the chosen test article or a hydrogel.  The test articles were secured in place 
with 4-0 Prolene at each of the four corners securing the device to the surrounding and underlying 
musculature allowing for mechanical loading of the test article during the normal abdominal wall 
activity of daily living, and facilitating identification at the time of explantation. Incisions were 
closed with 4-0 Vicryl sutures.  Animals were recovered from anesthesia, returned to the housing 
unit, and received 0.02 mg Buprenex (buprenorphine hydrochloride) by subcutaneous injection 
the day of surgery and for two additional days twice daily. Baytril (20 mg) was administered orally 
the day of surgery and for two additional days. The dietary habits, general health status, and the 
surgical site were monitored daily and recorded. The implant site containing test articles and 
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surrounding adjacent tissue were isolated and placed in 10% neutral buffered formalin (NBF). 
Samples were then embedded in paraffin and cut into 6 µm sections for histologic studies.  
8.3.9.2 Histomorphologic scoring: Tissue sections were stained with hematoxylin and eosin  
(H&E) for qualitative and semiquantitative histomorphologic analysis of remodeling outcomes. 
Two blinded investigators scored sections according to an established semi quantitative scoring 
method as shown in Table 7 (page 82). Scoring criteria were used to group devices according to 
the following categories: chronic inflammation and foreign body reaction (quantitative score < 5), 
early inflammatory cell infiltration with decreased cellularity and little evidence of constructive 
downstream remodeling (5 ≤ quantitative score ≤ 10), and early infiltration by inflammatory cells 
and signs of constructive remodeling at later time points (quantitative score > 10).  
8.3.9.3  Host response: macrophage immunolabeling: To characterize macrophage 
phenotype following ECM implantation, paraffin-embedded tissue sections were deparaffinized. 
Heat-mediated antigen retrieval was performed in heated citrate buffer for 20 minutes (10 mM 
citrate, pH 6.0 at 95-100°C).  Tissue sections were allowed to cool and were incubated in blocking 
solution consisting of 2% goat serum, 1% bovine serum albumin (BSA, Sigma), 0.1% Triton X-
100 (Sigma), and 0.1% Tween-20 (Sigma) in PBS to prevent non-specific antibody binding. After 
blocking, tissue sections were incubated with primary antibodies diluted 1:150 in blocking solution 
overnight at 4°C. CD68 (mouse anti-rat CD68 clone ED1, AbD Serotec) was used as a pan-
macrophage marker, CD86 (rabbit anti-human CD86, clone EP 1158Y, abcam) was used as an 
M1 macrophage marker, and CD206 (goat anti-human CD206 polyclonal, Santa Cruz) was used 
as an M2 marker. Following primary incubation, sections were washed in PBS and incubated in 
the following fluorescently conjugated secondary antibodies for 1 hour at room temperature 
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diluted in blocking solution: AlexaFluor donkey anti-mouse 594 at 1:200 (Invitrogen), PerCP-
Cy5.5 donkey anti-rabbit at 1:300 (Santa Cruz), and AlexaFluor donkey anti-goat 488 at 1:200 
(Invitrogen). Tissue sections were washed, counterstained with 4’,6-diamindino-2-phenylindole 
(DAPI), and coverslipped. Multispectral images were acquired with appropriate filter sets using a 
Nuance microscope and spectrally unmixed to remove tissue auto-fluorescence. Four images 
were taken along the defect and underlying transversalis interface at 200X magnification. Total 
cells expressing CD68 and either CD86 or CD206 were quantified using CellProfiler image 
analysis software. Macrophages were defined as CD68 positive colocalized with nuclei. M1 and 
M2 cells were defined as macrophages (CD68+) coexpressing CD86 or CD206 respectively. Cells 
expressing both CD86 and CD206 were subtracted from the M1 and M2 totals, and an M2:M1 
ratio was calculated for each image. 
8.3.10  Statistical analysis 
A two-tailed equal variance student’s t-test was used to determine whether the DNA, 
phospholipid, GAGs, HA, collagen, growth factor, and mechanics of the coECM were different 
than that of native colon (p < 0.05). A t-test was also used to determine differences in 
turbidometric and rheologic properties of 4 mg/mL vs. 8 mg/mL coECM hydrogels. A one-way 
analysis of variance (ANOVA) with post-hoc Tukey test was used to determine differences in the 
percentage of viable cells in culture, percentage of cells expressing macrophage phenotype 
markers, in-vivo histologic scores, and in-vivo macrophage phenotype ratio. All data are reported 
as mean ± standard error. 
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8.4  RESULTS 
8.4.1  Decellularization efficacy 
A protocol for effective decellularization of colonic submucosa was identified with the use of 
enzyme and detergent washes. Although previously described decellularization protocols for 
gastrointestinal tissue (e.g., esophageal and small intestine) do not require delipidization 138,162, 
the porcine colonic submucosa had high lipid content and thereby required delipidization for 
effective decellularization. The degree of decellularization following the described method was 
assessed using previously established guidelines for decellularization 175. No intact nuclei were 
visible by H&E or DAPI staining following decellularization (Figure 12A). The concentration of 
remnant DNA in coECM (43 ± 5.3 ng/mg) was markedly less (p<0.001) than that in native colonic 
tissue (7435 ± 420 ng/mg) and native submucosa (998 ± 31 ng/mg)  (Figure 12B). Residual DNA 
was present in fragments less than 200 bp in length (Figure 12C). In addition to DNA content, 
phospholipid concentration in the coECM was used as an indicator of decellularization efficacy. 
The concentration of phospholipids, a fundamental component of cell membranes, in the coECM 
was 876 ± 105 nmol/g and was much lower (p<0.001) than the native colon (Figure 12D). 
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Figure 12. Decellularization efficacy. (A) The presence of nuclei in the decellularized tissue 
was assessed by hemotoxylin and eosin (H&E) staining and 4',6-diamidino-2-phenylindole 
(DAPI) staining. (B) DNA concentration was quantified using PicoGreen® assay. (C) The 
fragment length of residual DNA was visualized by gel electrophoresis. (D) Residual cell 
membrane components were quantified using EnzyChrom™ phospholipid assay.  
Scale bar = 200 μm. ** = p<0.01 
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8.4.2  Biochemical and structural properties of coECM 
The preservation and spatial distribution of ECM proteins, including basement membrane-
associated laminin, and a non-basement membrane protein, fibronectin, were examined. 
Immunolabeling expectedly showed that laminin was present along the basement membrane of 
the native colon but this layer was mechanically removed during decellularization and thus 
laminin was largely absent in the coECM. Similarly, positive staining for fibronectin was present 
and distributed throughout the native colonic tissue but only diffuse staining for fibronectin was 
observed in the coECM (Figure 13A). The surface ultrastructure of the coECM scaffold was 
observed with SEM. SEM images of the luminal and abluminal surface of coECM showed a 
smooth surface on the luminal surface of the coECM. The abluminal surface, however, had a 
more textured and fibrous appearance (Figure 13B).  
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Figure 13. CoECM composition and ultrastructure. (A) The presence and distribution of 
laminin and fibronectin was assessed by immunohistochemical staining. (B) The ultrastructure 
of the luminal and abluminal surfaces of the scaffold was visualized at low and high (inset) 
magnification. Scale bar in 2A = 200 μm. Scale bar in 2B = 50 μm. 
Biochemical characterization of coECM showed that important ECM constituents are 
present in the decellularized colonic mucosa. GAGs, both sulfated and non-sulfated, were 
retained in coECM. A large percentage of sGAGs were preserved in the coECM although the 
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concentration was less than (p=0.012) the native tissue (Figure 14A). Hyaluronic acid, a non-
sulfated GAG, was present in the coECM while the concentration was also lower (p=0.001) than 
native tissue (Figure 14B). The amount of fibrilliar collagen in the coECM was expectedly greater 
(p=0.039) than native tissue as collagen represents a large proportion of the ECM (Figure 14C). 
Lastly, although present in reduced levels compared to native tissue, both bFGF (Figure 14D, 
p<0.001) and VEGF (Figure 14E, p<0.001) were retained in the coECM. 
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Figure 14. Biochemical composition. The retention of biochemical consitutents in coECM 
was compared to native colonic tissue. (A) The concentration of sulfated glycosaminogylcans 
(sGAGs) was measured using Blyscan™ assay. (B) Non-sulfated GAG hyaluronic acid (HA) 
content was measured using an ELISA. (C) Fibrilliar collagen was quantified using Sircol™ 
assay. The presence of two growth factors, bFGF (D) and VEGF (E), was detected using 
ELISA kits. * = p<0.05, ** = p<0.01 
8.4.3  Mechanical properties of coECM scaffold 
The equibiaxial stress response of the native colon showed anisotropic behavior with a 
maximum strain of 4.9% and 2.4% in the longitudinal and circumferential direction, respectively 
(Figure 15A,B). The coECM showed similar anisotropy, but had a lower compliance along both 
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the longitudinal (1.8%, p=0.042) and circumferential (0.5%, p=0.023) axes (Figure 15A,B). The 
multilaminate coECM scaffold, however, had marked increase (p<0.001) in suture retention 
strength compared to the native colon (Figure 15C).   
Figure 15. Scaffold mechanical properties.  (A) The response of the scaffold to equibiaxial 
stress was assessed using planar biaxial testing. (B) Maximum strain of the scaffold at a 
stress of 250 kPa was quantified in the longitudinal and circumferential direction. (C) The 
suture retention strength of multi-laminate scaffolds was compared prior to in-vivo 
implantation.  
* = p<0.05, ** = p<0.01
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8.4.4  Rheologic and turbidometric properties of coECM hydrogel 
The turbidometric and rheological properties of the coECM hydrogel were concentration 
dependent. Macroscopically, the higher ECM concentration 8 mg/mL hydrogels had a rigid 
structure with defined edges, and could be handled and manipulated with forceps while the 4 
mg/mL hydrogels were softer with rounded edges and not easily handled (Figure 16A). 
Compared to the 4 mg/mL hydrogel, the more concentrated 8 mg/mL hydrogel had a shorter lag 
time (17 ± 0.3 vs. 22 ± 0.8 min; p<0.001) prior to gelation (Figure 16B), and gelled more rapidly 
(Figure 16C-D).  Results of rheological testing showed that the 8 mg/mL pre-gel was more 
(p=0.027) viscous (Figure 16E) and the hydrogel that formed was much stiffer (p=0.001) than the 
4 mg/mL hydrogel (Figure 16F).  
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Figure 16. Hydrogel turbidometric and rheological properties. (A) Two concentrations of 
coECM hydrogel, 4 and 8 mg/mL, were formed in a ring mold and compared macroscopically. 
Turbidometric anaylsis was used to measure the tlag (B), t1/2 (C), and rate of gelation (D) of the 
hydrogel at two different concentrations. Parallel plate rheology was used to measure the 
viscosity of the pre-gel (E) and maximum storage modulus of the hydrogel (F).  
Scale bar = 1cm,  * = p<0.05, ** = p<0.01 
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8.4.5  In-vitro cell response to coECM 
Intestinal epithelial cells retained nearly 100% viability when seeded on coECM, XL-coECM, 
coECM gel, and submucosa (Figure 17A). There was no difference between these treatments 
and when compared to tissue culture plastic after 24 hours in culture (Figure 17B).  
Primary murine bone marrow derived macrophages were activated to the M1 (IFNγ/LPS) 
and M2 (IL-4) phenotypes for 18 hours or treated with 200 μg/ml of solubilized coECM. All 
experimental groups showed uniform F4/80 staining with 93.4 ± 0.5% of cells expressing the pan-
macrophage marker. The controls showed an expected increase (p<0.001) in iNOS when 
macrophages were treated with IFNγ/LPS and an increase (p<0.001) in Fizz1 when treated with 
IL-4. The coECM treatment was found to promote M2-like macrophage activation, similar to IL-4 
treated macrophages as shown by Fizz1 expression accompanied by little iNOS expression 
(Figure 17C). Results quantified using CellProfiler show a large Fizz1+ cell population and small 
iNOS+ cell population when treated with coECM, suggesting that coECM directly promotes a 
constructive, M2-like macrophage phenotype (Figure 17D). The presence of CD206, a cell 
surface receptor that is indicative of M2 macrophage phenotype, was assessed using western 
blot analysis and normalized to a β-actin loading control.  Similar to above with Fizz1 expression, 
the ratio of CD206:β-actin was on average greatest in macrophages following IL-4 (1.8 ± 0.4) and 
coECM treatment (1.2 ± 0.2) compared to IFNy/LPS treatment (0.6 ± 0.2) or the pepsin control, 
although not significant.  
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Figure 17. In-vitro cell response. (A) Intestinal epithelial cells cultured on coECM scaffold, coECM 
hydrogel, XL-coECM, and native submucosa were stained with LIVE/DEAD® cell viability dye and (B) 
the percentage of live and dead cells were quantified. (C) Bone marrow derived macrophages were 
cultured in the presence of enzymatically digested coECM and immunolabled for F4/80 (pan 
macrophage), iNOS (M1), and Fizz1 (M2). Controls included MCSF (baseline), IFNγ +LPS (M1), IL-4 
(M2), and pepsin (digestion buffer). (D) The percentage of cells expressing the markers indicative of 
M1 and M2 phenotypes was quantified and compared. ** = p < 0.01 
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8.4.6  In-vivo host response 
The in vivo host response to coECM was examined in a rat abdominal wall defect model at both 
14 and 35 days following implantation. In addition to coECM and coECM hydrogel, two additional 
groups were used as negative controls. Native colonic submucosa was used as a control to 
validate the necessity for effective decellularization 138. Cross-linked coECM was used to validate 
the need for scaffold degradation 328.  By 14 days, coECM sheet and gel implants showed 
histologic evidence of a robust cell infiltrate and partial scaffold degradation shown by hematoxylin 
and eosin staining (Figure 18A) with an average histologic score of 12.9 and 12.1, respectively 
(Figure 18B). In contrast, cross-linked coECM and native colonic submucosa implants were 
characterized by very little cellular infiltration and vessel formation and minimal scaffold 
degradation (Figure 18A). Disorganized connective tissue was present along the interface of XL-
coECM and submucosa with the native underlying muscle. The average histologic scores for XL-
coECM and native submucosa was 9.4 and 8.8, respectively (Figure 18B), which were both 
significantly less (p<0.05) than the coECM and coECM hydrogel. By 35 days, coECM sheets and 
gels were completely degraded while XL-coECM and native colonic submucosa remained almost 
completely intact (Figure 18A). The histologic scores for both coECM and coECM hydrogel were 
greater (p<0.05) than both XL-coECM and native submucosa (Figure 18B). 
Macrophage immunolabeling at 7 days post surgery (Figure 18C) showed a predominant 
CD68+CD206+ M2 macrophage population in coECM sheet and gel treated groups when 
compared to a predominant CD68+CD86+ proinflammatory M1 macrophage phenotype following 
XL-coECM or colonic submucosa implantation as shown in Figure 18C. The ratio of the M2:M1 
macrophages in the coECM scaffold was 1.46 ± 0.3 which was greater (p<0.01) than the XL-
coECM and native submucosa  (Figure 18D).  The M2:M1 ratio in the coECM gel was on average 
also greater than the XL-coECM and native submucosa, although not significant (p=0.055) 
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Figure 18.  Host response.  The host response to coECM scaffold and hydrogel was 
compared in-vivo to XL-coECM and native submucosa in a rat abdominal defect model. (A) 
Representative H&E images show the histologic response at 14 and 35 days. (B) The 
combined histologic score at each time point was quantified and compared across groups. (C) 
The macrophage response at 14 days post surgery was analyzed by immunoflourescent 
staining for M2 indicator CD206 (green), M1 indicator CD86 (orange), and pan-macrophage 
CD68 (red). (D) The ratio of M2 (CD68+/CD206+) to M1 (CD68+/CD86+) was quantified and 
compared across groups. Dashed lines indicate interface between scaffold and underlying 
muscle. * = p<0.05, ** = p<0.01 
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8.5  DISCUSSION 
 Functional replacement of injured or missing GI tissue requires a diverse tool set to promote the 
growth and differentiation of specialized cell types and tissue layers that vary from esophagus to 
small intestine to colon. The present study represents a thorough characterization of an ECM 
bioscaffold derived from porcine colon (coECM). The coECM scaffold was shown to be 
decellularized—meeting previously established stringent criteria 175. The decellularization protocol 
effectively removed native DNA while preserving essential structural and biochemical ECM 
components including sGAGs, hyaluronic acid, collagen, bFGF, and VEGF. The coECM scaffold 
was shown to retain similar mechanical properties and anisotropy as native colon. In vitro and in 
vivo coECM is cytocompatibile and promotes a constructive, M2-like macrophage phenotype 
when compared to its ineffectively decellularized or cross-linked counterparts. Such properties 
make coECM promising for use as an “off-the-shelf” gastrointestinal repair biomaterial.  
Regions of the GI tract, specifically the small intestinal submucosa (SIS) and esophageal 
mucosa, have been successfully decellularized previously 4,162. Just as the native GI tract is a 
highly complex and variable organ, the composition and properties of each of these bioscaffolds 
are also variable. Such properties are largely dependent on the method of decellularization 
utilized and the source tissue from which they are derived. SIS-ECM is prepared primarily by 
mechanical delamination and exposure to peracetic acid. Esophageal ECM (eECM), on the other 
hand, is exposed to a series of enzymatic and chemical detergent treatments after mechanical 
delamination methods, similar to coECM preparation 162 though an additional delipidization step 
is necessary for coECM decellularization. Each of these protocols results in scaffolds with unique 
properties and compositions. For example, when compared to eECM, coECM has a lower 
maximum strain along the longitudinal axis 162. Differences in these values could be important 
determinants of in vivo remodeling outcomes. Previous studies have shown that tensile strength 
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increases from proximal to distal intestine 341, likely stemming from the need of distal colon to 
accommodate changes in higher stress as fecal pellets become more solid. Distinguishing the 
mechanics of different regions of the gut and a thorough comparison and understanding of the 
similarities and differences between ECMs derived from different source tissues could have 
important implications for application-specific selection of bioscaffolds, particularly in 
gastrointestinal repair applications which are also inherently diverse and complex and require 
individualized mechanics for peristalsis, digestion, absorption, and gastric motility.  
While heterologous ECM bioscaffolds have been used with success in multiple anatomic 
locations for constructive tissue remodeling, a subset of studies have indicated that it may be 
advantageous to utilize site-specific ECM 109,110,113,114,172. Each tissue has a distinct composition 
of ECM in which the appropriate signaling molecules and structural components are present to 
allow for cell growth and differentiation and synergized tissue function. It is reasonable to assume, 
therefore, that decellularization of site-specific tissue would provide the optimal inductive template 
for tissue engineering in its respective anatomic location. Whether or not site-specific ECM use is 
relevant in all therapeutic applications, however, is not fully understood. Results of the present 
study show coECM facilitated constructive tissue remodeling in a heterologous location. Design 
of a tissue-engineered intestine should take into consideration gut function such as contractility. 
Biomaterials for gut replacement should allow for regeneration of functional muscle and 
directional self-organization of functionally distinct layers that perform a variety of functions 
including nutrient absorption, mucus secretion, and motility. Future studies are warranted to 
determine the efficacy of coECM as a bioscaffold in gastrointestinal, or specifically colon, disease 
/ injury models. 
Although the mechanism(s) of action of ECM-mediated tissue remodeling are only partially 
understood, the activation/polarization of infiltrating macrophages at the remodeling site from a 
pro-inflammatory, cytotoxic M1 phenotype to an immunoregulatory, constructive M2 macrophage 
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phenotype has been shown to be a predictor of favorable downstream remodeling outcomes 132. 
The present study shows that coECM promotes a predominant M2 (CD68+CD206+) macrophage 
phenotype when compared to native colonic submucosa and XL-coECM following implantation. 
The immunomodulatory properties of coECM may prove beneficial in cases of inflammatory bowel 
disease treatment in which it is postulated that the host lamina propria macrophages fail to 
polarize toward a more tolerant M2-like phenotype 342,343. The present study shows that coECM 
can also be prepared in a hydrogel form with unique and concentration-dependent viscoelastic 
properties, providing flexibility for in vivo applications such as injectable or enema administration. 
Biologic scaffolds are preferred over synthetic scaffolds for many tissue repair applications 
because of their degradability in vivo. It is now well accepted that cross-linking biologic scaffolds 
results in slower degradation and often encapsulation and fibrosis. Such inhibition of scaffold 
degradation prevents the release or exposure of matricryptic peptides and is consistently 
associated with less than desirable outcomes 90,270. Hematoxylin and eosin (H&E) staining of 
abdominal wall explants shows that coECM sheet and hydrogel formulations are characterized 
by a robust cellular infiltrate at 14 days and are largely degraded by 35 days, unlike the native 
(non-decellularized) submucosa and XL-coECM which were characterized by mostly 
disorganized connective tissue and some encapsulation as reflected by a lower histomorphologic 
score. This score differential is likely due to the incomplete decellularization of the submucosa 
graft and the inability of XL-coECM to degrade. Ineffective decellularization has been shown to 
be a crucial factor in provoking a foreign body reaction from the host following bioscaffold 
implantation138,344 (See Appendix 12.3, page 188 for more information). Degradation products of 
coECM have been shown to not only promote a predominant F480+/Fizz1+ macrophage 
population in vitro, but previous work has also shown that degradation products of ECM are 
chemotactic and mitogenic for progenitor cells both in vitro and in vivo 67,134,345. These results 
emphasize the importance for effective decellularization and scaffold degradation. 
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The present chapter has limitations. While coECM was shown to be conducive to intestinal 
epithelial cell survival in vitro, the tissue-specific effects of coECM on colonic progenitor cells and 
in a colonic repair animal model were not evaluated. Additionally, while retention of growth factors 
bFGF and VEGF protein were measured, their bioactivity was not measured. The role of these 
growth factors in constructive remodeling is not understood. Previous work shows that 
vascularization has been, to this point, a limiting step in tissue engineered construct survival 325. 
Future studies should determine whether coECM-retained VEGF remains active to promote an 
angiogenic response. While a high M2:M1 macrophage ratio has been shown to be a predictor of 
downstream remodeling outcomes in ECM-mediated tissue repair, macrophage phenotype 
polarizes along a spectrum. The present study utilizes CD206 and CD86 for M2 and M1 
macrophage markers, respectively; however, a more thorough characterization of macrophage 
activation phenotype would result from analyzing additional markers.  
8.6  CONCLUSION 
A biologic scaffold was successfully prepared from porcine colon. The coECM scaffold was 
effectively decellularized and retained important ECM constituents.  The decellularized tissue was 
prepared in hydrogel or lyophilized sheet forms to address diverse gastrointestinal repair 
applications. Both forms of ECM were conducive to intestinal epithelial cell growth and were 
shown to promote a constructive macrophage phenotype in-vitro. Surgically implanted coECM 
scaffold and hydrogel also promote an immunomodulatory host response and site appropriate 
tissue deposition. Given the large unmet clinical need for repair of GI tissue, further work is 
warranted to examine the specific effects of coECM upon colonic stem / progenitor cells and in 
vivo remodeling in a gastrointestinal disease model to assess site-specific effects of ECM 
bioscaffolds.  
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9.0 TISSUE-SPECIFIC EFFECTS OF ESOPHAGEAL EXTRACELLULAR MATRIX6
9.1  ABSTRACT 
Biologic scaffolds composed of extracellular matrix (ECM) have been used to facilitate repair or 
remodeling of numerous tissues, including the esophagus. The theoretical ideal scaffold for 
tissue repair is the ECM derived from the particular tissue to be treated; i.e., site-specific or 
homologous ECM. The preference or potential advantage for the use of site-specific ECM 
remains unknown in the esophageal location. The objective of the present chapter was to 
characterize the in-vitro cellular response and in-vivo host response to a homologous 
esophageal mucosal ECM (eECM) vs. non-homologous ECMs derived from small intestinal 
submucosa and urinary bladder. The in-vitro response of esophageal stem cells was 
characterized by migration, proliferation, and 3D organoid formation assays. The in-vivo 
remodeling response was evaluated in a rat model of esophageal mucosal resection. Results of 
the study showed that eECM retains favorable tissue-specific characteristics that enhance the 
migration of esophageal stem cells and supports the formation of 3D organoids to a greater 
extent than heterologous ECMs. The in-vivo response to eECM was also postive. However,  
6 Portions of this chapter were adapted from the following publication: 
Keane TJ, DeWard A, Londono R, Saldin L, Carey L, Castelton A, Nieponice A, Lagasse E, Badylak SF. 
Tissue-Specific Effects of Esophageal Extracellular Matrix. Tissue Engineering Part A. August 2015. DOI: 
10.1089/ten.tea.2015.0322 
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implantation of eECM facilitates the remodeling of esophageal mucosa following mucosal 
resection but no distinct advantage vs. heterologous ECM could be identified. 
9.2  INTRODUCTION 
Scaffolds derived from extracellular matrix (ECM) have been investigated for their ability to 
support tissue remodeling in nearly every body system, including parts of the gastrointestinal 
tract. Similarly, ECM scaffolds have been isolated from tissues ranging from urinary bladder and 
small intestine to spinal cord and brain 82,116,346, among others. Implantation and subsequent 
degradation of ECM scaffolds leads to the release or exposure of cryptic peptide fragments that 
affect cell behavior and tissue remodeling events. However, the necessity or preference for 
homologous ECM remains unknown for many therapeutic applications. 
The ECM represents the structural and functional molecules secreted by the resident 
cells of a tissue or organ. The biochemical composition and mechanical and ultrastructural 
characteristics of an ECM scaffold therefore vary according to the tissue source from which the 
ECM is isolated. Logically, the ideal substrate for cell survival, proliferation, differentiation, and 
functional tissue remodeling is the native ECM of the homologous tissue or organ. Recent work 
has described potential benefits of ECM scaffold materials derived from homologous tissue 
versus heterologous tissue when used in selected anatomic locations 109-116,118. Homologous 
ECM can preferentially maintain tissue-specific cell phenotypes 109-112, promote cell proliferation 
111,113, induce tissue-specific differentiation 114, and enhance the chemotaxis of stem cells 115-117.  
However, the preference or necessity for tissue-specific ECM has not been shown for all 
therapeutic applications 92,119,120.  
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The objective of the present chapter was to compare the cellular response to 
esophageal ECM (eECM) versus small intestinal submucosa (SIS-ECM) and urinary bladder 
matrix (UBM) in-vitro and in-vivo. The chemotaxis, proliferation, and capacity for eECM to 
support the formation of three dimensional (3D) organoids of esophageal stem cells, which are 
a candidate cell population that may play a role in functional tissue remodeling of the 
esophagus, was investigated. The eECM scaffold was then implanted in a rat esophageal 
mucosal defect model to determine the ability of the scaffold to facilitate remodeling of 
esophageal mucosa. 
9.3  MATERIALS AND METHODS 
9.3.1  Overview of experimental design 
Porcine esophageal mucosa was decellularized to produce eECM. Using a population of 
murine-derived esophageal stem cells 347, the ability for eECM to promote migration, 
proliferation, and 3D organoid formation was evaluated and compared to two benchmark ECM 
scaffolds; specifically urinary bladder matrix (UBM) and small intestinal submucosa (SIS). 
Subsequently, eECM and UBM scaffolds were implanted into a rat model of esophageal 
mucosa resection and the remodeling response was evaluated at 14 days post surgery. 
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9.3.2  Mice and rats 
Transgenic EGFP C57BL/6 mice were bred and housed in the Division of Laboratory Animal 
Resources facility at the University of Pittsburgh McGowan Institute for Regenerative Medicine. 
Female Sprague Dawley rats (350 – 400 g at implantation) were purchased from Harlan 
Laboratories and housed in the Division of Laboratory Animal Resources facility at the 
University of Pittsburgh McGowan Institute for Regenerative Medicine. Experimental protocols 
followed NIH guidelines for animal care and were approved by the Institutional Animal Care and 
Use Committee at the University of Pittsburgh. 
9.3.3  Harvesting and preparation of ECM and hydrogels 
The esophagus, urinary bladder, and small intestine were isolated from market weight pigs and 
frozen at -20 °C until use. All ECM scaffolds were prepared according to established 
decellularization protocols (Fig 1). Briefly, esophageal mucosal ECM (eECM) was prepared by 
mechanically separating the mucosa and submucosa from the muscularis externa and 
subjecting the mucosal layers to 1% trypsin/0.05% EDTA (Invitrogen, Carlsbad, CA) for 1 h at 
37 °C on a rocker plate, deionized water for 15 min, 1 M sucrose (Fisher Scientific, Pittsburgh, 
PA) for 30 min, deionized water for 30 min, 3.0% Triton X-100 (Sigma Aldrich, St. Louis, MO) for 
48 h, deionized water for 15 min, PBS (Fisher Scientific) for 15 min, 10% deoxycholate (Sigma 
Aldrich) for 4 h, deionized water for 30 min, 0.1% peracetic acid (Rochester Midland Corp., 
Rochester, NY) in 4.0% ethanol for 4 h, 100 U/mL DNAse (Invitrogen) for 2 h on a rocker plate, 
followed by 15 min washes with PBS, deionized water, PBS, and deionized water 162. All 
washes were at 300 rpm unless otherwise specified.  
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Small intestinal submucosa (SIS) was prepared by mechanically removing the superficial 
layers of the tunica mucosa, tunica serosa, and tunica muscularis externa from the intact small 
intestine, leaving the submucosa, muscularis mucosa, and basilar stratum compactum intact. 
Urinary bladder matrix (UBM) was prepared by mechanically removing the tunica serosa, tunica 
muscularis externa, the tunica submucosa, and majority of the tunica muscularis mucosa from 
the intact bladder, leaving the lamina propria and basement membrane intact. The SIS and 
UBM were then subjected to 0.1% peracetic acid in 4.0% ethanol for 4 h, followed by 15 min 
washes with PBS, deionized water, PBS, and deionized water as described above. All 
treatments were performed at room temperature with agitation on a shaker plate at 300 RPM 
unless otherwise stated. 
For implantation studies, the ECM scaffolds were lyophilized using an FTS Systems Bulk 
Freeze Dryer (Model 8-54) and sterilized with ethylene oxide. For studies using a hydrogel form 
of the ECM, the decellularized ECM sheets were lyophilized and comminuted to a particulate 
form using a Wiley Mini Mill. One gram of lyophilized ECM powder and 100 mg of pepsin 
(Sigma) were mixed in 100 ml of 0.01 M HCl and kept at a constant stir for 48 h at room 
temperature.  
9.3.4  SDS gel chromatography 
Pepsin solubilized (0.1% pepsin) forms of SIS, UBM, and eECM were diluted 1:1 in 2× Laemmli 
sample buffer (Bio-Rad, Hercules, CA) and boiled at 95 °C for 8 minutes. Samples were diluted 
and protein concentrations were approximated using a bovine serum albumin (BSA) with a 
Pierce BCA Protein Assay (Thermo Fisher, Waltham, MA) according to the manufacturer’s 
instructions. Samples (5 µg) were run on a 10%, 12-well SDS PAGE gel (Bio-Rad, Hercules, 
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CA) at 50V until the tracking dye moved below the stacking gel. The gel was then run at 150 V 
for 50 min, until the dye reached the end of the gel. After running, the gel was washed and fixed 
with 30% ethanol/10% acetic acid in a rocking staining dish. Silver stain was applied according 
to manufacturer’s instructions (Silver Stain Plus Kit, Bio-Rad) and developed for 15 minutes. 
The developed gel was imaged using a Nikon D7000 over a light table. 
9.3.5  Isolation and culture of esophageal stem cells 
The esophagus was removed from transgenic EGFP C57BL/6 mice (Jackson Laboratories) 
followed by physical separation of the mucosa using forceps. The mucosa was minced into 
small pieces and digested with 0.25 % Trypsin for 60 minutes. Cells and remaining tissue were 
passed through a 70 µm filter to obtain a single cell suspension. Cells were then placed in tissue 
culture flasks that were previously seeded with irradiated LA7 feeder cells. LA7 cells have been 
shown to select for esophageal epithelial cells with stem cell properties 347. Esophageal 
epithelial cells were expanded by passaging cells to flasks coated with irradiated LA7 cells.  
9.3.6  Migration assay 
Migration assays were performed using a 48 well chemotaxis chamber with polycarbonate filters 
containing 5 μm pores (Neuro Probe, Gaithersburg, MD). The filters were coated with 20 μg/ml 
laminin (Sigma) and dried prior to use. The bottom wells of the chamber were loaded with 30 μl 
containing 25 or 100 μg/ml of ECM digest and the top wells were loaded with 50 μl containing 
7×104 esophageal stem cells. Control wells consisted of serum free media and media containing 
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10% FBS.  Following 6 h incubation, the top filter surface (non-migratory) was scraped and the 
bottom of the filter was fixed in 95% methanol for 5 min and then mounted on a glass slide with 
mounting media containing DAPI (Vector Laboratories Inc, Burlingame, CA) and imaged. 
Migrated cells were quantified using ImageJ (NIH) to set the threshold and count cells, with 
binning to resolve cell clusters of various counts. The same ImageJ macro was used to analyze 
all images. Experiments were performed using 4 technical replicates with 4 separate biologic 
replicates (n=4). 
9.3.7  Generation of 3D organoids 
Esophageal cells were suspended in ECM hydrogels and were placed as a droplet in a tissue 
culture plate. Cells were incubated at 37º C for 30 minutes to allow for solidification of the 
hydrogels. Growth medium was added to the plate to initiate organoid formation. Growth 
medium consisted of Advanced Dubecco’s modified Eagle’s medium/F12, 1x N2, 1x B27 
Supplements, 1x Glutamas, 1x HEPES, 1x penicillin/streptomycin, 1 mM N-acetyl-L-cysteine, 
100 µM gastrin, 10 mM nicotinamide, 10 µM SB202190, 50 ng/mL epidermal growth factor, 100 
ng/mL Noggin, 100 ng/mL Wnt3A, 100 ng/mL R-Spondin 2, and 500 nM A8301. Media was 
changed every 2-3 days. 
9.3.8  Proliferation assay 
Esophageal organoids were generated followed by the addition of 5-ethynyl-2′-deoxyuridine 212 
to the culture media. Cells were exposed to EdU for 2 hours to allow incorporation of EdU into 
dividing cells. Organoids were fixed in 4% paraformaldehyde and embedded in gelatin. 
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Organoids were sectioned at 10 µm and EdU was detected using the Click-iT Alexa Fluor 594 
EdU labeling kit. Cells were counterstained with Hoechst to detect cell nuclei. EdU positive cells 
was counted to determine the number of proliferating cells per organoid.   
9.3.9  Surgical procedure and ECM implantation 
All surgical procedures were approved by the Institutional Animal Care and Use Committee at 
the University of Pittsburgh and the animal care complied with the National Institutes of Health 
Guidelines for the Care and Use of Laboratory Animals. Induction and surgical plane of 
anesthesia were achieved with 2% inhaled isoflurane and the animals were placed on a 
warming pad in supine position. The cervical skin was shaved and aseptically prepared with 
ethanol and betadine. A midline cervical incision was performed above the clavicle and the 
esophagus exposed via blunt dissection. A transverse incision of the muscularis externa layer 
was performed, and a window of full thickness mucosa extending 5-10 mm length including 70% 
of the circumference was resected. Animals treated with ECM received a single layer sheet that 
was placed over the denuded area and secured in place with interrupted 10.0 prolene sutures 
(Ethicon, Somerville, NJ). The denuded mucosa was left exposed in non-treated control 
animals. Skin was closed with 4.0 Vicryl (Ethicon) and buprenorphine (0.5 mg/kg, Benckiser 
Healthcare (UK) Ltd, Hull, England) was administered intramuscularly immediately 
postoperatively and twice a day for 3 days. Animals were placed on a soft diet for 5 days post 
operatively. 
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9.3.10   Histology and immunolabeling 
Two histology and immunolabeling studies were performed: 1) on the 3D organoids and 2) on 
the explanted esophageal tissue sections. Organoids were collected upon digestion of the 
hydrogel using 0.2% Dispase, 0.1% collagenase type II, and 20 ug/mL DNase I in 1x HBSS 
containing 1% HEPES. Organoids were embedded in 5% gelatin, fixed in 4% paraformaldehyde 
for 1 h, and embedded in paraffin. Explanted esophageal tissue sections were fixed in 10% 
neutral buffered formalin and paraffin embedded.  
Serial sections (5 μm) of the organoids and tissue sections were stained with 
hematoxylin and eosin or immunolabeled. Organoid and tissue sections were deparaffinized 
with xylene and rehydrated through a graded ethanol series. Antigen retrieval was performed by 
heating a citrate antigen retrieval buffer (10 mM citric acid with 0.05% Tween 20, pH 6) until 
boiling, and incubating the slides in the solution until returning to room temperature. Three 
washes in phosphate buffered saline (PBS) for five minutes at room temperature were 
performed. Organoid and tissue sections were permeabilized with 1x Tris-Buffered Saline with 
Tween 20 (TBST) for 10 minutes at room temperature. The slides were incubated in a blocking 
solution (5% BSA in 1x PBS) at room temperature to prevent non-specific binding. The slides 
were incubated in primary antibody blocking solution at 4°C overnight. Five washes in PBS were 
performed for 5 minutes at room temperature. Slides were incubated in secondary antibody in 
blocking buffer at room temperature for 1 hour. Five washes in PBS were performed for 5 
minutes at room temperature. The primary antibodies used for the immunolabeling studies were 
cytokeratin 13 (1:250; Ab92551, Abcam) and cytokeratin 14 (1:500; Ab7800, Abcam) for the 
organoids, and cytokeratin 14 (1:200; NBP1-67606, Novus Biologicals, Littleton, CO) for tissue 
sections. The secondary antibodies used were Alexa Fluor 488 (1:200; A-11034, Invitrogen) and 
Alexa Fluor 594 (1:200; A21203, Invitrogen). Sections were counterstained with 4',6-diamidino-
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2-phenylindole (DAPI) and mounted in fluorescence mounting medium (Dako). Stained sections
were visualized on Nikon E600 fluorescence microscope with Cri Nuance FX multispectral 
imaging system. 
9.3.11   Statistical analysis 
Data sets were analyzed with a one-way analysis of variance (ANOVA) using SPSS Statistical 
Analysis Software (SPSS Inc., IBM, Chicago, IL). A student t-test was used to identify the 
differences between means when the observed F ratio was statistically significant (p < 0.05). 
Data are reported as mean ± standard error. 
9.4  RESULTS 
9.4.1  ECM characteristics 
Esophagus, small intestine, and urinary bladder were decellularized according to established 
methods of decellularization. The attributes (thickness, cellularity, density, etc.) of each tissue 
are unique and therefore require different protocols for decellularization (Figure 19A). Effective 
decellularization, as defined by previously described metrics 175, was achieved for each tissue. 
Each ECM scaffold had a unique protein banding pattern and eECM had a prevalent band at 
approximately 30 kDa that was absent in both UBM and SIS (Figure 19B). 
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Figure 19. Preparation and characteristics of ECM scaffolds. (A) Overview of 
decellularization process for preparing UBM, SIS, and eECM. (B) Gel chromatography of 
ECM materials showing features in banding patterns of different ECM materials. 
9.4.2  Esophageal stem cell characteristics 
The chemotaxis of esophageal stem cells was evaluated using a Boyden chamber assay. Two 
concentrations of ECM were chosen to determine whether a migration dose response existed. 
The stem cells did not migrate toward serum free media or 10% FBS. Representative images of 
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migratory cells after DAPI staining (Figure 20A) showed an increased migration response of the 
esophageal stem cells toward eECM and SIS, but not UBM, versus the pepsin control. 
Quantification of migrating cells (Figure 20B) showed that eECM enhanced migration of 
esophageal stem cells at both 25 μg/ml (p = 0.01) and 100 μg/ml (p = 0.04). The SIS-ECM 
enhanced stem cell migration at 100 μg/ml (p < 0.01) but not at 25 μg/ml. 
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Figure 20. Migration of esophageal stem cells. (A) Representative images of DAPI stained 
migrating cells towards varying concentrations of ECM. (B) Quantification of migrated cells in 
response to ECM scaffolds. 
9.4.3  Organoid forming capacity of ECM hydrogels 
The ability of ECM hydrogels to support the formation of esophageal organoids was tested 
using two concentrations of ECM: 2 mg/ml and 6 mg/ml (Figure 21A). The number of organoids 
formed in eECM was greater than those formed in SIS and UBM at both 2 mg/ml (p = 0.04) and 
6 mg/ml (p=0.04). Interestingly, the lower concentration hydrogel (2 mg/ml) better supported the 
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formation of organoids compared to the 6 mg/ml ECM hydrogel (Figure 21B). Furthermore, SIS 
consistently performed the poorest among the ECM hydrogels in the ability to support organoid 
formation. Based upon these results, only the 2 mg/ml ECM hydrogels were used for 
subsequent proliferation studies and only eECM and UBM were used for in-vivo studies. 
Figure 21. Capacity of ECM hydrogels to support organoid formation. (A) Comparison 
number of organoids formed in different ECM types. Data are normalized to the number of 
organoids formed in SIS. (B) Comparison of number of organoids formed in ECM at 2 mg/ml 
and 6 mg/ml. Data are normalized to the number of organoids present at 2mg/mL 
concentration of ECM 
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Only eECM was able to support the growth of a substantial number of organoids 
necessary for histologic processing. Organoids that formed in eECM were sectioned and 
immunolabeled for cytokeratin 14 (CK14), a marker of basal epithelium, and CK13, a marker of 
suprabasal differentiated epithelial cells (Figure 22A) 347. Compared to native esophageal 
mucosa (Figure 22B), the organoids largely maintained the CK14+ phenotype at the periphery of 
the organoid while the cells at the organoid center exhibited a more differentiated CK13+ 
phenotype. 
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Figure 22. Cytokeratin immunolabeling. (A) Representative images of organoids formed in eECM. 
(B) Representative image of normal esophageal mucosa. Cytokeratin 14, a basal epithelial cell marker,
is stained red. Cytokeratin 13, a marker of suprabasal epithelial cells, is stained green. Nuclei (DAPI) is
shown blue. Scale bars = 50 μm. 
9.4.4  Proliferation of esophageal stem cells 
Proliferating cells were identified by incorporation of EdU and immunolabeling (Figure 23A). 
Proliferating cells within organoids were present in numbers similar to that in native tissue 347 
and there was no difference among the values for proliferating cells in organoids formed in UBM 
and eECM (Figure 23B). Similarly, the size of organoids (i.e., number of cells per organoid) 
were equivalent in the UBM and eECM hydrogels.  
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Figure 23. Proliferation of organoid cells. (A) Representative images of EdU stained 
organoids following 2h EdU exposure. EdU+ cells are shown in red. (B) Quantification of 
number of cells per organoid and number of EdU+ cells per organoid. Scale bar = 50 μm. 
9.4.5  Esophageal mucosal remodeling 
The ability of ECM to mediate tissue repair in the esophageal mucosa was tested in a rat model 
of mucosal resection. Following resection of approximately 7 mm length of esophageal mucosa 
consisting of 70% of the circumference, a size-matched ECM scaffold was placed at the site of 
tissue resection. Rats weighed 228 ± 2.5g prior to operation, and all animals lost weight 
following mucosal resection. The ECM treated rats gradually gained weight over time. Eighty-
three percent (5 out of 6) of the untreated control animals showed anorexia and complications 
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secondary to anastomotic leaks and stricture formation that required removal from the study 
prior to the predetermined experimental endpoint. The remaining control rat showed no signs of 
mucosal coverage of the implant site (Figure 24A). The eECM treated rats lost -7.4 ± 1.3% vs. -
11.9 ± 2.5% for the UBM treated rats by 3 days post surgery compared to the UBM treated rats 
although the difference was not significant (p=0.243). By 14 days post surgery both groups had 
recovered from the weight loss and exceeded their initial weight (eECM +2.4 ± 2.7% vs UBM 
+1.4 ± 2.6%). All of the ECM treated rats recovered from surgery and survived to the
experimental endpoint (14 days) without complications. Representative images show that 
remodeling of the esophageal mucosa was indistinguishable in rats treated with UBM (Figure 
24B) vs. eECM (Figure 24C).  Positive staining for CK14, a marker of basal esophageal 
epithelium, was absent in the control animals (Figure 24D) but was shown in cells lining the 
basement membrane of the esophageal mucosa in rats treated with both UBM (Figure 24E) and 
eECM (Figure 24F). 
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Figure 24. Histology and immunolabeling of explants at 14 days post-surgery. The in-vivo host 
response to no treatment (A, D), UBM scaffold (B, E), and eECM (C, F) was assessed histologically 
with hematoxylin and eosin (H&E) staining and by immunolabeling for stratified squamous epithelium 
(cytokeratin 14, green). Blood vessel endothelial cells stain positive for cytokeratin 14. Arrows indicate 
positive staining and scale bars = 100 μm. 
9.5  DISCUSSION 
Results of the present study show that a homologous eECM preferentially enhances the 
migration of esophageal stem cells and supports the formation of 3D organoids in culture but in-
vivo remodeling of the esophageal mucosa was similar with the use of heterologous (UBM) vs. 
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homologous (eECM) scaffolds. These collective results suggest that the mucosa of the 
esophagus contains favorable tissue-specific properties that are retained following the 
decellularization process but the contribution to these properties to the overall in-vivo 
remodeling process are either not identifiable in this model of are not require for a constructive 
remodeling outcome. 
While the cells that contribute to esophageal remodeling following mucosal resection in 
the present study are not completely identified, the resident esophageal stem cell population 
represents a plausible and logical candidate 348. These cells are present in the basal layer of the 
esophageal mucosa and following tissue resection must migrate the length of the mucosal 
resection to aid in tissue repair. Results of the present study show that ECM constituents 
facilitate the migration and differentiation of esophageal stem cells and that eECM in particular 
support these processes. Interestingly, the present study showed an inverse dose response of 
migrating cells toward esophageal ECM. It is known that chemoattractants often exhibit a bell 
shaped dose response curve 349. It is plausible tissue-specific chemoattractant molecule(s) are 
present in eECM and similar findings may be true for other tissues and organs 115,307. A unique 
gel chromatography protein-banding pattern in eECM was identified in the present study but the 
identities and biologic activity of the proteins have not yet been characterized. 
A key indicator of the success or failure of an ECM scaffold to facilitate constructive and 
functional tissue repair is the host response to the material following implantation. While a 
distinct and tissue-specific ECM-dependent cellular response was observed in-vitro in the 
present study, the in-vivo remodeling outcome at 14 days post surgery yielded an 
indistinguishable constructive outcome regardless of which ECM scaffold was used for repair. 
The fate of the control animals clearly indicated that the mucosal defect was critically sized and 
both ECM scaffolds promoted a constructive remodeling response compared to the healing 
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response of the untreated control animals. Whether the temporal remodeling response differed 
between UBM and eECM is unknown since only a single post-operative time point was studied. 
Previous studies in the esophagus have shown constructive outcomes with the use of 
UBM and SIS 92-94, both heterologous forms of ECM. The heterologous ECMs were successful 
in reducing stricture formation but the remodeled tissue did not fully reconstitute all components 
of normal esophageal tissue; for example, glandular tissue was absent. The present study 
showed that heterologous source ECM scaffolds were inferior to site-specific ECM in-vitro but 
in-vivo differences in outcomes in eECM vs. UBM at 14 days post mucosectomy were not 
identified. Species differences in the rat and human esophageal histology, namely the lack of 
submucosal glands in the rat esophagus, would require testing in a large animal model to 
determine whether eECM may have clinical benefits.  
A variable in the present study that should be noted is that the ECM materials were 
derived from xenogeneic tissues. However, this is quite representative of the clinical scenario, 
where a large majority of commercial scaffolds composed of ECM are from a porcine source 350. 
Practical considerations favor the use of xenogeneic tissues as they are in abundant supply 
through the agricultural supply chain. More importantly, the constituent molecules of ECM are 
some of the most highly evolutionarily conserved proteins across species 68-70. The present 
study shows that porcine eECM regulates murine esophageal stem cell behavior and also 
mediates esophageal remodeling in the rat, consistent with known species homology of ECM 
constituents. 
There were limitations to the present study. First, the response of only one cell type was 
evaluated. Esophageal stem cells are not the only cell population that may contribute to 
remodeling of the esophageal mucosa. Another potential contributing cell population is the 
multipotent perivascular stem cell 66,307. Perivascular stem cells are found surrounding 
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endothelium of normal tissue and are likely to be present in the vasculature within the 
esophagus. A number of studies have reported the chemotactic and mitogenic potential of ECM 
for the perivascular stem cell population 66,308. Another limitation of the present study was the 
use of different decellularization protocols for preparing the ECM scaffolds. Decellularization 
protocols are typically dictated by tissue-specific characteristics, which almost always differ to 
achieve effective decellularization. Use of a single decellularization protocol for all tissues in the 
present study would have resulted in ECM scaffolds with a different content of cell remnants 
and thus would have added a major variable. The effects of the different decellularization 
protocols upon the results in the present study are unknown, but protocols similar or identical to 
those in the present study would likely be used in the clinical setting and therefore have 
potential clinical relevance. 
9.6  CONCLUSION 
In conclusion, the present chapter showed a superior in-vitro response of esophageal stem cells 
to homologous ECM vs. heterologous ECM. Surgical placement of the scaffold into a rodent 
mucosal defect, however, showed no differences in remodeling response for homologous vs. 
heterologous ECM. A single time point limited conclusions from the in-vivo portion of the present 
chapter and the preference of homologous ECM in the esophageal location is worthy of further 
investigation considering the unmet clinical need for therapeutic options for esophageal 
pathology. 
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10.0 RESTORING MUCOSAL BARRIER FUNCTION AND MODIFYING MACROPHAGE
PHENOTYPE WITH AN EXTRACELLULAR MATRIX HYDROGEL: POTENTIAL
THERAPY FOR ULCERATIVE COLITIS 
10.1 ABSTRACT 
Despite advances in therapeutic options, more than half of all patients with ulcerative colitis 
(UC) do not achieve long-term remission, many require colectomy, and the disease still has a 
major negative impact on quality of life. Extracellular matrix (ECM) bioscaffolds facilitate the 
functional repair of many tissues by mechanisms that include the mitigation of pro-inflammatory 
macrophage phenotype and mobilization of endogenous stem/progenitor cells. The aim of the 
present study was to determine if an ECM hydrogel therapy could influence outcomes in an 
inducible rodent model of UC. The dextran sodium sulfate (DSS)-colitis model was used in male 
Sprague Dawley rats. Animals were treated via enema with an ECM hydrogel and the severity 
of colitis was determined by clinical and histologic criteria. Lamina propria cells were isolated 
and the production of inflammatory mediators was quantified. Mucosal permeability was 
assessed in-vivo by administering TRITC-dextran and in-vivo using transepithelial electrical 
resistance (TEER). ECM hydrogel therapy accelerated healing and improved outcome. The 
hydrogel was adhesive to colonic tissue, which allowed for targeted delivery of the therapy, and 
resulted in a reduction in clinical and histologic signs of disease. ECM hydrogel facilitated 
functional improvement of colonic epithelial barrier function and the resolution of the pro-
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inflammatory state of tissue macrophages. The present chapter shows that a nonsurgical and 
nonpharmacologic ECM-based therapy can abate DSS-colitis not by immunosuppression but by 
promoting phenotypic change in local macrophage function and rapid replacement of the colonic 
mucosal barrier. 
10.2 INTRODUCTION 
Ulcerative colitis (UC) is one of the most common forms of inflammatory bowel disease, and 
represents a significant global health problem351. Since the 1930s, the fundamental approach to 
treatment has been pharmacologic (e.g., 5-amino salicylic acid, immunosuppressive therapy) 
and/or surgical intervention (e.g., colectomy). Nearly a century later, the basic tenets of patient 
care remain unchanged despite inadequate and less than acceptable results. Each year more 
than 50% of UC patients suffer from active flares and associated systemic effects. Overall, 
greater than 20 percent of patients diagnosed with UC will eventually require radical tissue 
resection (i.e. colectomy)—an alarming incidence that has remained unchanged over the last 50 
years352. 
UC is a chronic relapsing disease consisting of acute flares followed by periods of 
remission and healing353. Active disease is characterized by chronic inflammation of the colon 
and defects in intestinal epithelial cell (IEC) barrier function354. Based upon observations that 
scaffolds composed of extracellular matrix (ECM) were shown to mitigate inflammation and 
support functional reconstruction of tissues including the gastrointestinal tract 92,93,96,355, we 
hypothesized that a similar approach to UC therapy will (1) abate inflammatory flares not by 
immune suppression but rather by promoting alternative activation of the local immune cell 
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population, and (2) induce rapid restoration of the colonic mucosal barrier function not by simply 
providing a physical barrier between colonic submucosa and luminal contents but rather by 
promoting  proliferation and replacement of the colonic  mucosal epithelium. This two-pronged 
approach was tested by local delivery (enema) of an ECM hydrogel in a rodent model of UC.  
The common mechanism associated with the successful clinical application of ECM 
bioscaffolds has been modulation of the innate immune response via embedded signaling 
molecules. Intact and solubilized/hydrogel forms of ECM have been shown to facilitate a rapid 
and dramatic transition away from an M1-like, pro-inflammatory macrophage phenotype toward 
an M2-like, pro-healing/regulatory macrophage phenotype 108,134. Simultaneously, naturally 
occurring cryptic peptide motifs released or exposed during in-vivo degradation of the ECM 
material, combined with the secreted products of ECM-exposed alternatively activated 
macrophages, promote stem/progenitor cell chemotaxis, proliferation, and differentiation 66,241. 
The objective of the present study was to determine if the above-mentioned ECM-induced 
biologic effects could influence outcomes in an inducible rodent model of UC.  
10.3 MATERIALS AND METHODS 
10.3.1  Experimental design 
Ulcerative colitis was induced in male Sprague Dawley rats and treated with a daily enema of 
ECMH or vehicle (pepsin buffer) only for 7 days to determine the effect of an extracellular matrix 
hydrogel (ECMH) on colonic inflammation and barrier function. Animals were sacrificed at 7 
days and 14 days post-DSS to evaluate the temporal response (n = 14 per time point per 
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treatment) as shown in Figure 1. Healthy control rats, which did not receive DSS, were included 
for comparison at both 7 and 14 days (n = 6 per time point). The study endpoints included 
clinical response, histologic scores of colon pathology, characterization of the inflammatory 
response, and barrier function. The effect of ECMH on cell phenotype and epithelial barrier 
function was also measured in-vitro with lamina propria mononuclear cells (LPMCs) and 
intestinal epithelial cells, respectively. 
Figure 25. Schematic of experimental overview. Rats were administered 5% DSS in 
drinking water for 7 days to induce ulcerative colitis followed by daily enema treatments with 
either ECMH or the vehicle buffer (pepsin). Animals were sacrificed at days 7 and 14. 
10.3.2   ECM hydrogel preparation and formulations 
ECM composed of porcine small intestinal submucosa (SIS) was prepared according to a 
standard protocol83. In brief, porcine small intestine was harvested immediately following 
euthanasia, rinsed of contents in deionized water, and frozen. The tissue was thawed and the 
tunica mucosa, the tunica serosa, and tunica muscularis externa were mechanically removed, 
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leaving behind the tunica submucosa and basilar portions of the tunica mucosa (termed SIS). 
Decellularization of the SIS material was conducted by rinsing in deionized water for 24-72h 
prior to treatment with 0.1% peracetic acid / 4% ethanol and subsequent saline and water 
rinses. SIS-ECM was frozen, lyophilized, and comminuted with a Wiley Mill using a #60-mesh 
screen, and digested at 10 mg/mL dry weight with 1 mg/mL pepsin (Sigma, St. Louis, MO) in 
0.01N HCl while stirring for 20-26 h at 21-23°C. Digest was stored in aliquots at -20°C and pH 
neutralized with 0.1M NaOH prior to use. Hydrogel formation was induced by the neutralization 
step and an accompanying temperature increase to approximately 37°C following administration 
of the enema. All in-vivo studies used an ECM hydrogel (ECMH) concentration of 8 mg/mL and 
all in-vitro studies used an ECMH concentration of 500 μg/mL. 
14C-labeled ECMH was prepared as stated above with the intestines of pigs that were 
injected with 14C-tagged proline, as previously described 356. FITC-labeled ECMH was prepared 
with a protein labeling kit (Thermo PierceNet) per manufacturer’s instructions66. 
10.3.3. Characterization of ECM hydrogel 
Decellularization efficiency was determined by the absence of nuclei by H&E and DAPI staining. 
Remnant DNA was measured via PicoGreen assay (Invitrogen) and DNA fragmentation was 
determined using gel electrophoresis. Sulfated glycosaminoglycan content in the ECM was 
measured using a Blyscan Sulfated Glycosaminoglycan Assay (Biocolor Ltd.) per 
manufacturer’s guidelines. The rheological characteristics of ECMH were determined with a 
rheometer (AR2000, TA instruments, New Castle, DE) operating with a 40 mm parallel plate 
geometry and the steady shear viscosity was measured by applying a stress of 1 Pa at a 
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frequency of 0.159 Hz, as described previously. All characterization assays were completed on 
4 independent preparations of ECM (n = 4). 
10.3.4.  ECM adhesion testing 
The mucoadhesion strength of ECMH was measured using a modified detachment force 
technique357. A uniaxial tensile testing machine (MTS Insight; MTS Systems Corp., Eden Prairie, 
MN) equipped with a 10 N load cell was used for all tensile strength measurements. Two colon 
sections were glued to steel washers (diameter 12.7 mm) with mucosa facing outward and one 
washer was glued to the bottom of a 24-well plate (diameter 15.6 mm). The ECMH was 
prepared by neutralizing with one tenth volume of 0.1M NaOH and one ninth volume of 10x PBS 
then 0.5 mL of ECMH was added onto the bottom tissue and the top tissue was added and 
allowed to penetrate into the gel to a predetermined depth before incubating at 37°C for 1 hour. 
After incubation, the upper washer was slowly withdrawn at a constant speed of 5 mm/min until 
a failure occurred between the surfaces. 
10.3.5   Animals and husbandry 
All procedures and animal studies were approved and conducted in compliance with the 
University of Pittsburgh Radiation Safety Committee and the Institutional Animal Care and Use 
Committee. Male Sprague Dawley rats, 8-12 weeks of age, were obtained from standard vendor 
(Harlan) and were housed and environmentally acclimated for 7-10 days. Animals were housed 
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in standard laboratory conditions with a temperature of 21-23 °C and 12 hr dark/light cycles. 
Rats were allowed ad libitum access to food and water throughout the study. 
10.3.6    Disease induction and monitoring 
Five percent dextran sulfate sodium (DSS) salt (36,000-50,000 MW; MP Biomedical) was 
prepared daily in deionized water and administered to rats by ad libitum drinking for 7 days and 
the animals were monitored daily. Animal weight and consumption of food and water were 
tracked for each animal. Disease activity (i.e., stool consistency, presence of blood in stool, and 
weight loss) was measured every other day (i.e., days 1, 3, 5, 7, etc.) and scored on a range of 
0 to 4 as shown in Table 9. Stool was scored for consistency (0=normal, 2=loose, 4=diarrhea) 
and presence of blood (0=none, 2=occult, 4=gross bleeding). Stool was tested for the presence 
of blood using ColoScreen ES Lab Pack Fecal Occult Tests. Weight loss compared to baseline 
was scored as follows: 0=none, 1= 1-5%, 2= 5-10%, 3= 10-20%, and 4= >20%. 
Table 9. Criteria for clinical symptom scoring 
Score Weight loss Stool consistency Stool Blood 
0 None Normal None 
1 1-5%
2 5-10% Loose stools Occult 
3 10-20%
4 >20% Diarrhea Gross bleeding 
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10.3.7  Enema administration 
Rats were anesthetized with 2-4% inhaled isoflurane and enemas were delivered using a 
flexible Surflo winged infusion catheter (Terumo, OD= 2mm). Enemas (5mL) were administered 
at 3 sites along the colon utilizing a syringe attached to the catheter (approximately 1.7 mL per 
site), starting at 8 cm proximal to anus and at 5 cm and 3 cm while gradually removing the 
catheter with approximate total infusion time of 60 seconds (i.e., 20 sec per site).   
10.3.8   ECM retention studies with FITC- and 14C-ECMH 
To determine hydrogel retention time, rats were administered FITC-labeled or 14C-labeled 
ECMH via enema following disease induction. Eighteen rats were divided into 2 groups based 
on ECMH formulation (FITC- and 14C-ECMH) and sacrificed at 2 hr, 12 hr, and 24 hr post 
enema (n = 3 per time point per ECMH formulation). Explanted colons from FITC-ECMH treated 
rats were processed to be optically clear such that the luminal contents were visible by 
fluorescent imaging. Immediately following sacrifice all samples were protected from light to 
prevent photo bleaching of the FITC conjugate. Optical clearing of the colons was initiated by 
incubating in Dent’s fixative (1:4 dimethyl sulfoxide (DMSO): acetone) for 2 hours. Colons were 
then permeabilized and bleached in Dent’s bleach (1:4:1 DMSO: acetone: H2O2) for 1 hour. 
Optically cleared colons were then imaged on a Fluorescent gel imager (Chemidoc Touch, 
Biorad). Exposure time was set to a control sample of FITC-ECMH and kept constant for all 
subsequent images. 
For 14C measurements, the entire colon of each rat was individually flash frozen in liquid 
nitrogen and homogenized. The frozen tissue was ground with mortar and pestle and mixed 
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until homogenous. Approximately 40 mg of tissue samples was analyzed by accelerated mass 
spectrometry (AMS). Non-treated controls were used to subtract the background 14C levels in 
native tissue. 
10.3.9  Explanting and scoring colonic tissue 
Animals were sacrificed at predetermined time points as described previously. Euthanasia was 
achieved by CO2 inhalation and subsequent cervical dislocation in accordance with the 
guidelines of the American Veterinary Medical Association (AVMA). Following euthanasia, the 
colon was resected following a ventral abdominal midline incision. A continuous colon segment 
was collected, spanning from the rectum to the cecum, and photographed. Colon length was 
measured as an indicator of disease activity. The colon was opened longitudinally and assessed 
grossly by investigators blinded to the treatment group for damage according to the metrics 
outlined in Table 10. 
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Table 10. Criteria for gross anatomical scoring of colon specimens 
Score Appearance 
0 Normal 
1 Localized hyperemia, no ulcers 
2 Ulceration without hyperemia or bowel wall thickening 
3 Ulceration with inflammation at one site 
4 Two or more sites of ulceration and inflammation 
5 Ulceration at multiple sites or extending >1 cm along the length of the colon 
6-10 When an area of damage extended >2 cm along the length of colon, the score 
was increased by 1 for each additional cm of involvement 
The distal region of colon, 9 cm in length, was cut into thirds and opened longitudinally.  
Specimens were then collected for histologic examination, ex-vivo organ culture, and 
myeloperoxidase measurement. The colon specimens were paraffin embedded and tissue 
sections (5 μm) that were obtained from 2 to 8 cm from distal to proximal colon were stained 
with hematoxylin and eosin (H&E) for representative histologic scoring. The distal and proximal 
tissue sections were separated onto 2 slides and histologic scoring was performed according to 
Table 11 by six blinded investigators. 
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Table 11. Criteria for histologic scoring of colon specimens 
Feature Score Description 
Inflammation 
extent 
0 No inflammation 
1 Mild inflammation in mucosa 
2 Moderate-severe inflammation in mucosa 
3 Mild inflammation into the submucosa 
4 Moderate-severe inflammation into the submucosa 
Ulceration 
0 0% 
1 1-25%
2 26-50%
3 51-75%
4 76-100%
10.3.10 TRITC-Dextran permeability assay 
Colonic mucosal permeability was assessed by enteral administration of TRITC-dextran 
(molecular mass 4.4 kDa; Sigma). Rats were administered TRITC-dextran (1mL, 10 mg/mL) 4 h 
before sacrifice. Whole blood was obtained at the time of sacrifice in serum collection tubes and 
allowed to clot undisturbed at room temperature for at least 30 minutes. The clot was removed 
by centrifuging at 1,000 x g for 10 minutes at 4°C. TRITC-dextran concentraiton in the serum 
were determined in triplicate on a SpectraMax plate reader (Molecular Devices), with serial 
dilutions of TRITC-dextran used as a standard curve. 
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10.3.11  Organ cultures 
Full thickness biopsies were obtained following sacrifice from the explanted colon of each 
experimental and control animal at day 7 and day 14 using a 3 mm dermal punch as described 
previously 358. Tissue specimens were cultured at 37°C with 5% CO2 for 48 h. The supernatants 
were then harvested and stored at -80°C until the amount of TNFα and PGE2 was measured 
using ELISA assays. 
10.3.12  LPMC isolation and culture 
Lamina propria mononuclear cells (LPMCs) were isolated from rats following colitis induction with 
DSS as described above. The colon was explanted, cleared of mesenteric fat tissue, and regions 
of Peyer’s patches were excised. The colon was then split in half longitudinally, cut into pieces, 
and dissociated into single cell suspensions using a lamina propria dissociation kit (Miltenyi) 
according to manufacturer’s instructions. The suspension was then separated along a 40/70% 
Percoll gradient. The cells were suspended in RPMI 1640 containing 10% FBS and 100 U/mL 
penicillin and streptomycin, and then placed in 96-well plates at 2×105 cells per well with or without 
the addition of 500 μg/mL ECMH or vehicle (i.e., pepsin buffer).  After 48 hours incubation, the 
supernatant was collected and stored at -80°C until assayed for TNFα and PGE2 with ELISAs. 
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10.3.13  IEC culture 
For in-vitro barrier function assays, IECs (Caco-2, passages 24-28, ATCC) were cultured 
to approximately 80% confluence in MEM containing non-essential amino acids, 1mM 
sodium pyruvate, and 20% FBS. The functional response of IECs to ECMH was evaluated 
using rapid differentiation system (Corning Biocoat HTS Caco-2 Assay) per manufacturer’s 
instructions. Confluent and differentiated cell monolayers were challenged with 100 ng/mL 
LPS for 2 hours and then treated with ECMH for 48 hours.  
10.3.14  Trans-epithelial electrical resistance (TEER) measurement 
TEER of Caco-2 monolayers was measured with an Epithelial Voltohmmeter (EVOM2, World 
Precision Instruments). Before seeding Caco-2 cells, electrical resistance of the supporting filter 
and buffer medium was measured and subtracted from the total electrical resistance determined 
with the monolayer to calculate the TEER of the monolayer. Only differentiated monolayers with 
TEER values greater than 300 Ω×cm2 were used in the study. 
10.3.15    Immunolabeling 
To determine the macrophage response following ECMH treatment, paraffin embedded 
histologic sections were deparaffinized and immunolabeled for a pan-macrophage marker 
(CD68) and indicators of the M1-like (TNFα) and M2-like (CD206) macrophage phenotypes. All 
primary antibodies were confirmed to cross-react with rat epitopes. For visualizing the presence 
of Caco-2 adhesion proteins, sections were imaged at five random fields per 
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tissue section. Quantification of localized staining was achieved using a custom image analysis 
algorithm developed using CellProfiler Image Analysis Software.  
For macrophage immunolabeling, tissue sections were deparaffinized using xylene and 
rehydrated using a graded ethanol series. Heat-mediated epitope retrieval was performed using 
001 M citrate buffer (pH=6) at 95°C for 20 minutes. Tissue sections were subjected to Tris-
Buffered Saline Tween-20 (TBST) for 15 min, followed by incubation in blocking buffer (2% 
horse serum / 1% bovine serum albumin/0.05% tween-20/0.05% Triton X-100) for 1 hour. The 
primary antibodies, diluted in blocking buffer, were added to the slides for 16 h at 4 C in a 
humidified chamber. The slides were then washed three times in TBS prior to the addition of 
secondary antibody for 1 h in a humidified chamber at room temperature. Slides were 
counterstained 4’6-diamidino-2-phenylindole (DAPI) to visualize nuclei. Primary antibodies used 
were mouse anti-rat CD68 (AbD Serotec, Raleigh, NC) at a 1:150 dilution as a pan macrophage 
marker, rabbit polyclonal to TNFα (abcam) at a 1:200 dilution as an M1-like marker, and goat 
polyclonal CD206 (Santa Cruz Biotech, Santa Cruz , CA) at a 1:100 dilution. The secondary 
antibodies used were Alexa Fluor donkey anti-mouse 594 (1:200, Invitrogen), Alexa Fluor 
donkey anti-goat 488 (1:200, Invitrogen), and Alexa Fluor donkey anti-rabbit 546 (1:200, 
Invitrogen). All primary antibodies were confirmed to cross-react with rat epitopes. 
For Caco-2 immunolabeling, the primary antibodies were diluted in blocking solution and 
added to trans-well inserts for 16 h at 4°C in a humidified chamber.  The slides were then 
washed three times in PBS prior to the addition of the secondary antibody for 1 h in a humidified 
chamber at room temperature.  DAPI was used as a nuclear counterstain. The primary antibody 
used was rabbit anti-E-cadherin (Abcam, AB15148. 1:50).  The secondary antibody used was 
Alexa Fluor® goat anti-rabbit 488 (Invitrogen, A11008, 1:400). The primary antibody was 
confirmed to cross-react with human epitopes.  
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10.3.16   Statistical analysis 
The sample size used in the present study was determined based on a power analysis using pilot 
study data in combination with previously published relevant studies.  All animals were numbered 
and randomly assigned to a treatment. All investigators responsible for scoring were blinded to 
the experimental groupings. Quantitative outcomes were compared with a one-way or two-way 
analysis of variance (ANOVA) and post-hoc Tukey test to determine differences between groups. 
All statistical analysis was performed using SPSS Statistical Analysis Software (SPSS, IBM). Data 
are reported as mean ± standard deviation unless otherwise stated. 
10.4 RESULTS 
10.4.1  ECMH is adhesive to colon tissue 
The therapeutic efficacy of ECMH is reliant upon its ability adhere to the colon wall and interface 
with the resident cells. ECMH has the distinctive property of reverse thermal gelation and the 
hydrogel properties are dependent upon material characteristics (Figure 26). 
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Figure 26. Material properties of ECMH. (A) ECMH material properties allow injection as a 
liquid and the subsequent gelation at 37°C ensures that the treatment remains localized. (B) 
Viscoelastic properties of ECMH, including storage modulus (G’) and loss modulus (G”), were 
measured with parallel plate rheology. (C) The biochemical and hydrogel properties were 
measured in 6 separate batches of ECMH. 
Results of adhesion testing show that ECMH is mucoadhesive, with a dose-dependent 
increase in adhesion strength when tested on healthy colon (Figure 27A). Importantly, the 8 
mg/mL ECMH dose used in the present study maintains equivalent adhesion strength in colitic 
rat colon when compared to healthy tissue (Fig 2B).  It is noteworthy that mucosal adherence is 
not simply a property of thermoreversible gels.  For example, Pluronic F-127 (20%; Sigma) did 
not show adhesion strength greater than the negative control (data not shown). When delivered 
via enema to colitic rats, the residence time of the ECMH is greater than 24 hours. Two hours 
after administering the enema, about 50% of the 14C-ECMH remains in the colon and 
approximately 10% of the initial ECMH enema remained after 24 hours (Figure 27C). These 
results were corroborated by visualization of FITC-ECMH (Figure 27D). Together the results 
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show that ECMH material properties allow injection as a liquid and the subsequent gelation 
ensures that the treatment remains localized for at least 24 hr. Based on these data, a daily 
enema treatment was used to measure the therapeutic efficacy of ECMH. 
Figure 27. ECMH is Mucoadhesive. Tensile tests show dose-dependent increase in 
adhesion strength of ECMH to healthy colon (A) and equivalent adhesion in healthy vs. 
diseased colon (B). The resident time of ECMH following enema delivery was tested with 14C 
(C) and FITC-labeled ECMH (D).
10.4.2   ECMH treatment mitigates disease state 
The DSS experimental model is a well-accepted UC-like self-limiting colitis phenotype with 
epithelial barrier defects359. Clinical signs of colitis (e.g., weight loss, stool blood, and stool  
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Figure 28. DSS-colits model effectively induces disease. Weight change (A), the 
presence of blood in stool (B), and stool consistency (C) were tracked as clinical indicators of 
disease. Following 7 days of exposure to DSS, colon length (D) was measured as an 
indicator of disease severity and barrier dysfunction was measured by TRITC-dextran 
permeability (E). 
consistency) were present following 3 days of exposure to 5% DSS in drinking water and reach 
their peak following 6 days (Figure 28). ECMH treatment diminished clinical symptoms of UC in 
this rodent model. ECMH treated animals did not lose as much weight (at days 1 and 3) and 
had less blood in stool (at days 3 and 5) compared to the vehicle control. The shortening of the 
colon that was present at day 0 (Figure 28D) was no longer evident by days 7 and 14 across all 
groups (Figure 29D). ECMH treatment resulted in a reduction in the gross score compared to 
the vehicle at day 7 (Figure 29E).  
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Figure 29. ECMH Treatment Reduces Disease Activity. The effect of ECMH treatment on 
clinical symptoms (A-C), colon length (D), and gross score at explant (E) was tracked and 
compared to the vehicle (i.e., pepsin buffer) alone. 
Histomorphologic analysis also showed that ECMH is therapeutic in the present model 
as evident in representative images (Figure 30). ECMH treatment resulted in diminished signs 
of inflammation and a lower the degree of ulceration at 7 and 14 days in both distal and 
proximal tissue sections (Figure 31). 
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Figure 30. Histologic Response to ECMH. Histomorphologic scoring of hematoxylin and 
eosin stained tissue sections was used to assess the effect of ECMH treatment on ulceration 
and inflammation extent. 
Figure 31. ECMH Treatment Lowers Histologic Score. Distal and proximal tissue sections 
stained with hematoxylin and eosin were scored by blinded investigators and compared with 
vehicle/pepsin buffer. The extent of inflammation and degree of ulceration were quantified at 
7 days (A,B,E,F) and 14 days (C,D,G,H). 
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10.4.3  ECMH restores epithelial barrier function 
A defect in gut barrier function and increased permeability can lead to inflammatory bowel 
disease even in the presence of an intact immune system 360. Results of the TRITC-Dextran 
permeability assay showed that the barrier function of ECMH-treated animals is similar to 
healthy animals at 7 days while the colonic epithelial barrier in the vehicle-treated control group 
remain impaired compared to the healthy control (Figure 32A). Differentiated and LPS-damaged 
monolayers of IECs respond to ECMH treatment in-vitro with functional recovery as shown by 
TEER readings (Figure 32B). The increased barrier function was associated with an increased 
presence of E-cadherin, one of the most important cell-cell adhesion proteins in the gut. ECMH 
treatment leads to approximately 50% increase in E-cadherin positive cells compared with 
negative controls (Figure 32C-D).  
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Figure 32. ECM Restores Barrier Function. TRITC-Dextran permeability assay show that 
the barrier function of ECMH-treated animals is similar to healthy animals while the colonic 
epithelial barrier in the vehicle-treated control group remain impaired compared to the healthy 
control (A). Differentiated and LPS-damaged monolayers of IECs respond to ECMH treatment 
in-vitro with functional recovery as shown by TEER readings (B). The increased barrier 
function is associated with an increased presence of E-cadherin compared with negative 
controls (C-D). 
10.4.4  ECMH mitigates the inflammatory response 
Recognized inflammatory mediators of IBD (i.e., TNFα and PGE2) were measured in the 
present study. LPMCs isolated from colitic rats were plated and exposed to ECMH. The ECMH 
treatment resulted in a substantial reduction in the production of TNFα (Figure 33A) by the 
LPMCs but had no effect on PGE2 production (Figure 33B). Organ cultures of biopsies collected 
from rats following ECMH or vehicle control treatment showed secreted PGE2 was similar to 
healthy controls in the ECMH treated animals while the vehicle controls had significantly 
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elevated levels of mucosal PGE2 (Figure 33C). Secreted levels of αα were below detection in 
the organ cultures regardless of experimental condition at the time points studied.  
The effect of ECMH on macrophage phenotype in DSS-colitis was evaluated by 
quantifying the number of CD68+ macrophages in the colon that co-express TNFα or CD206. 
Interestingly, the absolute number of individually labeled CD68+, CD206+, and TNFα+ cells was 
the same across all treatment groups (data not shown) but ECMH treatment resulted in a 
reduction in the number of co-labeled CD68+/TNFα+ inflammatory macrophages at day 7 (Figure 
33D). The fact that ECMH did not affect the amount of global TNFα+ cells but did reduce the 
number of CD68+/TNFα+ cells suggests a direct role for ECMH in modulating the macrophage 
response by reducing the number of inflammatory macrophages present in the colonic tissue. 
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Figure 33. ECMH Mediates Inflammation. Lamina propria cells exposed to ECMH results in 
lowered levels of TNFα (A) but didn’t affect PGE2 production (B). Organ cultures, however 
showed ECMH had a significant impact on PGE2 levels (C). ECMH treatment led to a 
decrease in total number of M1, TNFα expressing macrophages (D).  
10.5 DISCUSSION 
The present study shows that an ECM hydrogel composed of ECM mitigates the 
proinflammatory macrophage phenotype and restores barrier function in a rodent model of UC.  
It is noteworthy that the total number of macrophages was not changed by ECMH treatment, but 
rather the phenotype of this cell population was changed.  In addition, the barrier function was 
not restored by the physical presence of the hydrogel but rather by the restoration of an 
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effective mucosal epithelium.  These effects are a distinct departure from the 
immunosuppressive (defensive) and surgical (salvage) methods currently used to treat UC in 
humans. More than half of all patients with UC do not achieve long-term remission and many 
require colectomy. 
The findings of the present study are consistent with, and analogous to, the known 
mechanisms by which ECM-based approaches facilitate the constructive remodeling of injured 
tissues in other anatomic locations87,89,92,129,361,362. Specifically, ECM materials derived via 
decellularization of a variety of allogeneic or xenogeneic source tissues have been shown to 
induce a phenotypic transition from the proinflammatory macrophage and lymphocyte 
phenotype toward a regulatory, “anti-inflammatory” and healing phenotype 132,134,305,363, and to 
promote endogenous stem/progenitor cell activation and recruitment 66,67,345,362.  Furthermore, 
the findings are similar to the results in patients with esophageal adenocarcinoma who were 
subjected to surgical removal of the affected esophageal mucosa and placement of a solid (i.e., 
not hydrogel) form of an ECM bioscaffold.  These patients showed a rapid restoration of the 
esophageal mucosa without recalcitrant stricture, and normal esophageal function.   
The combination of promoting a shift in macrophage function from inflammation to 
wound healing and facilitating the restoration of an intact colonic mucosa is a departure from 
current therapeutic strategies for UC.  Current therapies are focused upon immune suppression 
(e.g., corticosteroids and anti-TNFα compounds) with the associated local and systemic effects.  
Immune suppression is clearly different than maintaining complete functionality of the immune 
system while redirecting its’ biologic objectives. In fact, a robust immune system is necessary 
for a healthy, functional gastrointestinal tract 364-367.  
The use of immunosuppressive and/or anti-inflammatory compounds has a limited effect 
on mucosal healing 368,369 and yet the disrupted mucosal barrier integrity is a key component in 
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the pathogenesis of UC. Barrier dysfunction enables the ingress of luminal antigens and 
pathogens, continuous immune cell activation in the lamina propria, and the associated chronic 
inflammation that is the hallmark of UC. Restoration of barrier function is therefore an important 
therapeutic target in UC. In the present study, ECMH therapy had a protective effect on the 
epithelial cells of the colonic mucosa. Results show that ECMH facilitates functional 
improvement of the epithelial barrier function and suggest that ECMH acts therapeutically either 
by limiting epithelial cell damage and/or by actively salvaging mucosal integrity. Given the 
mucoadhesive properties of ECMH it would also be feasible to use ECMH as a carrier for local 
delivery of pharmocologics. 
Recognition that effector cells of the immune system, such as the macrophages and T-
helper cells, not only promote classic inflammatory processes but also orchestrate the temporal 
inhibition of inflammation and initiation of functional tissue remodeling 132,291,370-373 provides the 
opportunity to re-examine immunosuppressive strategies for treatment of diseases such as UC. 
Although the signaling molecules that influence macrophage and lymphocyte phenotype 
transition are not fully understood, there is suggestive evidence that at least some of these 
regulators reside within the ECM 108,134,370. Results of the present study suggest that ECMH 
modulates the innate immune response not by directly promoting an M2-like macrophage 
phenotype but rather by reducing the number of M1-like pro-inflammatory macrophages, thus 
shifting the microenvironmental milieu from inflammation to repair.   
Limitations of the present study include the use of one animal model and only 2 surface 
markers for macrophage phenotype. The DSS-colitis model was chosen because the model 
features innate immunity and epithelial barrier defects that are central to the present study’s 
hypothesis. The outcomes in the DSS-colitis model can also be effective in predicting clinical 
treatment of IBD 359. While only two markers for macrophage phenotype were used for 
immunolabeling, we chose the most representative marker of UC-like inflammation (TNFα) and 
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for M2-like macrophages (CD206). Macrophages are a heterogeneous cell population and the 
use of a single marker to delineate phenotype can result in ambiguity. TNFα, in particular, was 
chosen for the present study because of its integral role in the pathogenesis of UC 374, however 
it is logical and plausible that the use of other markers could provide additional insight into the 
effects of ECMH treatment upon the resident macrophage population in the colitic 
microenvironment.     
10.6 CONCLUSION 
Despite limitations, the present study shows that ECMH restores epithelial barrier function and 
modulates macrophage phenotype away from a pro-inflammatory state. Two physiologic 
processes, the colonic barrier function and pro-inflammatory response, were positively 
influenced by ECMH therapy. One benefit of ECMH, in addition to the therapeutic efficacy, is 
that the well-accepted safety profile of ECM products may allow for accelerated transition to the 
clinic. 
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11.0 SUMMARY OF MILESTONES AND FUTURE DIRECTIONS
The central hypothesis addressed in this thesis is that ECM hydrogels support constructive 
remodeling of GI tissue by modulation of the microenvironment and local immune cells. The 
following milestones were achieved: 
Milestone 1: Gastrointestinal extracellular matrix (GI-ECM) bioscaffolds derived from porcine 
esophagus and colon were decellularized and quantitatively described. 
Summary Milestone 1: The composition and structure of ECM are directly attributed to the cell 
population of the tissue from which the ECM is derived. The esophageal mucosa is a smooth 
dense tissue has anisotropic mechanical properties with 83% and 18% maximal strain in the 
circumferential and longitudinal direction, respectively. Decellularized esophageal mucosa 
retains similar anisotropy (but with lower compliance along both axes) and retains biochemical 
constituent’s bFGF and GAGs (see Chapter 7 for more details). In contrast, the colonic mucosa 
is a loose thin permeable tissue that, while also shows anisotropy, is much weaker than the 
esophageal mucosa with 5% and 2% maximal strain in the longitudinal and circumferential 
direction. The anisotropy is similarly retained following decellularization and the biochemical 
constituents are retained following decellularization, although the concentrations of GAGs and 
bFGF are lower in the colonic mucosa when compared to the esophageal mucosa (see Chapter 
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8 for more details). Interestingly, esophageal mucosal ECM retains tissue-specific 
characteristics that enhance the migration of esophageal stem cells and supports the formation 
of 3D organoids to a greater extent than heterologous-derived ECM (see Chapter 9 for more 
details). 
Future Directions Milestone 1:  Future experiments should focus on determining if either 
esophageal- or colon-derived biologic scaffolds can be used to treat diseases of the GI tract. In 
particular, it would be interesting to characterize the response to these GI-derived ECM 
scaffolds to site-specific diseases. While some site-specific effects of esophageal ECM were 
shown in the present study, future experiements could examine the effects of colonic ECM on 
colonic cells to determine if there are tissue-specific benefits with the use of site-specific ECM. 
Milestone 2: The effect of GI-ECM on the remodeling and inflammatory response of intestinal 
epithelial cells and macrophages, respectively, was characterized. 
Summary Milestone 2: Effective treatment of UC requires (1) a reduction in inflammatory state 
and (2) rapid reformation of a robust epithelial barrier. The body’s largest reservoir of 
macrophages are positioned in the lamina propria (LP) of the GI tract and are increased in 
number in UC with enhanced production of inflammatory cytokines (e.g., TNFα) in IBD. 
Discovery work in the Badylak lab over the past 2 decades has identified the modulation of the 
innate immune response as a contributing mechanistic factor for ECM-induced tissue 
remodeling. ECM derived from esophageal and colonic mucosal tissues were cell-friendly in-
vitro, and supported a constructive response when implanted in a partial thickness abdominal 
wall defect in-vivo. The macrophage response to ECM from the GI tract was activated towards 
and M2-like phenotype in-vitro and promoted an M2 predominance (i.e., the M2/M1 ratio at the 
scaffold-tissue interface was equal to 1.3 for eECM and 1.5 for coECM at 14 days post-surgery) 
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in-vivo compared to controls (see Chapters 7 and 8 for more details). The inflammatory state of 
mononuclear cells isolated from the LP of colitic rats is also affected by GI ECM, showing about 
75% reduction in TNFα production following ECM treatment (see Chapter 10, Figure 33 for 
more details). The epithelial cell response to GI ECM was also constructive and showed a 
functional healing response in-vitro. Differentiated monolayers of epithelial cells had increased 
TEER values and E-cad staining when treated with ECM hydrogel in-vitro (see Chapter 10, 
Figure 32 for more information). 
Future Directions Milestone 2: The cellular response to the GI-ECM scaffolds can be largely 
responsible for improved therapeutic outcomes in-vivo. Future experiments should focus on 
determining what component(s) of ECM elicit a cellular response. In addition, while the present 
thesis shows that the ECM materials promote a shift in innate immune cell phenotype, future 
experiments should aim to determine the effect of these materials on the adaptive immune 
response that also contributes to disease. 
Milestone 3: The efficacy of ECM hydrogel in treating inflamed colonic mucosal tissue was 
determined.  
Summary Milestone 3: Inflammation mitigation and remodeling (i.e., restoration of colonic 
epithelial barrier) is central to effect treatment of UC. Chapter 10 shows that topical application 
of ECM hydrogels mitigate the inflammatory response in colitic rats by modulating the 
microenvironmental milieu towards an anti-inflammatory state and thereby facilitating 
constructive remodeling of colonic mucosa. This constructive response resulted in functional 
improvement in the epithelial barrier function as shown with decreased mucosal permeability 
(see Figure 32). This combination of immune activation and restoration of the colonic mucosa is 
a distinct departure from current therapeutic strategies for treating IBD. Whereas current 
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theapries focus on immune suppression (i.e., lowering total number of immune cells in the 
tissue), the ECM hydrogel therapy maintains complete functionality of the immune system but 
redirects the pro-inflammatory response to a pro-remodeling one. Together these effects, if 
successful on the clinical scale, could create a paradigm shift in the approach to IBD treatment 
away from the immunosuppressive and surgical methods currently used. 
Future Directions Milestone 3:  Future experiments should be designed to further elucidate the 
mechanisms by which ECM is able to facilitate tissue repair. Determining the mechanisms of 
tissue repair could allow for improvements and optimization of therapies to treat ulcerative 
colitis. Further study is also necessary to determine whether ECM hydrogels can be used to 
treat diseased tissue at the opposite end of the GI tract (i.e., esophageal tissue). Development 
of therapies to treat other inflammation-mediated disease (e.g., rheumatoid arthritis, necrotizing 
enterocolitis) should be the focus of future studies. 
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CONSEQUENCES OF INEFFECTIVE DECELLULARIZATION OF BIOLOGIC 
SCAFFOLDS ON THE HOST RESPONSE 
A.1  Abstract
Despite known variations in tissue remodeling outcomes,  no systematic evaluation of the host 
response to cell remnants has been conducted.  As a result, the amount of retained cellular 
material varies widely among commercial products. The objective of the present chapter was 
to evaluate the consequences of ineffective decellularization on the host response.  Three 
different methods of decellularization were used to decellularize porcine small intestinal ECM 
(SIS-ECM).  The amount of cell remnants was quantified by the amount and fragmentation of 
DNA within the scaffold materials.  The M1/M2 phenotypic polarization profile of 
macrophages, activated in response to these ECM scaffolds, was assessed in vitro and in vivo 
using a rodent model of body wall repair.  The results of this study show that, in vitro, more 
aggressive decellularization is associated with a shift in macrophage phenotype 
predominance from M1 to M2.  While the macrophage phenotype shift was not quantitatively 
apparent in vivo, notable differences were found in the distribution of M1 
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vs. M2 macrophages within the various scaffolds.  A clear association between macrophage 
phenotype and remodeling outcome exists and effective decellularization remains an important 
component in the processing of ECM-based scaffolds. 
A.2  Introduction
The use of biologic scaffolds derived from decellularized mammalian tissues is commonplace. 
Such scaffolds are composed of extracellular matrix (ECM) and have been used to repair or 
replace a variety of damaged or diseased tissues including cardiac 375-377, esophageal 378,379, 
dermal 380, and musculotendinous tissues 90,381-384, among others. These materials are typically 
regulated as devices and marketed as surgical mesh products; however, these ECM-based 
scaffolds can also serve as an inductive template for tissue repair and regeneration 385,386. 
Numerous commercial products composed of allogeneic or xenogeneic ECM are now available 
for clinical use.    
Results of preclinical and clinical studies with biologic scaffolds have varied from very 
successful 387-391 to complete failure 392-395. The host response to these materials can be 
attributed to factors such as the source species (e.g., human, porcine, equine, or bovine), the 
tissue from which the ECM is isolated (e.g., dermis, small intestine, or pericardium), mechanical 
loading 396,397, and the niche factors to which the scaffold is exposed following implantation. The 
decellularization, disinfection, and sterilization methods used during the manufacturing process 
can markedly influence the tissue remodeling response and functional outcome 175,213. Despite 
these known variations in functional outcome, no quantitative criteria by which decellularization 
can be assessed have been suggested until recently 175 and as a result, the amount of retained 
cellular material varies widely among commercial products composed of decellularized tissues 
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398. The consequences of ineffective or incomplete decellularization upon the host response
have not been systematically investigated. 
The innate and acquired immune response to non-autologous cells is well established 
and understood by the tissue and organ transplantation community.  However, the response to 
acellular xenogeneic or allogeneic biologic scaffold materials is less well understood. The 
macrophage represents a key component of the host response. Macrophages are activated in 
response to tissue damage, infection, or the presence of foreign antigens and subsequently 
release a variety of cytokines and chemokines 399. Macrophages are now recognized to assume 
a variety of phenotypes characterized by distinct functional properties, surface markers, and 
their secreted cytokine profile 400. Polarized macrophages are referred to as either M1 or M2 
cells, mimicking the Th1/Th2 nomenclature. Classically activated, M1 proinflammatory 
macrophages express IL-12high, IL-23high, IL-10low; metabolize arginine; produce high levels 
of inducible nitric oxide synthetase 228; secrete toxic reactive oxygen and nitric oxygen 
intermediates and inflammatory cytokines such as IL-1β, IL-6, and TNF. M1 macrophages are 
inducer and effector cells in Th1 type inflammatory responses. In contrast, M2, alternatively 
activated macrophages are induced by exposure to a variety of signals including the cytokines 
IL-4, IL-13, and IL-10, immune complexes, and glucocorticoid or secosteroid (vitamin D3) 
hormones. M2 activated macrophages express IL-12low, IL-23low, and IL-10high; have high 
levels of scavenger, mannose, and galactose receptors; produce arginase in the place of 
arginine which results in the secretion of ornithine and polyamines; are involved in polarized Th2 
reactions; and possess the ability to facilitate tissue repair and constructive remodeling 399,401,402. 
It is known that cell death incites a series of events that typically results in the classic 
cascade of inflammatory processes including polymorphonuclear leukocyte (PMN) and 
mononuclear cell infiltration, edema, fibroblast infiltration, and eventual scar tissue formation 403-
405. The presence of cells within a biologic scaffold material has been shown to elicit a greater
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proinflammatory response than use of the acellular biologic scaffold alone 133.  It is logical, 
therefore, that cell remnants within a partially decellularized tissue could elicit a proinflammatory 
response that would adversely affect a constructive tissue remodeling outcome.  In fact, it has 
been shown that the presence of intact cells within implanted scaffolds can be associated with 
adverse remodeling through stimulation of a pro-inflammatory M1 macrophage response 133. In 
contrast, thoroughly decellularized biologic ECM scaffolds are known to promote a host 
response that is polarized towards the M2 macrophage phenotype and is associated with 
constructive tissue remodeling 133,406-408. These two responses sit at the extremes of the normal 
cellular response to an implanted biologic scaffold. Little is known about which cellular 
components stimulate an M1 macrophage response or if a threshold level for cellular material 
exists below which the M2 macrophage phenotype predominates. It has been suggested that 
the presence of mitochondria may be a stimulator of M1 macrophages given their primitive 
bacterial origin 262. In light of the heterogeneity with regard to the amount and efficacy of 
decellularization in commercially available ECM-scaffolds 398, a more thorough understanding of 
the effects of cell remnants upon the host response is needed. 
The objective of the present study was to evaluate the effect of cell remnants (i.e., 
ineffective tissue decellularization) within biologic scaffolds upon in vitro and in vivo outcome 
measures.  Three different methods were used to decellularize porcine small intestinal 
submucosal ECM (SIS-ECM). The amount of cellular material remaining was quantified by the 
amount and fragmentation of DNA. The polarization profile of activated macrophages in 
response to these ECM-scaffolds was then assessed in vitro and in vivo using a rodent model of 
body wall repair.   
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A.3 Materials and Methods 
A.3.1 Harvest and preparation of ECM from porcine small intestine: Preparation of 
small intestinal submucosa (SIS) ECM has been previously described 409,410. Briefly, jejunum 
was harvested from market weight (240-260 lbs.) pigs and split longitudinally for processing. 
The superficial layers of the tunica mucosa were mechanically removed. Likewise, the tunica 
serosa and tunica muscularis externa were mechanically removed, leaving the tunica 
submucosa and basilar portions of the tunica mucosa. To produce ECM with differing amounts 
of remnant cellular material, three different chemical treatments were performed on the tissue. 
In rank order of most to least decellularization, the SIS material was treated with: (1) 0.1% 
peracetic acid (PAA) for two hours with mechanical agitation and subsequent 15 min washes 
with phosphate buffered saline (PBS), deionized water, PBS, and deionized water; (2) As 
above, but with the PAA treatment limited to 1hr; or 37 PBS for two hours followed by 
subsequent 15 min washes with PBS, deionized water, PBS, and deionized water. For in vivo 
studies the prepared ECM was vacuum pressed to form a 4-layer laminate. In vitro assays were 
performed on single layer sheets of SIS-ECM.  All devices were lyophilized and sterilized using 
ethylene oxide.    
A.3.2 Histologic assessment of decellularization: Representative samples of SIS with each 
amount of decellularization were fixed in 10% neutral buffered formalin and embedded in 
paraffin.  Sections were cut at 5μm thickness and stained with hematoxylin and eosin (H&E) and 
4', 6-diamidino-2-phenylindole (DAPI) to identify the presence of any residual intact nuclei within 
the tissue samples. 
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A.3.3  Quantification of DNA content: DNA was extracted from representative samples of
SIS prepared by each of the three decellularization protocols. One hundred mg of lyophilized,
powdered SIS-ECM was digested with proteinase K digestion buffer [100 mM NaCl, 10 mM
Tris-HCl (pH=8), 25 mM EDTA (pH=8), 0.5% SDS, 0.1 mg/mL proteinase K] at 50°C for 24
hours.  The digest was extracted twice using 25:24:1 (v/v/v) phenol/chloroform/isoamyl alcohol.
DNA was precipitated from the aqueous phase at -20°C with the addition of 2 volumes of
ethanol and 0.1 volume of 3M sodium acetatate (pH=5.2). The DNA was then centrifuged at
10,000 g for 10 minutes and resuspended in 1mL of TE buffer [10mM Tris (pH=8), 1mM EDTA].
The concentration of each extracted DNA sample was determined using Quant-iT 
PicoGreen dsDNA Assay Kit (Invitrogen #P7589) using the manufacturers recommended 
protocol.  A standard curve was constructed by preparing samples of known DNA 
concentrations from 0-1000 ng/mL.  Samples were read using SpectraMax M2 Plate Reader.  
DNA samples were diluted to ensure their absorbencies that fell into the linear region of the 
standard curve. 
To determine DNA fragment size, equal concentrations of extracted DNA from each 
sample were separated on a 2% agarose gel containing 0.5% ethidium bromide and visualized 
with ultraviolet transillumination using a reference 100bp ladder (New England BioLabs). All 
assays were performed in triplicate. A quantitative comparison of the specimens prepared by 
the three different decellularization methods was then completed using recently established 
guidelines 175.   
A.3.4  In-vitro culture of macrophages on SIS-ECM devices: Characterization of the
macrophage response to devices with varying amounts of cell remnants was performed by in-
vitro culture of mouse monocyte macrophage cells (RAW 264.7 from ATCC) on single layer
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sheets of SIS-ECM prepared using the three described methods of decellularization. Cells were 
maintained in Dulbecco’s Modified Eagle Medium (DMEM Invitrogen) supplemented with 20% 
fetal bovine serum (FBS, Hiclone), 2mM -glutamine (Invitrogen), 100 units/ml penicillin, 100 
μg/ml streptomycin (Invitrogen) at 37°C in a humidified atmosphere with 5% CO2.   
At confluency, the cells were passaged and seeded onto 1.5 cm × 1.5 cm sheets of 
lyophilized SIS-ECM at a density of  1×106 cells/scaffold in 12-well plates (N=4 per scaffold 
type). At 4 days post-seeding, the scaffolds were fixed with 4% paraformaldehyde and snap 
frozen in OCT embedding media for frozen sectioning. 
A.3.5  In-vivo macrophage response to SIS-ECM scaffolds: All procedures were performed
in accordance with the National Institute of Health (NIH) guidelines for care and use of
laboratory animals, and with approval of the Institutional Animal Care and Use Committee
(IACUC) at the University of Pittsburgh. Twelve adult female Sprague–Dawley rats weighing
approximately 300 g (Charles River Laboratory, Wilmington, MA) were randomly assigned to 3
separate groups (N=4/group) based on scaffold type: (1) acellular (2hr PAA) (2) partially
decellularized (1hr PAA) and 37 cellular (PBS).  A partial thickness abdominal wall defect model
406,407 was used to evaluate the host response to each scaffold type.
Each animal was anesthetized by inhalation with 2% isoflurane in oxygen, and the 
ventral abdominal wall was prepared for sterile surgery. A ventral midline abdominal skin 
incision was created, and the skin and subcutaneous tissue were separated from the underlying 
muscle tissues on one side of the midline. A 1cm × 1cm section of the external and internal 
oblique muscles on the ventral lateral abdominal wall was excised leaving the underlying 
transversalus fascia and peritoneum intact. The defect was repaired with a size-matched piece 
of the chosen test scaffold. A single 4–0 Prolene suture was placed at each of the four corners 
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of the test article to secure the device to the surrounding musculature, allow for mechanical 
loading of the test article during the normal abdominal wall activity of daily living, and to 
demarcate the implant for identification at the time of necropsy. A subcuticular placement of 4–0 
Vicryl suture was used to close the skin incision. Each animal was recovered from anesthesia 
and was returned to the housing unit. Each animal was housed individually in shoebox cages. 
The rats were fed a diet of Purina Isopro rodent chow ad libitum (LabDiet ProLab Isopro RMH 
3000, PMI Nutrition International, St. Louis, MO). The housing environment was maintained at 
68° to 76 °C for 24 h a day and with a light:dark cycle of 12:12 h. Each rat received 0.02 mg 
Buprenex (buprenorphine hydrochloride) by subcutaneous injection the day of surgery and for 
two additional days. Baytril (20 mg) was given orally the day of surgery and for two additional 
days. The dietary habits, general health status, and the surgical site were monitored daily and 
recorded. 
Animals were sacrificed at 14 post surgery. Each rat was euthanized with 5% isoflurane 
in oxygen followed by an intracardiac injection of 5 mL of potassium chloride to induce cardiac 
arrest. The implant site, including the surrounding native abdominal wall tissue was excised, 
mounted on a fixed support structure to maintain the size and shape of the in situ tissue, and 
placed in 10% neutral buffered formalin (NBF). The sections were then processed for routine 
paraffin sectioning.  
A.3.6   Immunolabeling
Immunolabeling of both in vitro and in vivo tissue samples was performed on 5 µm sections.  
Frozen sections were fixed in ice cold 50:50 acetone: methanol (v/v) for 5 minutes and rinsed 3 
times in PBS. Paraffin embedded sections were deparaffinized with xylene and rehydrated 
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through a graded ethanol series. Heat-mediated antigen retrieval was performed with 0.1 mM 
EDTA buffer at 95–100 °C for 25 min.  
The tissue sections were subjected to Tris-Buffered Saline Tween-20 (TBST) for 15 
minutes, followed by incubation in blocking buffer (1% bovine serum albumin/0.05% Tween-
20/0.05% Triton X-100) for 1 hour. The primary antibodies, diluted in blocking buffer, were 
added to the slides for 16 hours at 4°C in a humidified chamber.  The slides were then washed 
three times in PBS prior to the addition of the secondary antibody for 1 hour in a humidified 
chamber at room temperature. The primary antibodies used in this study were Alexa Fluor® 488 
anti-mouse CD206 (1:50, BioLegend #123008), goat polyclonal CD206 (Santa Cruz Biotech), 
rabbit monoclonal CCR7 (1:100, Epitomics #2059-1) and mouse anti-rat CD68 (1:50, Serotec).  
The secondary antibodies used were Alexa Fluor® goat anti-rabbit 568 (Invitrogen), Alexa 
Fluor® donkey anti-goat 488 (Invitrogen) and Alexa Fluor® donkey anti-mouse 350 (Invitrogen). 
CD68 is a pan-macrophage marker.  CCR7 is an M1 marker.  CD206 is an M2 marker. For in 
vitro studies, 4',6-diamidino-2-phenylindole (DAPI) was used as a nuclear counterstain. For in 
vivo studies, Draq5 (Cell Signaling Technologies) was used as a nuclear counterstain by the 
manufacturers recommended protocol. All primary antibodies were confirmed to cross-react with 
either mouse or rat epitopes.  
A.3.7  Quantification of M1/M2 macrophage staining: All tissue sections were imaged using
a Zeiss Axiovert Z1 microscope with appropriate brightfield and fluorescent filter sets. For
analysis of in vitro macrophage polarization, 5 x320 magnification fields of view per scaffold
were obtained at random intervals along the length of the scaffold. For analysis of in vivo
macrophage polarization, 10 random x320 magnification fields of view were obtained which
spanned the area between the anastomoses with the native tissue.
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Quantification of M1/M2 polarization was achieved using a custom image analysis 
pipeline developed using the cell profiler image analysis package 309,411. This custom pipeline 
identified and quantified the number of CD68+CCR7+ (M1 phenotype) and CD68+CD206+ (M2 
phenotype) cells present within the tissue sections. These numbers were then expressed as a 
ratio of M1/M2. 
A.3.8  Statistical analysis: Analysis of variance was used to determine statistical significance
of the difference in scaffold decellularization using M1/M2 ratio. Where samples variances were
found to be non-homogenous, the Kruskal-Wallis analysis was used as an alternative. The
Tukey multiple comparison procedure was used to determine which pairs of decellularization
methods were significantly different when a main effect was statistically significant.
A.4.  Results
A.4.1  DNA concentration and fragmentation in scaffolds: The amount of tissue
decellularization following the three preparation methods was assessed using previously
established guidelines for decellularization 175.  Intact nuclei were visible by H&E and DAPI
staining on samples prepared with PBS washing only (Figure 34A & B). No intact nuclei were
seen by H&E staining on samples treated with PAA for either 1hr (Figure 34C) or 2 hrs (Fig 1E)
although potential fragments of DNA were seen attached to the ECM fibers in DAPI stained
samples following 1hr PAA protocol (Figure 34D). No nuclear material was seen in samples
following the 2hr PAA protocol (Figure 34F).
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Figure 34. Histologic images of SIS-ECM scaffolds. Decellularization of ECM devices was 
assessed histologically by hematoxylin and eosin (H&E) and 4’,6-diamidino-2-phenylindole 
(DAPI) staining.  Scaffolds prepared by the PBS protocol contained intact nuclei visible by 
H&E and DAPI staining (A,B).  No intact nuclei were seen on scaffolds prepared following the 
1 hr PAA protocol and 2 hr PAA protocol by H&E staining (C,E).  While no DNA fragments 
were seen by DAPI staining in samples following the 2 hr PAA protocol (F), small fragments 
were seen in scaffolds following the 1 hr PAA protocol (D).   
The concentration of remaining DNA within the ECM materials was used as a measure 
of remaining cellular material. ECM prepared using the 1hr PAA protocol contained the greatest 
concentration of DNA with 959 ± 9.2 ng/mg ECM. Interestingly, ECM prepared using the PBS 
only protocol showed a lesser concentration of DNA (p<0.05) with 423 ± 29.7 ng /mg ECM. Both 
of these concentrations were greater (p<0.05) than those of the ECM prepared using the 2hr 
PAA protocol which had an average DNA concentration of 62 ± 16.4 ng/mg ECM. The isolated 
DNA was assessed for fragment size using agarose gel electrophoresis. In samples prepared 
using the 1hr or 2hr PAA protocols, all residual DNA was less than 500bp in length. In 
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contrast,scaffolds prepared using the PBS only protocol showed the residual DNA to range from 
100bp to greater than 1500bp and most likely included intact full length DNA (Figure 35).  
Figure 35. Concentration of remnant DNA in ECM scaffolds. The amount of DNA 
remaining in the ECM scaffolds prepared by varying methods was quantified as a marker of 
remaining cellular material.  Dagger symbol indicates ECM prepared using the 1 hr PAA 
protocol contained the highest DNA concentration while, interestingly, ECM prepared using 
the PBS protocol showed lower levels of DNA.  Asterisk indicates both of these levels were 
significantly higher (p<0.05) than ECM prepared using the 2 hr PAA protocol (B).  DNA 
fragment length was assessed by gel electrophoresis using a reference 100bp ladder (A). 
A.4.2    In-vitro macrophage response: The response of macrophages to the ECM scaffolds
swith differing amounts of residual DNA was assessed in vitro using the RAW 264.7
macrophage cell line.  Immunolabeling for CCR7 (M1 marker) and CD206 (M2 marker) showed
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a distinct pattern of macrophage polarization depending on the method of ECM preparation. On 
scaffolds prepared using the PBS protocol 90.3% ± 16.9% were CCR7+ (Figure 36A). On ECM 
prepared using the 1hr PAA protocol the phenotype of CCR7+ macrophages decreased to 
55.0% ± 17.1% (Figure 36C). ECM prepared using the 2hr PAA protocol showed only 25.2% ± 
15% of macrophages with a CCR7+ marker (Figure 36E). The percentage of CD206+ cells on 
each scaffold was 18.0% ± 9.2% (Figure 36B), 28.0% ± 15.9% (Figure 36D) and 46.0% ± 6.1% 
(Figure 36F) for scaffolds prepared using PBS, 1hr PAA and 2hr PAA, respectively. Since 
CD68+ macrophages were present on the scaffolds and some of these cells did not stain 
positive for surface markers indicative of polarization, it is logical that the percentage of CCR7+ 
and CD206+ cells does not add to 100%. Calculation of the M1/M2 ratio for each ECM showed 
that scaffolds prepared using the PBS protocol promoted a strong M1 polarization while 
scaffolds prepared using the1hr PAA and 2hr PAA protocols had a significantly lower (p < 0.05) 
M1/M2 ratio. 
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Figure 36. Macrophage response in-vitro. In vitro immunolabeling images of macrophage 
phenotype. The macrophage response to ECM scaffolds was assessed in vitro using the 
RAW 264.7 macrophage cell line.  Immunolabeling for M1, CCR7+, macrophages (orange) 
and M2, CD206+, macrophages (green) showed that macrophages show distinct polarization 
profiles depending on the method of decellularization.  On scaffolds prepared following the 
PBS and 1hr PAA protocols, macrophages showed high levels of CCR7+ staining (A, C) and 
lower levels of CD206+ staining (B, D).  However, macrophages responded with a 
predominant M2 phenotype on scaffolds prepared using the 2hr PAA protocol with high levels 
of CD206+ staining (F) and little CCR7+ staining (E). Arrows indicate positive staining and 
scale bars= 50 μm. 
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A.4.3   Macrophage response In-vivo: Four-layer multilaminate scaffolds prepared with sheets 
of ECM from each of the decellularization protocols were implanted for 14 days in the rat partial 
thickness abdominal wall defect model. All of the animals survived the surgical procedure and 
post-operative period without complications. The host response to the implanted scaffolds was 
assessed by macroscopic examination and by both qualitative and quantitative histologic 
methods. Macrophage phenotype was characterized by immunolabeling methods.  All scaffolds 
showed a robust macrophage presence although there were distinct differences in the density 
and distribution M1 vs. M2 phenotype dependent upon the decellularization method.  CD68+ 
macrophages were present within the wound site, some of which did not stain positive for either 
M1 or M2 surface markers.  These macrophages may have just arrived at the site and not yet 
express polarization towards an M1 or M2 phenotype.  Macrophages that have not been 
polarized would not show markers indicative of polarization (i.e., CCR7 or CD206).  Therefore is 
it logical that the percentages of CCR7+ and CD206+ cells would not equal 100%.     
A.4.3.1  Macrophage response to PBS-treated scaffolds: Devices prepared using the 
PBS protocol showed the highest density of mononuclear cell infiltration. Macroscopically the 
implant sites all showed swelling and seroma formation that were not present in either the 1hr 
PAA or 2hr PAA treated scaffolds. The mononuclear cells formed dense accumulations 
particularly within the middle of the implant site (Figure 37A-B). A strong angiogenic response 
was present with large numbers of blood vessels present within the implant site. The device 
was clearly distinguishable and mononuclear cells surrounded the scaffold fibers in a dense 
layer. Immunolabeling studies showed that these scaffolds had the highest value for 
concentration of macrophages with the mean of 455 ± 82.7 CD68+ cells per field of view. 
However, this value was not statistically different from the 1hr PAA or 2hr PAA treated scaffolds. 
The M1 macrophage phenotype predominated in a cell layer immediately surrounding the ECM 
scaffold 
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(Figure 37C), and M2 cells were mainly located near the anastomoses with the native tissue 
and in areas of remodeling peripheral to the ECM scaffold. Quantitative analysis of macrophage 
phenotype showed that the percentages of M1 and M2 over the entire implant site (scaffold plus 
adjacent tissue) were similar with 53.7 ± 9.6% and 57.4% ± 6.6% respectively.  As a result, the 
M1/M2 ratio slightly favored the M2 phenotype with a ratio of 0.93 ± 0.17:1.  
A.4.3.2 Macrophage response to 1hr PAA treated scaffolds: Devices prepared using  the
1hr PAA protocol showed an intense mononuclear cell response at 14 days. Macroscopically, 
there was a slight swelling at the implant site but no sign of seroma formation. Small and 
scattered remnants of the ECM device were visible and mononuclear cells were distributed 
more evenly throughout the individual layers of the multi-laminate device than was observed in 
the PBS only treated samples. A robust angiogenic response was present and there was 
abundant neomatrix deposition (Figure 37D-E). Immunolabeling studies showed large numbers 
of CD68+ macrophages throughout the scaffold with an average of 395.4 ± 83.9 CD68+ cells 
per field. The macrophages surrounding the scaffold fibers predominately expressed the M1 
marker CCR7. However, some CD206+ M2 macrophages were also observed immediately 
adjacent to the scaffold and the distribution of M2 cells was more uniform than was observed in 
the PBS treated scaffold (Figure 37F).  Quantitative analysis of polarized macrophages over the 
entire implant site showed that M1 macrophage percentage was similar to that found in the PBS 
only treated devices with 56.3% ± 16.0% CCR7+ and 65.0% ± 7.6% CD206+ with a M1/M2 
ratio of 1.02 ± 0.23:1.       
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A.4.3.3  Macrophage response to 2hr PAA treated scaffolds:  Devices prepared using  
the 2hr PAA protocol showed a strong mononuclear cell response at 14 days. Macroscopically 
there was no sign of swelling or seroma.  Histologic examination showed mononuclear cells 
present throughout the scaffold and between layers of the multi-laminate device similar to the 
1hr PAA treatment (Figure 37G-H).  Remnants of the device were still visible along with 
deposition of a neomatrix and a strong angiogenic response. Immunolabeling studies showed 
that these scaffolds had similar numbers of macrophages to the 1hr PAA scaffolds with an 
average of 407 ± 100.7 CD68+ cells per field. The spatial distribution of polarized macrophages 
showed that M1 macrophages were still the predominant phenotype immediately adjacent to the 
scaffold fibers. However, M2 macrophages were more evenly distributed throughout the implant 
site rather than being limited to the periphery of the implant site as was seen with the PBS 
treated scaffolds (Figure 37I). Quantitative analysis of M1 and M2 phenotype showed no 
difference to either the PBS or 1hr PAA treated scaffolds with an average 53.7% ± 15.8% of 
macrophages expressing the M1 marker and 61.2% ± 7.6% of macrophages expressing the M2 
marker. Overall the M1/M2 ratio slightly favored the M2 phenotype with a ratio of 0.87 ± 0.22:1 
although this value was not significantly different to the values for either the 1hr PAA or PBS 
only treated scaffolds (Figure 37J).  
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Figure 37. Histologic and immunolabeling images of the tissue surrounding implant 
site at 14 weeks post-surgery. The in vivo host response to scaffolds prepared using 
varying methods of decellularization was assessed histologically with Masson’s Trichrome 
and hematoxylin and eosin (H&E) staining and by the immunolabeling of macrophages.  
Devices prepared using the PBS protocol (A-C) showed the highest levels of mononuclear 
cell infiltration with M1 cells (orange) predominating in a layer surrounding the ECM scaffold, 
while M2 cells were mainly located toward the anastomoses and in areas surrounding the 
ECM scaffold.  Devices prepared using the 1hr PAA protocol (D-F) showed a similar 
distribution of macrophages, however, some M2 cells were observed surrounding the scaffold 
and the M2 cell distribution was more even than the PBS treated scaffold.  Characterization of 
the polarized macrophages in the 2hr PAA treated scaffolds (G-I) showed that while M1 
macrophages still predominated around the scaffold fibers, M2 macrophages were more 
evenly distributed throughout the scaffold rather than being limited to the margins of the 
wound as seen with PBS scaffolds.  Immunohistochemical staining showed the presence of 
macrophages (red) in all scaffolds and used DRAQ5 (blue) as a nuclear stain. Calculation of 
the M1/M2 ratio (J) for PBS and 2hr PAA  showed the macrophage response favored M2 
while 1hr PAA favored M1 slightly.  However, no treatment resulted in a significantly different 
macrophage profile. A M1/M2 value of 1 indicates equal amounts of cells expressing CCR7 
and CD206.  M1/M2 ratios above 1 indicates an M1 majority and below 1 is an M2 majority. 
Scale bars=50 μm, asterisks=scaffold 
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A.5  Discussion
The present study is the first attempt to determine the association between decellularization 
efficacy and host response by qualitative and quantitative methods. Quantitative criteria of 
decellularization have not been described until recently 175. The presence of xenogeneic DNA 
within biologic scaffold materials has been suggested as a possible cause of an “inflammatory 
response” 392 in patients. Indeed, many commercial biologic scaffolds contain varying amounts 
of remnant DNA 398,412. This remnant DNA is typically present as small fragments less than 300 
bp in length398, and it is therefore unlikely to play any substantive role in an adverse tissue 
remodeling response.  However, the question remains as to whether there is a threshold level of 
cellular “debris” that will elicit an adverse remodeling outcome.   
The negative effects of the presence of intact allogeneic or xenogeneic cells within a 
biologic scaffold are widely recognized; therefore, it is logical that the effective removal of 
antigenic epitopes and intracellular components of source tissues and organs is necessary to 
minimize an adverse immune response by recipients of an ECM scaffold device.  It has been 
shown that the presence of cells within a scaffold is associated with increased amounts of pro-
inflammatory cytokines, increased macrophage M1 polarization, and a poor remodeling 
outcome in a primate model 413.  Previous studies have shown that the implantation of a 
xenogeneic ECM scaffold containing a cellular component results in the classic cascade of 
inflammatory processes with mononuclear cell infiltration, including macrophages predominantly 
of an M1 phenotype at 3 days post implantation, with eventual scar tissue formation 133.  
Furthermore, when the same scaffold materials are prepared by methods that remove the 
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cellular component, the mononuclear cell response is marked by macrophages primarily of an 
M2 phenotype 133.   
The current chapter used DNA content as a quantitative marker of cellular remnants. 
The decellularization protocols developed resulted in three distinct levels of decellularization; 
one which retained intact cells and full length DNA, one with large amounts of small fragment 
DNA, and one that contained small amounts of small fragment DNA. While all three protocols 
were effective at removing or lysing intact cells and cellular material with only 1 or 2 isolated 
nuclei detected per field, even with in the PBS alone protocol, the aggressiveness of the 
decellularization process had a marked in vitro effect on macrophage polarization and was 
associated with a more favorable macroscopic host tissue response in vivo, including less 
swelling and absence of seroma formation. While ECM treated with the 1hr PAA protocol 
contained a greater amount of DNA compared to the PBS treated ECM, more M2 macrophage 
polarization was seen suggesting that DNA content alone is not the sole determinant of the host 
response. This study also demonstrated that PAA treatment, rather than mechanical agitation, is 
the key factor in the dissociation of DNA and most likely other cellular components from the 
remaining ECM. The dissociated cell remnants can then be effectively removed by the 
mechanical agitation process.   It is important to note that DNA was used in this study as an 
indicator of the presence of cell remnants and it is almost certain that other cell components 
capable of causing an adverse response are retained in the scaffold through the process of 
decellularization. For example, mitochondria are known to release damage associated 
molecular patterns (DAMPs) that promote a pro-inflammatory response 262.   It is unknown if 
DNA quantification is the best indicator, or even a good indicator, of “decellularization” but 
alternative sensitive and quantitative methods of assessing the presence of cell remnants were 
not available or used in this study.  The results of the present study clearly show that less 
complete removal of the cell remnants and increased DNA fragment size are associated with a 
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more proinflammatory macrophage phenotype in vitro and that more thorough removal of cell 
remnants and effective fragmentation of cellular material are associated with a more liberal and 
widespread distribution of the constructive M2 phenotype. 
Analysis of the macrophage response to these biological scaffold materials in vitro 
examined the response of macrophages at a relatively early time point.  The devices containing 
significantly more cellular material, prepared by the PBS only and 1hr PAA protocol, showed a 
predominantly M1 macrophage response while the device containing less amounts of DNA, 
prepared using the 2hr PAA protocol, resulted in a macrophage response predominantly of an 
M2 phenotype.  This data supports the findings of previous studies using an in vivo model 
where a cellular scaffold promoted a clear M1 phenotype macrophage response at 3 days 
whereas the equivalent acellular scaffold promoted a strong M2 phenotype 133. Rieder et al have 
shown that decellularization can reduce the chemotactic potential of heart valve tissue for 
macrophages but does not inhibit the activation of macrophages although they did not study 
macrophage polarization 414 . In addition, Ariganello et al. have shown that in vitro exposure of a 
macrophage cell line to decellularized tissue elicited lower esterase and phosphatase activity 
consistent with a subdued inflammatory response comparable to the M2 phenotype observed in 
the present study 415.  
Interestingly, the significant differences seen with the in vitro assays were not 
quantitatively apparent when the macrophage response in vivo was evaluated 14 days after 
implantation. All the scaffold materials elicited a mixed macrophage response with no significant 
differences observed in total number of macrophages of M1/M2 ratio.  The notable and perhaps 
more important differences were found in the distribution of macrophages within the various 
scaffolds. Scaffolds treated with only PBS contained dense accumulations of M1 cells within the 
scaffolds and especially at the scaffold interface with native tissue whereas the M2 
macrophages were mainly located peripheral to the ECM scaffold.  As the method for 
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decellularization became more aggressive, M1 macrophages still were the dominant phenotype 
immediately adjacent to the scaffold fibers but the distribution of M2 cells became more 
uniformly and widely distributed throughout the implant site. It is unknown whether certain 
regions, such as the interface between the ECM implant and the native tissue, are a more 
important determinant of downstream tissue remodeling outcomes than regions more peripheral 
to the implant.  In addition, macrophage phenotype may not be a strong indicator of remodeling 
outcomes at all time points and it may be necessary to examine macrophage phenotypes only 
at early times after surgery to predict the remodeling outcome.   
There were several limitations in the present study.  Only 1 time point, 14 days after 
implantation, was examined because it has been shown to be a useful time point in previous 
studies with this model 90,133,416.  Another limitation was that macrophage phenotype was 
determined solely upon cell surface markers. The present study used CCR7 and CD206 as 
markers of M1 and M2 macrophages respectively. Neither is specific for macrophages alone 
and co-staining with CD68 was used to identify polarized macrophages. However, the polarized 
macrophages can be subdivided into a number of subgroups 400 and these subgroups may not 
have been accurately counted using just two markers.  A more complete picture of macrophage 
phenotype may have been provided by concomitant cytokine analysis.  Finally, any systemic 
effect of the ECM scaffolds was not accessed and only the local tissue response was evaluated. 
Circulating DNA has been associated with clinical signs of sepsis 417, may be the cause of a 
sepsis-like systemic response 418, and is present in patients with chronic inflammatory diseases 
419. Although there are limitations, this study represents the first systematic effort to determine
the relationship between decellularization efficacy and host response to the implantation of a 
biologic scaffold material. 
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A.6  Conclusion
The results of this chapter show that decellularization efficacy of biologic scaffold materials is at 
least one determinant of the macrophage phenotype response. Although a cause-effect 
relationship between macrophage phenotype and remodeling outcome has not been definitely 
shown, a clear association exists. Effective decellularization remains an important component in 
the production of ECM-based scaffolds for therapeutic applications.  
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 THE EFFECT OF TERMINAL STERILIZATION ON THE MATERIAL 
PROPERTIES AND IN-VIVO REMODELING OF A PORCINE DERMAL BIOLOGIC 
SCAFFOLD 
B.1      Abstract
The Food and Drug Administration typically regulates biologic scaffolds as medical devices, 
thus requiring terminal sterilization prior to clinical use.The objective of the present study was to 
characterize the effect of sterilization on the material properties and the host remodeling 
response of a porcine dermal biologic scaffold. Outcome measures included biochemical, 
structural, and mechanical properties as well as cytocompatibility in vitro. The host response to 
each experimental group was determined by quantitative histologic methods and by 
immunolabeling studies.  Results showed that increasing irradiation dosage resulted in changes 
in the collagen fiber architecture and a dose dependent decrease in mechanical properties 
compared to untreated controls.  Ethylene oxide-treated porcine dermal ECM resulted in 
decreased DNA content and bFGF content compared to untreated controls. All ETO treated, 
gamma irradiated, and e-beam irradiated samples had similar cytocompatibility scores 
 APPENDIX B
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in-vitro. In-vivo results showed an increased rate of degradation of the biologic scaffold material 
following 14 and 35 days in the high dose irradiated samples compared to the other groups. 
B.2     Introduction
Biologic scaffolds composed of extracellular matrix (ECM) are commonly used in a variety of 
surgical applications to reinforce soft tissue, particularly in the abdominal wall and pelvic floor and 
in reconstructive breast surgery 420. ECM scaffolds are produced by decellularization of source 
mammalian tissues and organs, including small intestine, urinary bladder, and dermis, among 
others. Over the last decade, a wide array of manufacturing protocols have been described for 
ECM scaffold materials, each of which vary widely in their use of chemical, enzymatic, and/or 
physical methods of decellularization.  While it is inevitable that all processing methods used to 
prepare biologic scaffold materials will adversely affect the mechanical, biochemical, and cell 
signaling properties of the resulting ECM to some degree, the preferred methods will mitigate 
these effects as much as possible. Preservation of native ECM composition and ultrastructure in 
biologic scaffolds has been shown to facilitate beneficial constructive remodeling outcomes 175. 
Specifically, the host response to biologic scaffold materials has been shown to be directly related 
to the efficacy of decellularization 138. These finding have led to the proposal of a standard criteria 
for defining effective decellularization 175. While much progress has been made to this end, 
relatively little has been studied regarding preferred methods of terminal sterilization.  
The Food and Drug Administration (FDA) regulates biologic scaffolds derived from 
xenogeneic source tissue, including materials derived from decellularized porcine dermis, as 
medical devices; thus requiring these products to be terminally sterilized prior to clinical use. 
Common methods of terminal sterilization include electron beam (e-beam) and gamma (γ) 
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irradiation and ethylene oxide (ETO) 421. While it is known that each method exerts its sterilizing 
effect by modifying the structure or function of the critical components (e.g. proteins and nucleic 
acids) of target microorganisms and has directed guidelines regarding bacterial load (e.g., 
ISO/DIS 11135-1, ISO/DIS 11137-3), each method also has the potential to alter material 
properties of the ECM, including mechanics, susceptibility to degradation, biocompatibility, and 
ultimately the elicited in vivo remodeling response 422. In contrast to the aforementioned 
decellularization criteria, currently no consensus exists for the most effective yet minimally 
destructive sterilization protocol for any biologic scaffold material. The objective of the present 
study was to characterize the effect of several types and doses of terminal sterilization on the 
material properties and elicited in vivo remodeling response of a biologic scaffold material derived 
from porcine dermis. 
B.3     Methods
B.3.1        Experimental Design:  The effect of terminal sterilization on a porcine dermal biologic
scaffold was examined using in vitro and in vivo test systems. Porcine dermal ECM scaffold
materials were exposed to one of three terminal sterilization methods – ETO, γ-irradiation, and e-
beam irradiation. The γ-irradiation and e-beam irradiation groups were further subdivided into
three dosage levels – 10, 25, and 40 kGy.  Two non-sterilized control groups (non-sterilized
porcine dermal ECM and non-sterilized intact porcine dermis) were also evaluated. All materials
were evaluated for biochemical (DNA, sulfated glycosaminoglycan, & bFGF content), structural
(scanning electron microscopy), and mechanical (thickness, porosity index, ball burst, suture
retention) properties as well as cytocompatibility with human microvascular endothelial cells
(HMEC-1). In the in vivo experiments, a rodent 1.5 cm x 1.5 cm bilateral partial thickness
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abdominal wall defect model was used to examine the host response to the materials following 7, 
14, or 35 days (n=4 / group / time point). The host response to each experimental group was 
determined by quantitative histologic methods and by immunolabeling for macrophage 
polarization (M1/M2) within explanted specimens. 
B.3.2       Preparation and Sterilization of Dermal ECM Scaffolds: Porcine full thickness skin
from the dorsolateral flank of market weight pigs was harvested and processed immediately after
euthanasia as previously described 142. All full thickness skin sheets were cut into 35-cm × 50-cm
rectangles. All samples were then mechanically delaminated to remove subcutaneous fat, excess
connective tissue and the epidermis. The harvested sheets of porcine dermis were immediately
frozen at −80 °C. Porcine dermis sheets designated to be treated with decellularization protocols
were removed from the freezer and cut into sections measuring 3–7 cm × 3–7 cm. Dermis
sections were decellularized as described previously 142. Briefly, dermis was treated on a vortex
shaker at 300 RPM at room temperature in the following solutions: 0.25% trypsin for 6 h, 1x;
deionized water, 15 min, 3x; 70% ethanol, 10–12 h, 1x; 3% H2O2, 15 min, 1x, deionized water,
15 min, 2x; 1% Triton X-100 in 0.26% EDTA/0.69% Tris, 6 h, 1x and then overnight, 1x; deionized
water, 15 min, 3x; 0.1% peracetic acid/4% ethanol, 2 h, 1x; PBS, 15 min, 2x; and finally deionized
water, 15 min, 2x. Following decellularization, all dermal ECM sheets were lyophilized.
Lyophilized dermal sheets were sterilized with ETO gas (16 h cycle at 50 °C in a Series 3plus
EOGas Sterilizer, Anderson Sterilizers, Inc., Haw River, NC), γ-10 kGy, γ-25 kGy, γ-45 kGy, e-
beam 10 kGy, e-beam 25 kGy, or e-beam 45 kGy.
B.3.3           Assessment of Cellular Content: Decellularization efficacy of dermis samples was
assessed by three previously published criteria: (1) the absence of visible nuclear material on
hematoxylin and eosin (H&E) stained and 40,6-diamidino-2-phenylindole (DAPI) stained sections;
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(2) a Quant-iT Pico-Green assay (Invitrogen, Carlsbad, CA) for quantification of double-stranded
DNA; and (3) evaluation of a 2% agarose gel to determine the size of remaining DNA fragments 
175. 
B.3.4      Measuring DNA content: Scaffolds were digested in 0.6% proteinase K solution for at
least 24 h at 50°C, until no visible tissue remained. Phenol/chloroform/isoamyl alcohol was added,
and samples were centrifuged at 10,000g for 10 min at 4°C. The top aqueous phase containing
the DNA was transferred into a new tube. Sodium acetate and ethanol was added to each sample,
and the solution was mixed and placed at -80°C overnight. While still frozen, the samples were
centrifuged at 4°C for 10 min at 10,000g. The supernatant was discarded, and all residual alcohol
was removed. The pellet was suspended in TE (10 mM Tris / 1 mM EDTA) buffer. Double stranded
DNA was quantified using Quant-iT PicoGreen Reagent (Invitrogen Corp., Carlsbad, CA)
according to the manufacturer’s instructions. The dsDNA assay was performed twice (n=2) with
two technical replicates per assay.
B.3.5        DNA Fragmentation Analysis: To determine the fragment size of remnant DNA, equal
concentrations of extracted DNA from each sample were separated on a 2% agarose gel
containing 0.5% ethidium bromide and visualized with ultraviolet transillumination using a
reference 100-bp ladder (New England BioLabs, Ipswich, MA).
B.3.6                Sulfated Glycosaminoglycan Assay: Sulfated glycosaminoglycan concentrations of
porcine dermis samples were determined using the Blyscan Sulfated Glycosaminoglycan Assay
Kit (Biocolor Ltd., Carrickfergus, Co Antrim, United Kingdom). Samples were prepared by
digestion of 50 mg/ml dry weight of each sample with 0.1 mg/ml proteinase K in buffer (10 mM
Tris–HCl, pH 8, 100 mM NaCl, 25 mM EDTA) for 48 h at 50 °C. Digested samples were assayed
216 
following the manufacturer’s protocol, and the assay was performed in duplicate on three different 
samples. 
B.3.7               Growth Factor Quantification: Three hundred (300) mg of ECM powder was
suspended in 4.5 ml of urea–heparin extraction buffer. The extraction buffer consisted of 2 M urea
and 5 mg/ml heparin in 50 mM Tris with protease inhibitors (1 mM phenylmethylsulfonyl fluoride,
5 mM benzamidine and 10 mM N-ethylmaleimide) at pH 7.4. The extraction mixture was rocked
at 4°C for 24 h and then centrifuged at 3000g for 30 min at 4°C. Supernatants were collected, and
4.5 ml of freshly prepared urea–heparin extraction buffer was added to each pellet. Pellets with
extraction buffer were again rocked at 4°C for 24 h, centrifuged at 3000g for 30 min at 4°C, and
supernatants were collected. Supernatants from first and second extractions were dialyzed
against Barnstead filtered water (three changes, 80–100 vol. per change) in Slide-A-Lyzer
Dialysis Cassettes, 3500 MWCO (Pierce, Rockford, IL). The concentration of total protein in each
dialyzed extract was determined by the bicinchoninic acid (BCA) Protein Assay (Pierce, Rockford,
IL), following the manufacturer’s protocol, and extracts were frozen in aliquots until time of assay.
Concentrations of basic fibroblast growth factor (bFGF) in urea–heparin extracts of dermis 
samples were determined with the Quantikine Human FGF basic Immunoassay (R&D Systems, 
Minneapolis, MN). Manufacturers’ instructions were followed. Assays were performed in duplicate 
with two biologic replicates per sample (n = 2). The ELISA assay is cross-reactive with porcine 
growth factors and does not measure growth factor activity. 
B.3.8                Scanning Electron Microscopy: Scanning electron micrographs were taken to
examine ECM surface topology. Sterilized dermis samples were sputter coated with a 3.5 nm
layer of gold/palladium alloy using a Sputter Coater 108 Auto (Cressington Scientific Instruments,
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Watford, UK) and imaged with a JEOL JSM6330f scanning electron microscope (JEOL, Peabody, 
MA) according to methods established in multiple previously reported studies. 
B.3.9      Thickness Measurements of Sterilized Samples: Each experimental samples was
measured for thickness by a blinded operator applying equivalent compressive force (8.5 ± 0.5
N) to all samples. Thickness after rehydration was measured by subjecting the specimens to
lyophilization and then fully rehydrating the samples by soaking for at least 48 h before 
measurement by the same operator in the same fashion. Fourteen samples were measured for 
each material. 
B.3.10  Porosity Index: The hydrostatic porosity index (PI) measurement has been 
previously described 337. Briefly, the test specimens were placed on the top orifice of the porosity 
testing apparatus. Distilled water was added to the upper reservoir and a hydrostatic pressure 
head of 120 mmHg was maintained throughout the duration of the test (3 min). To achieve this 
pressure head, a height of 163.2 cm was sustained between the water surface and the test 
specimen. A graduated cylinder was placed beneath the hydrostatic permeability testing 
apparatus and the clamp was released to allow passage of water to the test specimen. The clamp 
was closed after 3 min and the volume collected in the graduated cylinder was recorded. The test 
was performed with both sides of the material (n = 6 for each surface). The hydrostatic PI was 
calculated by dividing the volume collected by the area of the porosity testing apparatus’ orifice 
and the duration of the test and reported as mL/min/cm2.  
B.3.11   Ball-burst Testing: The ball burst strength measurement has been previously 
described 423. Samples from each test group were cut to a size of at least 6 cm x 6 cm and frozen 
at -80°C until time for testing (not more than 72 h). The specimens were rehydrated in 0.9% 
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sodium chloride solution for approximately 15 min. Each specimen was mounted into a ball-burst 
fixture within the grips to prevent slippage. The ball-burst test, a measure of strength in response 
to multi-axial loading was conducted in compliance with the Standard Test Method for Bursting 
Strength of Knitted Goods, Constant-Rate-of-Traverse (CRT) Ball-burst Test (ASTM D 3787-89). 
A uniaxial tensile testing machine (MTS Insight; 2 kN capacity, MTS Systems Corp., Eden Prairie, 
MN) was equipped with a ball-burst compression cage in which a 25.4-mm (1-inch) polished 
stainless steel hemisphere rod was pushed against the material at a rate of 25.4 mm/min until 
failure. A total of 8 specimens were tested within each group. 
B.3.12  Suture Retention Strength: The suture retention strength (SRS) test was 
performed according to ANSI/AAMI VP20–1994 Guidelines for Cardiovascular Implants-
Vascular Prostheses. The SRS of a material is defined as the force required to pull a suture 
through the full thickness of the material at a specified bite depth and a specified pull rate. A 
2–0 Prolene suture with a SH taper needle was passed through a square piece of test 
material with a 2-mm bite depth as shown in Figure 3. The specimen was clamped at one end 
while the suture was tied with a square knot and the loop attached to the Instron machine 
(Model 3345 Single Column Materials Testing System) and pulled at a constant rate of 10 
cm/min. At least two tests were performed at locations that were 1.5 cm apart on the same 
edge of the square piece of each test material and the maximum load was recorded. At least 
12 tests were performed for each group. 
B.3.13 In-vitro Cytocompatibility: Dermal ECM sheets from each group were cut to 
2 cm diameter circles for use in cell growth studies. Human microvascular endothelial cells 
(HMEC-1; a gift from Francisco J Candal, Center for Disease Control and Prevention, Atlanta, 
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GA) were cultured in MCDB-131 medium (Sigma, St. Louis, MO) containing 10% fetal bovine 
serum, 2 mM L-glutamine (Sigma), 100 U/mL penicillin/ 100 μg/mL streptomycin (Sigma), and 1 
μg/mL hydrocortisone (Sigma) as previously described 424. Cells were grown at 37°C and 5% 
CO2, and media was changed every other day. After allowing the cells to propagate to sufficient 
numbers, test articles were briefly hydrated with sterile saline in sterile 6-well plates prior to cell 
seeding. Approximately one million cells were plated per test article. Test articles were seeded in 
quadruplicate. Cells were placed inside of stainless steel cell culture rings (inner diameter 1.3 cm) 
and allowed to attach to the test articles for 24 hours. Cell culture rings were removed and cell 
culture media was changed at 24 hours and every other day throughout experiments. 
After 7 days of growth, cell culture media was removed and cells on test articles were 
immediately fixed in 10% Neutral Buffered Formalin for at least 18 hours. Following fixation, test 
articles were paraffin embedded, sectioned (5 μm), and mounted on glass slides. Slides were 
stained with hematoxylin and eosin (H&E) and imaged for analysis. Eight representative 
microscopic images (40x magnification) were captured for each test article. All images were 
scored by five blinded investigators using a previously described scoring system based upon 
cellular confluence (0 to 100%), infiltration (surface only to 100% infiltration), and phenotype (0 to 
100% normal) 209. 
B.3.14 Surgical Procedure and Test Article Collection: All procedures were 
performed in accordance with the National Institute of Health (NIH) guidelines for care and use of 
laboratory animals and with approval of the Institutional Animal Care and Use Committee (IACUC) 
at the University of Pittsburgh. Sprague Dawley rats (female; 250–350 g) were anesthetized with 
1.5–3% isoflurane and maintained at a surgical plane of anesthesia. The surgical site was shaved, 
disinfected with a betadine solution, and an incision was made into the ventrolateral abdominal 
wall. Bilateral partial thickness abdominal body wall defects were created by excision of a 1.5 
cm × 1.5 cm  piece of tissue comprising the internal and external oblique muscles but leaving the 
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transversalis muscle intact as described previously 425 (Figure 1A). Size matched dermal ECM 
scaffolds were then sutured into the defect site using nonresorbable 4-0 proline sutures at each 
of the 4 corners of the device. The skin was closed using 3-0 resorbable vicryl sutures. 
Animals were sacrificed at 7, 14 or 35 days post implantation, and test articles were 
excised. Following euthanasia, the skin was gently dissected, reflected, and the entire body wall 
that includes the test or control article was explanted en bloc.  The sample was then cut in half 
and each half immersed in 10% Neutral Buffered Formalin (NBF) for histologic analysis. 
B.3.15     Histologic Analysis of Tissue Explants: Explanted test articles were paraffin
embedded, sectioned (5 μm), and mounted on glass slides. Slides were stained with 
hematoxylin and eosion (H&E) or Masson’s Trichrome and imaged microscopically for analysis. 
Eight representative microscopic images (40x magnification) were captured for each test article 
across two distinct interfaces: within the center of the scaffold material and at the abdominal 
wall / ECM interace (Figure 38B). Five blinded investigators scored all of the images using a 
previously described semi-quantitative scoring system for cellularity, neovascularization, and 
multinucleate giant cell formation (Figure 38B)162,328.  
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Figure 38. Overview of animal model and histologic evaluation schema. (A) Schematic of 
animal model and histologic cross section. The green “x” represents site of suture placement 
at corners of each device (yellow squares). The material is explanted en bloc and bisected. 
The histologic cross section depicts the rat abdominal wall defect, where the external and 
internal oblique is removed and replaced with a dermal ECM scaffold material. (B) Table 
describing the scoring system used to evaluate the histologic sections. (C) Schematic of 
histologic evaluation of explanted materials. Colored boxes represent the approximate 
location of 20X images used for histologic evaluation for each location. 
B.3.16 Macrophage Immunolabeling: Immunolabeling of macrophages was performed 
on tissue sections from day 14 explants. Paraffin embedded sections were deparaffinized with 
xylene and rehydrated through a graded ethanol series. Heat-mediated antigen retrieval was 
performed with 0.01 M citrate buffer (pH = 6) at 95–100 °C for 25 min. The tissue sections were 
subjected to Tris-Buffered Saline Tween-20 (TBST) for 15 min, followed by incubation in blocking 
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buffer (2% horse serum albumin/1% bovine serum albumin/0.05% Tween-20/0.05% Triton X-100) 
for 1 h. The primary antibodies, diluted in blocking buffer, were added to the slides for 16 h at 4 °C 
in a humidified chamber. The slides were then washed three times in PBS prior to the addition of 
the secondary antibody for 1 h in a humidified chamber at room temperature. DAPI was used as 
a nuclear counterstain. The primary antibodies used in this study were mouse anti-rat CD68 
(1:150, AbD Serotec, Raleigh, NC), goat polyclonal CD206 (Santa Cruz Biotech, Santa Cruz, CA), 
rabbit anti-rat CD86 (1:150, Abcam, Cambridge, MA) and mouse anti-rat CD68 (1:50, Serotec, 
Raleigh NC). The secondary antibodies used were Alexa Fluor® donkey anti-mouse 594 (1:200, 
Invitrogen), Alexa Fluor® donkey anti-goat 488 (1:200, Invitrogen) and donkey anti-rabbit IgG-
PerCP-Cy5.5 (1:300, Santa Cruz Biotech, Santa Cruz, CA). CD68 is a pan-macrophage marker. 
CD86 is an M1 marker. CD206 is an M2 marker. All primary antibodies were confirmed to cross-
react with rat epitopes. The sections were imaged at random fields along the interface of the 
native tissue and ECM scaffold. Quantification of M1/M2 polarization was achieved using a 
custom image analysis algorithm developed using the cell profiler image analysis package 162. 
This algorithm identified and quantified the number of CD68+CD86+ (M1 phenotype) and 
CD68+CD206+ (M2 phenotype) cells present within the tissue sections. Any cells that co-
expressed CD86 and CD206 were not counted. These numbers were then expressed as a ratio 
of M2/M1. 
B.3.17 Statistical Analysis: Data sets were analyzed with either a one-way or a two- way 
analysis of variance (ANOVA) using SigmaStat 12.2 (sigma Aldrich, St. Louis, MO). The 
Student Newman-Keuls post-hoc test was used to locate the differences between means when 
the observed F ratio was statistically significant (p < 0.05).  Data are reported as mean and 
standard error. 
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12.2.4. Results 
B.4.1  Cellular Content: No intact nuclei were visible by H&E (Figure 39A) or DAPI  
staining (Figure 39B) in the decellularized samples. All dermal samples contained less than 100 
ng/mg dsDNA following decellularization (Figure 39C). The ETO sterilized samples contained 30 
± 10 ng/mg which was significantly lower (p<0.01) than all other sterilized samples. All 
DNA remnants were present in fragments less than 200 bp in length (Figure 39D).  
Figure 39. Decellularization Quantification. Cellular content of dermis samples was assessed 
by three previously published criteria: (1) a Quant-iT Pico-Green assay for quantification of 
double-stranded DNA (A); (2) evaluation of a 2% agarose gel to determine the size of 
remaining DNA fragments (B); [23] the absence of visible nuclear material on hematoxylin 
and eosin (H&E) stained (C) and 40,6-diamidino-2-phenylindole (DAPI) stained sections (D). 
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B.4.2    Biochemical Properties: The amount of urea-heparin extractable protein varied  across
sterilization treatments (data not shown). Extracted protein per gram of dry weight increased with 
increasing doses of γ and e-beam irradiation. ETO treated dermal ECM had the least (p<0.05) 
amount of extractable protein. The amount of bFGF in the ECM samples (Figure 40) was similar 
across groups with the exception of ETO, which had less (p<0.01) extractable bFGF than 
scaffolds from the other sterilization conditions. The amount of sGAGs in the test samples was 
equivalent to non-sterilized control values (405 ± 12 μg/g; Data not shown).  
Figure 40. Biochemical Composition. Concentration of basic fibroblast growth factor (bFGF) in 
urea–heparin extracts of samples were determined with the Quantikine Human FGF basic 
Immunoassay (A). All results were normalized to dry weight tissue. Assays were performed in 
duplicate on three independent samples for each treatment group. 
B.4.3   Ultrastructural Properties: Scanning electron micrographs show that the  ECM
scaffolds subjected to ETO and low dose e-beam and γ irradiation (i.e., 10 kGy) show similar 
surface topology as control samples (Figure 4). However, alterations to the dermal ECM 
collagen fiber ultrastructure were observed with increasing doses of γ and e-beam irradiation. 
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Figure 41. Scanning Electron Microscopy. SEM was used to examine the surface topology of 
each experimental group. SEM images were captured using a JEOL 6335F Field Emission 
SEM instrument with a backscatter detector. 
B.4.4  Mechanical Properties and Porosity: The thickness of the scaffold was not affected by
type or level of sterilization. Multiaxial strength of the test articles following ETO, γ and e-beam 
exposure was compared to controls (Figure 42). Burst strength of the ETO-treated sample was 
similar to that to that of the control, whereas there was a dose-dependent decrease (p<0.01) in 
the burst strength of scaffolds exposed to increasing dosages of irradiation (Figure 42A). Suture 
retention strength was not significantly altered by exposure to ETO and 10 kGy of γ and e-beam 
irradiation (Figure 42B). However, higher doses of irradiation (i.e., 25 kGy and 40 
kGy) resulted in a decreased (p<0.01) suture retention strength compared to the control samples. 
Porosity index levels trended towards a lower index level with decreasing doses of γ and 
e-beam irradiation, when compared to the non-sterilized control (Figure 42C). Gamma and e-
beam at 10kGy had the lowest porosity index in their respective groups. The ETO treatment group 
was found the have the lowest porosity index level compared to control, γ and e-beam.  
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Figure 42. Mechanical Properties & Hydrostatic Porosity Index. The ball-burst test conducted 
in compliance with the Standard Test Method for Bursting Strength of Knitted Goods, 
Constant-Rate-of-Traverse (CRT) Ball-burst Test (ASTM D 3787-89) (A). The suture retention 
test was performed according to ANSI/AAMI VP20–1994 Guidelines for Cardiovascular 
Implants-Vascular Prostheses (B). The hydrostatic PI was calculated by dividing the volume 
collected by the area of the porosity testing apparatus’ orifice, and the duration of the test (C). 
B.4.5 Cytocompatibility: All dermal ECM test articles showed equivalent 
cytocompatibility scores for HMEC cells at the time point studied. After 7 days in culture, the 
HMEC cells reached approximately 60% confluence with minimal infiltration and essentially 
normal cell phenotype (Figure 43).  
227 
Figure 43. Cytocompatibility. HMEC were grown on each test article for 7 days and 
subsequently scored for cellular confluence, infiltration, and phenotype. 
B.4.6 Host Response: The host response to dermal ECM scaffolds was evaluated at  7, 14,
and 35 days (Figure 44). Gross images of the test article in-situ at time of sacrifice show that the 
test articles were clearly identifiable at all time points with the exception of those test articles 
subjected to 40 kGy doses of γ and e-beam which were nearly transparent at 35 d post-op 
(Figure 44A). These observations were corroborated by representative Masson’s Trichome 
stained histologic sections where less scaffold (indicated by blue color) was present at the higher 
doses of irradiation compared to the ETO and 10 kGy irradiation samples (Figure 44B). 
Qualitatively, cell infiltration into all scaffolds increased with time. Little or no cell infiltration was 
present at 7 days and increasing depth and number of cells was present at 14 and 35 d post 
operatively, respectively (Figure 44C). 
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Figure 44. In Vivo Remodeling Response. Following euthanasia, the skin was gently 
dissected, reflected, and photographs were taken of each animal and each test or control 
article in situ (A).  The entire body wall that includes the test or control article was explanted 
en bloc.  The sample was then cut in half and submitted for histological analysis.  Masson’s 
Trichrome stained slides were mosaic imaged to illustrate the entire cross section of each test 
article at each time point (B). Additional slides were stained with H&E and imaged for 
histomorphologic analysis. Representative microscopic images (40x) were captured for each 
test article (C). 
Histologic scoring showed the highest level of cellularity in 40 kGy γ sample at 14d and 
40 kGy e-beam sample at 35d (Figure 45A). Vascularity in the samples was largely the same in 
all test articles with the exception of the 35d e-beam 40 kGy samples (Figure 45B). Similarly, the 
40 kGy e-beam samples had the most multinucleate giant cells (MNGCs) among test articles, 
although it should be noted that on average there were still less than 1 MNGC per high-powered 
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field of view (Figure 45C). Qualitative histologic scoring showed that the 40 kGy e-beam at 35d 
had the greatest degree of degradation (Figure 45D). 
Figure 45. Semi-Quantitative Histomorphologic Scoring. Semi-quantitative scoring of each 
interface of each device was conducted for cellularity (A), neovascularization (B), 
multinucleate giant cell formation (C), and material degradation (D). Four blinded individuals 
scored each image independently and the average score was used to compile the results. 
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Macrophage immunolabeling at 14d post-operative showed a similar M2/M1 ratio among 
all test articles with a slightly increased ratio in 25kGy γ (Figure 46A). Total number of infiltrating 
macrophages was similar across groups with the exception of 40kGy γ, which had an increase in 
macrophage number at 14d post-surgery (p<0.01, Figure 46B).   
Figure 46. Macrophage Phenotype Assessment. Quantification of M1/M2 polarization was 
achieved using a custom image analysis pipeline developed using the cell profiler image 
analysis package. This custom pipeline identified and quantified the number of 
CD68
+
CD86
+
 (M1 phenotype) and CD68
+
CD206
+
 (M2 phenotype) cells present within the 
tissue sections. These numbers were then expressed as a ratio of M2/M1. Any cells that co-
express the CD86
+
 and CD206
+ 
markers were counted separately. 
B.5  Discussion
The present study shows that increasing dosage of irradiation results in ultrastructural changes 
in the collagen fiber architecture, increased total protein extraction, and a dose dependent 
decrease in mechanical properties compared to untreated controls.  ETO-treated porcine dermis 
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ECM resulted in decreased DNA content, total protein extracted, and bFGF content compared to 
untreated controls. All ETO, γ, and e-beam treated samples had similar cytocompatibility scores 
in-vitro. In-vivo results showed an increased rate of degradation of the biologic scaffold materials 
sterilized by high dose radiation compared to the other groups at both 14 and 35 days post-
surgery. 
The FDA’s classification of biologic scaffold materials as medical devices requires terminal 
sterilization to assure sterility guidelines are met. Common terminal sterilization methods, such 
as ETO exposure and irradiation, can achieve effective sterilization but these processes are 
known to affect the ultrastructure and mechanical properties of the ECM 346.  Material and 
structural properties, such as burst strength and stiffness, are important parameters for clinical 
applications such as ventral hernia repair and reconstructive breast surgery 426. Although ECM 
scaffolds tend to degrade quickly after implantation due to the host tissue response and the 
remodeling process, initial material and structural properties are important when the scaffold is 
intended for load bearing applications 427. The present study shows that exposure to high levels 
of e-beam and γ irradiation results in a dose-dependent decrease in the multiaxial strength and 
suture retention strength of the material. 
Previous studies have described effects of terminal sterilization upon the mechanical 
properties of tissue grafts and different naturally derived biomaterials 161. However, these studies 
included materials which differed in preparation methods, hydration states during sterilization, and 
sterilizing dosage; therefore direct translation of this information to the sterilization method effects 
on biologic scaffolds is not possible. Since each method of sterilization has distinct effects on 
ECM constituents (e.g., collagens, proteoglycans, and glycosaminoglycans), a valid comparison 
of sterilization methods a direct comparison of sterilization requires the same starting material. 
The present study used the same starting substrate (i.e., decellularized porcine dermis) and 
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therefore the observed differences in host response and material properties are directly 
attributable to the method and dose of sterilization. 
ETO is a chemical sterilant with an unstable ring structure that alkylates functional groups 
(amino, carboxyl, hydroxyl, and sulfhydryl) resulting in the inactivation of nucleic acids and 
proteins 428. Previous studies have shown little or no change in the mechanical properties of a 
device following ETO sterilization 161. The present study showed that ETO exposure resulted in 
changes to the biochemical composition but, consistent with previous studies, the ultrastructure 
and mechanical properties were largely unchanged compared to untreated controls. ETO 
treatment can leave toxic residues that have been implicated as the cause of pro-inflammatory 
processes and poor outcomes 429; however, these toxic residues dissipate quickly and it is unlikely 
that notable amounts remain within a week of ETO exposure. Sterilization with ETO did not 
adversely affect in-vitro cellular growth or the in-vivo host response in the present study. 
The most common technique for sterilization of biologic scaffolds is ionizing radiation, 
including e-beam and γ irradiation. Radiation exerts sterilization by the production of free radicals 
that are thought to result in scission of peptide backbones, disruption of hydrogen bonds, and 
crosslink formation 430. Previous studies have shown a reduction in mechanical properties of 
biologic scaffolds following ionizing radiation sterilization 431. Similarly, radiation has been shown 
to impair the attachment and growth of cells on biologic scaffolds 432. Results of the present study 
showed irradiation results in alterations to the collagen fiber architecture and a dose-dependent 
decrease in both suture retention strength and maximum tangential stiffness. Radiation did not 
significantly change in-vitro cytocompatibility but at higher doses of radiation the scaffolds 
degraded more rapidly in-vivo than those exposed to low dose irradiation or ETO, likely due to 
increased scission of collagen backbone. The porcine dermal specimens exposed to high dose 
radiation were also associated with an increased infiltration of macrophages. 
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There are several key variables associated with the terminal sterilization of an ECM 
scaffold material. For example, hydration status (lyophilized vs hydrated) and temperature 
(room temp vs frozen) of the ECM scaffold during sterilization have been suggested to affect the 
material properties. Although the present study was conducted upon extracellular matrix derived 
from porcine dermis, it is unknown whether or not the results will be applicable to the 
preparation of biologic scaffolds from other tissues and organs. Each individual scaffold 
material, prepared by a specific method, will require similar studies to fully evaluate the effects 
of terminal sterilization. Studies should be conducted to systematically address these areas in 
an effort to further improve outcomes. 
B.6  Conclusion
The present study shows that 40 kGy of e-beam and γ irradiation causes an adverse effect on 
the material properties and changes the response to a porcine dermal biologic scaffold both in 
vitro and in vivo. However, effective methods of terminal sterilization, such as ETO exposure, can 
be used with minimal effects upon the structure and function of biologic scaffold materials. These 
findings emphasize the importance of selecting an appropriate type and dose sterilization for 
biologic scaffold materials to identify preferred material properties and performance in vivo. 
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